PIPERIDINE DERIVATIVES

Abstract

The present refers to piperidine derivatives of formula (1) where Ar 1 , Ar 2 , R Ar1 , R 1 , R 2 and R 3 They are as described in the description, to their preparation, to their pharmaceutically acceptable salts and to their use as pharmaceutical products, to pharmaceutical compositions containing one or more compounds of formula (1) and especially to their use as modulators of the CXCR7 receptor.

Description

PIPERIDINE DERIVATIVES The present invention relates to new piperidine derivatives of formula (I) that are suitable as pharmaceutical products that are modulators of the CXCL11 / CXCL12 CXCR7 receptor, and to related aspects including processes for the preparation of the compounds of formula (I), compositions pharmaceuticals containing one or more compounds of formula (I), and to the use of the compounds of formula (I) as modulators of the CXCL11 / CXCL12 CXCR7 receptor. The invention further relates to the compounds of formula (I) and their use as pharmaceuticals in combination with one or more therapeutic agents and / or radiotherapy and / or targeted therapy in the treatment of cancers (especially brain tumors including malignant gliomas, glioblastoma multiforme; pancreatic cancer including pancreatic adenocarcinoma / pancreatic ductal adenocarcinoma; gastrointestinal cancers including colon carcinoma, hepatocellular carcinoma; ; rhabdomyosarcoma; prostate cancer, esophageal squamous cell carcinoma; bladder; multiple myelomas; osteosarcoma; head and neck cancer, and renal carcinomas including renal clear cell carcinoma, metastatic renal clear cell carcinoma). Chemokine receptors are a group of G protein-coupled receptors (GPCRs) that bind chemokine peptide ligands with high affinity. The predominant function of chemokine receptors is to guide leukocyte trafficking to lymphoid organs and tissues under resting conditions as well as during inflammation, but a role has also been recognized for IF-2019-79621737-APN-ANP#INPI Page 1 of 351 certain chemokine receptors in non-hematopoietic cells and their progenitors. CXCR7 (aka ACKR3, aka RDCi, aka CMK0R1, aka GPR159) has two known chemokine ligands: CXCL12 (aka stromal cell-derived factor 1, SDF-1, aka pre-B cell growth-stimulating factor, PBSF) and CXCL11 -TAC, alias T cells inducible by INF-y, a chemo-attractant). CXCL12, a stromal-derived chemo-attractant, participates in immune surveillance and regulation of inflammatory responses. CXCL12 is secreted by bone marrow stromal cells, endothelial cells, heart, skeletal muscle, liver, brain, kidney, parenchymal cells and plays an essential role in the proliferation, survival and nesting of hematopoietic stem / progenitor cells in the bone marrow ( Rankin SM et al.; Chemokine and adult bone marrow stem cells; CXCL12 also recruits bone marrow-derived progenitor cells to sites of blood vessel formation. Furthermore, it plays a prominent role in carcinogenesis. CXCL12 promotes the recruitment of endothelial progenitor cells and myeloid-derived suppressor cells to tumor sites, as well as other bone marrow-derived cells. Furthermore, CXCL12 regulates angiogenesis / vasculogenesis related to tumor progression and plays a key role in seeding circulating tumor cells at metastatic sites. In addition to its chemotactic functions, CXCL12 has been shown to regulate the proliferation, motility and survival of tumor cells (Kryczek I et al.; CXCL12 and vascular endothelial growth factor synergistically induces neoangiogenesis in human ovarian cancers; Cancer Res. 2005, 65( 2):465-72; Teicher BA et al.; CXCL12 (SDF-1) / CXCR4 pathway in cancer; IF-2019-79621737-APN-ANP#INPI Page 2 of 351 Domanska UM et al.; A review on CXCR4 / CXCL12 axis in oncology: no place to hide; European J of cancer. 2013, 49(1):219-30). In addition to CXCR7, CXCL12 binds and activates CXCR4 (aka Fusin, alias leukocyte-derived seven-transmembrane domain receptor, LESTR, alias D2S201E, alias seven-transmembrane segment receptor, alias HM89, alias lipopolysaccharide-associated protein 3; Iap3, Alias ​​proteina associated with LPS 3) while CXCL11 binds and activates CXCR3 (aka GPR9, alias CD183). The interaction of CXCR7 and its ligands CXCL12 and CXCL11 (hereinafter referred to as CXCR7 axis) is involved in the guidance of receptor-bearing cells to specific locations in the body, particularly at sites of inflammation, immune injury and immune dysfunction and is also associated with tissue damage, induction of apoptosis, cell growth and angiostasis. CXCR7 and its ligands are upregulated and highly expressed in various pathological situations including cancer, autoimmune disorders, inflammation, infection, transplant rejection, fibrosis, and neurodegeneration. Cancers are among the leading causes of death worldwide. Tumors are composed of abnormally proliferating malignant cancer cells, but also a functional supporting microenvironment. This tumor microenvironment is composed of a complex matrix of cells, extracellular matrix components and signaling molecules and is established by altered communication between stromal and tumor cells. As tumors expand in size, they induce the production of various factors that can help the tumor grow, such as angiogenic factors (which promote the growth of blood vessels) or that can help evade attack by the immune response. of the guest. CXCL12 is an angiogenic and immunomodulatory factor produced in tumors. IF-2019-79621737-APN-ANP#INPI Page 3 of 351 The present CXCR7 modulators may be useful, alone or in combination in cancers in which the expression of the CXCL11 / CXCL12 CXCR7 receptor correlates with disease progression in cancer (among others in pancreatic cancer, pancreatic adenocarcinoma, breast cancer , hormone-refractory prostate cancer, renal cell carcinoma, cervical cancer, cervical intraepithelial neoplasia, papillary thyroid carcinoma, bladder cancer, Ewing sarcoma, colon cancer, colorectal cancer, lung cancer, lung adenocarcinoma, non-small cell lung cancer, meningiomas, MALT lymphoma, cutaneous squamous cell carcinoma, neuroendocrine tumors, nasopharyngeal carcinoma, glioblastoma multiforme, astrocytomas, gliomas, hepatocellular carcinoma, estrogen-positive breast cancer, osteosarcoma, gallbladder cancer, tumors kidney and renal cell carcinoma CXCR7 is also expressed in leukemias, adenocarcinomas, brain metastases, multiple myelomas, head and neck cancer, primary cutaneous melanoma, melanoma, metastatic melanoma, rhabdomyosarcoma, pituitary adenoma, oral squamous cell carcinoma, tumors. oral, lymphoplasmacytic lymphoma, adult T-cell leukemia, brain tumors, esophageal squamous cancer, esophageal cancer, ovarian carcinoma, lymphoma, virus-induced tumors, otorhinolaryngological neoplasia, Burkitt lymphoma, Hodgkin lymphoma, thyroid cancers, cervical cell carcinoma squamous cell, endometrial cancer, neuroblastoma, gastrointestinal cancer, lymphoproliferative disease, acute myeloid leukemia, acute lymphoid leukemia, gastric cancer, nerve sheath tumors and choriocarcinoma, malignant pleural mesothelioma, neurilemnoma, meningioma, diffuse large B-cell lymphoma, oral leukoplakia, Kaposi sarcoma and alveolar rhabdomyosarcoma (for review see Sun et al.; CXCL12 / CXCR4 / CXCR7 Chemokine Axis and Cancer Progression; Cancer Metastasis Rev. 2010, 29(4), 709-722). IF-2019-79621737-APN-ANP#INPI Page 4 of 351 The present CXCR7 modulators may be useful, alone or in combination, in diseases in which CXCR7 modulation using siRNA, shRNA, microRNAs, overexpression, CXCR7 knockout animals, CXCR7 agonists, CXCR7 antagonists, antibodies or nanobodies have been shown to alter tumor growth in experimental disease models as single agents, or in combination with cytotoxic therapies including, among others, hepatocellular carcinoma (Xue TC et al.; Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential; Exp Ther Med. 2012, 3(1):117-123; Zheng et al.; Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells; 2010, 11 ;29:31), Kaposi sarcoma Raggo C et al.; Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus; Cancer Res. 2005, 65(12):5084-95), T cell leukemia (Jin Z et al. ¡ CXCR7 is inducible by HTLV-1 Tax and promotes growth and survival of HTLV-1infected T cells; Int J Cancer. 2009, 125(9):2229-35), lymphoma (Burns JM et al.; A novel chemokine receptor for SDF-1 and l-TAC involved in cell survival, cell adhesion, and tumor development; J Exp Med. 2006, 203(9):2201-13), lung carcinomas, breast cancer (Miao Z et al.; CXCR7 (RDCi) promotes breast and lung tumor growth in vivo and is expressed on tumorassociated vasculature. PNAS. 2007, 104(40 ):15735-40), rhabdomyosarcoma (Grymula K et al.; Overlapping and distinct role of CXCR7-SDF-1 / ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas; Int J cancer. 2010, 127( 11):2554-68), prostate cancer (Wang J et al.; The role of CXCR7 / RDCi as a chemokine receptor for CXCL12 / SDF-1 in prostate cancer; J biol Chern. 2008, 283(7):4283 -94), pancreatic cancer (Shakir M et al.; The chemokine receptors CXCR4 / CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12 / high mobility IF-2019-79621737-APN-ANP#INPI Page 5 of 351 group box 1 in pancreatic cancer growth and development: finding flow; Pancreas. 2015, 44(4):528-34), esophageal squamous cancer (Zhou SM et al.; miR-100 suppresses the proliferation and tumor growth of esophageal squamous cancer cells via targeting CXCR7; Oncol Rep. 2016, 35(6): 3453-9), endometrial cancer (Long P et al.; Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer; Tumor boil. 2016, 37(6):7473-80), papillary thyroid carcinoma (Zhang H et al.; The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo; Tumor boil. 2016, 37(2):2415-23), oral carcinoma squamous cell (Chen N et al. ¡ CXCL12-CXCR4 / CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma; Tumor boil. 2016, 37(1):567-75), lung metastasis (Goguet-Surmenian et al .; CXCR7-mediated progression of osteosarcoma in the lungs.; Br J Cancer. 2013, 109(6):1579-85), melanoma (McConnell AT et al.; The prognostic significance and impact of the CXCR4 / CXCR7 / CXCL12 axis in primary cutaneous melanoma; Br J Dermatol. 2016, doi: 10.1111 / bjd. 14720), bladder cancer (Liu L et al.; Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7; Mol Med Rep. 2013, 8(1):140-6), multiple myeloma ( Azab AK et al.; CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma; Blood. through inhibition of the PI3K / Akt and βarrestin pathways; Oncol Rep. 2014, 32(3):965-72), colon cancer (Wang HX et al.; Role of CXC chemokine receptor type 7 in carcinogenesis and lymph node metastasis of colon cancer; Mol Clin Oncol. 2015, 3(6):1229-1232), grade IV astrocytomas (Walters MJ et al.; Inhibition of CXCR7 extends survival following irradiation of brain tumors in mice and rats; Br J Cancer. 2014, 110(5):1179-88), head and neck cancers (Maussang D et al·; Llama IF-2019-79621737-APN-ANP#INPI Page 6 of 351 derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduces head and neck cancer cell growth in vivo; J biol Chem. 2013, 288(41):29562-72), neuroblastoma (Liberman J et al.; Involvement of the CXCR7 / CXCR4 / CXCL12 axis in the malignant progression of human neuroblastoma; Pios One. 2012, 7(8):e43665) and glioblastoma (Liu Y; Targeting chemokine receptor CXCR7 inhibits glioma cell proliferation and mobility; Anticancer Res. 2015, 35(1):53-64 ; Walters MJ et al.; Inhibition of CXCR7 extends survival following irradiation of brain tumors in mice and rats ; Br J Cancer. 2014, 110(5):1179-88; ); to alter tumor-associated blood vessels (Miao Z et al.; CXCR7 (RDCJ promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. PNAS. 2007, 104(40):15735-40); reduce tumor cell seeding (Grymula K et al.; Overlapping and distinct role of CXCR7-SDF-1 / ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas; Int J cancer. 2010, 127(11) :2554-68): to regulate leukocyte migration (Berahovich RD et al.; Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels; Immunology. 2014, 141(1):111-22): to reduce clinical scores of rheumatoid arthritis in mice with collagen-induced arthritis (Watanabe K et al.; Pathogenic role of CXCR7 in rheumatoid arthritis; Arthritis Rheum. 2010, 62(11):3211-20): to reduce the clinical severity of experimental autoimmune encephalomyelitis that influences leukocyte infiltration and microglial chemotaxis (Cruz-Orengo L et al.; CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity; J Neuroinflammation. 2011, 6; 8:170; Bao J et al.; CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis; Biochem Biophys Res Commun. 2016 Jan 1; 469(1):1-7): to reduce the disease activity of • . IF-2019-79621737-APN-ANP#INPI Page 7 of 351 experimental autoimmune nephritis (Brunn A et al.; Differential effects of CXCR4CXCL12- and CXCR7-CXCL12-mediated immune reactions on murine P0106-125 -induced experimental autoimmune neuritis; Neuropathol Appl Neurobiol. 2013, 39(7)772- 87); to promote remyelination in a cuprizone model, which promotes the maturation of oligodendroglial cells (Williams JL et al.; Targeting CXCR7 / ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system; J Exp Med. 2014, 5; 211(5)791-9; Gottle P et al.; Activation of CXCR7 receptor promotes oligodendroglial cell maturation; to attenuate pulmonary hypertension induced by chronic hypoxia (Sartina E et al.; Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension; Pediatr Res. 2012, 71 (6):682-8); to induce anxiolytic-like behavior (Ikeda Y et al.; Modulation of circadian glucocorticoid oscillation via adrenal opioid-CXCR7 signaling alters emotional behavior; Cell. 2013, 5; 155(6):1323—36); to activate an angiocrine response to initiate liver regeneration and resolve fibrosis, to promote alveolar repair and reduce lung fibrosis (Cao Z et al.; Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis; Nat Med. 2016,; 22(2): 154-62); to limit macrophage migration that reduces atherosclerosis (Zhao D et al.; Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor and; Biochemistry. 2015, 17; 54(45):6806-14: Ma W. et al.; Atorvastatin inhibits CXCR7 induction to reduce macrophage migration. Biochem Pharmacol. 2014, 1; 89(1):99-108): and to improve the beneficial effects of mesenchymal stem cell-based therapies for renal ischemia. reperfusion injury (Liu H et al.; The role of SDF-1-CXCR4 / CXCR7 axis in the therapeutic effects of hypoxiapreconditioned mesenchymal stem cells for renal ischemia / reperfusion injury; Pios One. 2012, 7(4):e34608). IF-2019-79621737-APN-ANP#INPI Page 8 of 351 Furthermore, it has been proposed that CXCR7 is involved in cardiac stem cell migration (Chen D et al.; Crosstalk between SDF-1 / CXCR4 and SDF-1 / CXCR7 in cardiac stem cell migration; Sci Rep. 2015, 5:16813 ), chronic allograft vasculopathy (Thomas MN et a ; SDF-1 / CXCR4 / CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy; Transpl Int. 2015, 28(12):1426-35), inflammatory bowel disease (Werner L et al.; Involvement of CXCR4 / CXCR7 / CXCL12 Interactions in Inflammatory bowel disease; Theranostics. 2013, 3(1):40-6), chronic rhinosinusitis (Patadia M et al.; Evaluation of the presence of B- cell attractant chemokines in chronic rhinosinusitis; Am J Rhinol Allergy. 2010, 24(1):11-6), human pulmonary vascular diseases (Rafii S et al.; Plateletderived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration ; Nat Cell Biol. 2015, 17(2):123-36) and development of severe preeclampsia (Lu J et al.; CXCR4, CXCR7, and CXCL12 are associated with trophoblastic cells apoptosis and linked to pathophysiology of severe preeclampsia.; Exp Mol Pathol. 2016, 100(1):184-91). In addition to the diseases mentioned above, CXCR7 modulators may be useful in the treatment of renal allograft rejection, systemic lupus erythematosus, osteoarthritis, pulmonary vascular diseases, acute renal failure, ischemia, chronic allograft rejection, acute coronary syndrome, central nervous system injured; hyperlipidemia, HSC transplantation, cerebral ischemia, hypertension, pulmonary hypertension, hemolytic uremic syndrome associated with Shiga toxin, HIV / AIDS; acute lung injury, asthma, cirrhosis, stress-related disorders, proliferative diabetic retinopathy, West Nile virus encephalitis, vascular injury and pulmonary fibrosis. From a mechanistic point of view, recent studies have provided increasing evidence that activation of the CXCL12 pathway is a potential mechanism of tumor resistance to both conventional therapies and biological agents through multiple complementary actions: (i) IF-2019-79621737-APN-ANP#INPI 9 Page 9 of 351 by directly promoting the survival, invasion of cancer cells and the phenotype of cancer stem and / or tumor-initiating cells; (li) by recruiting distal stroma (i.e., myeloid bone marrow-derived cells) to facilitate immune suppression, tumor recurrence and metastasis; and (iii) by promoting angiogenesis directly or in a paracrine manner (Duda DG et al: CXCL12 (SDF1alpha)-CXCR4 / CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?; Clin Cancer Res; 2011, 17(8 ); recently described preclinical and clinical data supporting the potential use of anti-CXCL12 agents that include CXCR7 modulators as sensitizers to currently available therapies in cancer treatments. Furthermore, increasing CXCR7 expression in the endothelium appears to be critical for. inflammatory infiltration in autoimmune diseases. CXCL12 and CXCL11 are key ligands in the inflammatory immune response: (i) through action on cell migration, cell adhesion and cell survival (Kumar R et al.; CXCR7 mediated Gia independent activation. of ERK and Akt promotes cell survival and chemotaxis in T cells; Cell Immunol 2012, 272(2):230-41); W. et al.; Atorvastatin inhibits CXCR7 induction to reduce macrophage migration. Biochem Pharmacol. 2014, 1; 89(1):99-108), CD4+ T cells / Zohar Y et al.; CXCL11dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis; J Clin Invest. 2014, 124(5):2009-22), oligodendrocyte progenitors (Gottle P et al.; Activation of CXCR7 receptor promotes oligodendroglial cell maturation; Ann Neurol. 2010, 68(6):915-24): (H) by participating in nesting processes (Lewellis SW et al.; Precise SDF1-mediated cell guidance is achieved through ligand clearance and microRNA-mediated decay. J Cell Biol. 2013, 4; 200(3):337-55). Consequently, the targeting of CXCR7 and therefore the regulation of IF-2019-79621737-APN-ANP#INPI 10 Page 10 of 351 level of their ligands may play a decisive role in the pathogenesis of a wide variety of autoimmune and inflammatory diseases. SanchezMartin et al (Sanchez-Martin et al.; CXCR7 impact on CXCL12 biology and disease; Trends Mol Med. 2013, 19(1):12-22) recently discussed the deregulation of CXCR7 in disease and highlighted the fact that this receptor is an attractive therapeutic target for the treatment of autoimmune diseases and inflammation. Thus, the present CXCR7 antagonists may be useful, alone or in combination with one or more therapeutic agents and / or chemotherapy and / or radiotherapy and / or immunotherapy; in particular in combination with chemotherapy, radiotherapy, EGFR inhibitors, aromatase inhibitors, immunotherapy such as especially PD1 and / or PDL1 blockade and / or CTLA4 blockade or other targeted therapies; for the prevention / prophylaxis or treatment of cancers such as carcinomas; adenocarcinomas; neuroendocrine tumors; skin cancer including melanoma and metastatic melanoma; lung cancer including non-small cell lung cancer; metastatic cancer; lung metastasis; bladder cancer including urinary bladder cancer; urothelial cell carcinoma; renal carcinomas including renal cell carcinoma; metastatic renal cell carcinoma, metastatic renal clear cell carcinoma; gastrointestinal cancers including colon carcinoma, colorectal adenoma, colorectal adenocarcinoma, colorectal cancer, metastatic colorectal cancer, familial adenomatous polyposis (FAP), esophageal cancer, oral squamous cell carcinoma; gastric cancer, gallbladder cancer, cholangiocarcinoma, hepatocellular carcinoma; pancreatic cancer such as pancreatic adenocarcinoma or pancreatic ductal carcinoma (adeno); endometrial cancer; ovarian cancer; cervical cancer; neuroblastoma; prostate cancer including castration-resistant prostate cancer; brain tumors including brain metastases, gliomas IF-2019-79621737-APN-ANP#INPI . eleven Page 11 of 351 malignant, glioblastoma multiforme, medulloblastoma, meningiomas; breast cancer including triple negative breast carcinoma; oral tumors; nasopharyngeal tumors; chest cancer; Head and neck cancer; leukemias including acute myeloid leukemia, adult t-cell leukemia; thyroid carcinoma including papillary thyroid carcinoma; choriocarcinoma; Ewing sarcoma; osteosarcoma; rhabdomyosarcoma; Kaposi sarcoma; lymphoma including Burkitt lymphoma, Hodgkin lymphoma, MALT lymphoma; primary intraocular B-cell lymphoma, multiple myelomas, and virus-induced tumors; and diseases involving CXCR7 and / or CXCL12 and / or CXCL11-mediated metastasis, chemotaxis, cell adhesion, trans-endothelial migration, proliferation and / or cell survival. Specifically, the potential role of CXCR7 in brain tumors, malignant glioma, and glioblastoma multiforme is known from the literature. Modulators of the CXCL12 pathway including CXCR7 modulators have been mentioned as potential therapeutic agents to treat brain cancer in combination with chemotherapeutic agents or radiotherapy. For example, (Hattermann et al.; The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects; Cancer research 2010, 70 (8):3299-3308) show that stimulation with CXCL12 prevented camptothecin-induced apoptosis. and temozolomide and that a CXCR7 antagonist reduced the antiapoptotic effect of CXCL12 The authors concluded that CXCR7 is a functional receptor for CXCL12 in astrocytomas / glioblastomas and mediates resistance to drug-induced apoptosis. Furthermore, Hattermann et al (Hattermann et al.; CXCL12 mediates apoptosis resistance in rat C6 glioma cells; Oncol Rep. 2012, 27: 1348-1352) teach that CXCL12 abrogates the antiproliferative effect of temozolomide. The authors also show that this effect can be almost completely abrogated by a specific CXCR7 antagonist, indicating that the anti-apoptotic effect of CXCL12 is mainly mediated through IF-2019-79621737-APN-ANP#INPI Page 12 of 351 CXCR7. Ebsworth et al (Ebsworth et al.; Neuro Oncol (2013) 15 (suppl 3):iii37— ¡¡61. Ebsworth et al. ¡37 ¡¡61 ET-023) show that a CXCR7 antagonist significantly prolongs survival when administered in combination with radiotherapy in a rat model of glioblastoma. This finding is supported by other studies (e.g., Ebsworth K et. al.; The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of glioblastoma; and rats; Br J Cancer. 2014, 110(5):1179-88) revealing that in vivo inhibition of CXCR7 in concert with radiotherapy produces a significant extension of survival time in another rat model of glioblastoma. SC et al (Liu SC et al.; Neuro-Oncology 2014; 16(1):21-28) teach that inhibition of CXCL12 after irradiation inhibits tumor recurrence in indigenous brain tumors in rats. (Liu SC et al.; Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats; Neuro Oncol. 2013, 16(1):21-8) also teach that inhibition of CXCL12 in a metastasis model brain after irradiation produced marked inhibition of tumor growth and prolongation of lifespan compared with irradiation alone. Calatozzolo C et al (Calatozzolo C et al.; Expression of the new CXCL12 receptor, CXCR7, in gliomas; Cancer Biol Ther. 2011, 11(2), 1-12) show in in vitro experiments that CXCR7 antagonists showed a Complete inhibition of glioma proliferation. Specifically, a role for CXCR7 in pancreatic tumors has been described in the literature. Shakir et al. (Shakir M et al.; The chemokine receptors CXCR4 / CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12 / high mobility group box 1 in pancreatic cancer growth and development: finding flow; Pancreas. 2015, 44(4):528-34) observed that CXCR4 and CXCR7, after interaction with CXCL12, activate the proteins IF-2019-79621737-APN-ANP#INPI Page 13 of 351 downstream kinases that promote more aggressive behavior. Furthermore, the expression of CXCR7 and CXCI12 correlates with the histological grades of the tumors (Liu Z et al.; Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma. World J Surg Oncol. 2014, 12: 348). These findings were confirmed by Heinrich EL et al. (Heinrich EL et al.; Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells; J Transí Med. 2012, 10:68). Therefore, CXCR7 modulators may be useful in the treatment of pancreatic cancers. CXCR7 modulators may also be useful in the treatment of papillary thyroid carcinoma. Liu Z et al. (Liu Z et al.; The involvement of GXCR7 in modulating the progression of papillary thyroid carcinoma; J Surg Res. .2014, 191(2):379-88) described that CXCR7 messenger RNA and protein levels increased markedly in papillary thyroid carcinoma and was correlated with tumor progression. CXCR7 can regulate proliferation, cell cycle, apoptosis, invasion and the expression of cell cycle regulatory proteins involved in the S-G2 phase transition. Inactivation of CXCR7 in papillary thyroid carcinoma cells suppressed cell proliferation and invasion, induced S-phase arrest, and promoted apoptosis. Zhang H et al further demonstrated that CXCR7 affects the growth of papillary thyroid carcinoma cells and participates in the tumorigenesis of papillary thyroid carcinoma, probably through the regulation of angiogenesis by VEGF or proangiogenic IL-8. (Zhang H et al.; The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo; Tumor Biol. 2016, 37(2):2415-23). The expression and function of CXCR7 axis in thyroid cancer was confirmed by Zhu X et al. (by Zhu IF-2019-79621737-APN-ANP#INPI Page 14 of 351 CXCR7 modulators may also be useful in the treatment of lung cancer: using a combination of RNA interference overexpression. (Miao Z et al.; CXCR7 (RDCi) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. PNAS. 2007, 104(40):15735-40) established that CXCR7 promotes the growth of tumors formed from breast and lung cancer cells and improves experimental lung metastases. Iwakiri S et al. (Iwakiri S et al.; Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer; Cancer. 2009, 115(11):2580-93) observed that higher expression of CXCR7 is linked to early and metastatic recurrence in pathological stage I non-small cell lung cancer. CXCR7 modulators may also be useful in the treatment of hepatocellular carcinoma: CXCR7 expression has been reported to be increased in hepatocellular carcinoma tissues. Knockdown of CXCR7 expression significantly inhibited hepatocellular carcinoma cell invasion, adhesion, and angiogenesis. Furthermore, downregulation of CXCR7 expression leads to reduced tumor growth in a xenograft model of hepatocellular carcinoma (Zheng K et al.; Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells ; J Exp Clin Cancer Res. 2010, 29:31). Monnier J et al. also observed in a cohort of 408 human hepatocellular carcinoma, that CXCR7 was significantly higher in tumors compared to normal liver controls (Monnier J et al.; CXCR7 is up-regulated ¡in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells; Eur J Cancer. 2012, 48(1):138— 48). Immunohistochemical staining on human hepatocellular carcinoma sections confirmed that CXCR7 expression was much higher in cancer tissues. Using CXCR7 RNAi in a cell line IF-2019-79621737-APN-ANP#INPI Page 15 of 351 hepatocellular carcinoma, TC et al observed that CXCR7 downregulated tumor growth and the number of lung metastases in nude mice. Furthermore, tissue microarrays showed that HCCs with high expression of CXCR7 were prone to metastasis to the lungs. Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential ; Exp Ther Med. 2012, 3(1):117-123). CXCR7 modulators may also be useful in the treatment of metastatic colon cancer: Guillemot et al. (Guillemot et al.; CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver; Br J Cancer. 2012, 107(12):1944-9) observed that after injection of colorectal cancer cells, treated mice with CXCR7 antagonists exhibited a significant reduction in lung metastasis. Wang HX et al studied the expression of CXCR7 in a colon cancer sample and observed that CXCR7 levels were significantly higher in colon tumors compared with those in normal colon tissue. Furthermore, lymph node metastatic colon tumors showed significantly higher expression of CXCR7 compared to non-metastatic tumors (Wang HX et al.; Role of CXC chemokine receptor type 7 in carcinogenesis and lymph node metastasis of colon cancer; Mol Clin Oncol . 2015, 3(6):1229-1232). CXCR7 modulators may also be useful in the treatment of head and neck cancer: a nanoantibody directed against CXCR7 reduced head and neck cancer growth in vivo Maussang D et al.; Llamaderived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduces head and neck cancer cell growth in vivo; J biol Chern. 2013, 288(41):29562-72). In addition, the same authors analyzed a wide ' IF-2019-79621737-APN-ANP#INPI Page 16 of 351 variety of tumor biopsies and showed high expression of CXCR7 in head and neck cancer. CXCR7 is also reported to be expressed in brain metastases (Salmaggi et al.; CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther.2009, 8:17, 1-7). The authors concluded that the CXCL12 / CXCR4 / CXCR7 pathway could be an interesting target for additional research investigating the role of these molecules in the invasion and proliferation of metastatic cells. Specifically, the impact of CXCR7. on inflammatory demyelinating diseases is known from the literature. CXCR7 is expressed in diverse regions throughout the adult mouse brain and its expression is upregulated in the mouse model for multiple sclerosis (Banisadr G et al.; Pattern of CXCR7 Gene Expression in Mouse Brain Under Normal and Inflammatory Conditions ; J Neuroimmune Pharmacol. 2016 Mar. 11(1):26-35. Altered expression patterns of CXCL12 at the blood-brain barrier (BBB) ​​are involved in multiple sclerosis and correlate with disease severity (McCandless EE et al.; Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis; Am J Pathol. 2008, 172(3):799-808). CXCR7 antagonism has been shown to be effective in experimental autoimmune encephalomyelitis in mice. These recent studies strongly implicate CXCR7 as a disease-modifying molecule in multiple sclerosis through complementary mechanisms: (i) by facilitating leukocyte entry into the perivascular space through redistribution of CXCL12 to the BBB (Cross- Orengo L et al.; CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity; abluminal CXCL12 abundance during autoimmunity; J Exp Med. IF-2019-79621737-APN-ANP#INPI Page 17 of 351 2011, 14; 208(2):327-39) and regulate CXCR4-mediated activation (Hartmann TN et al.; A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokinetriggered motility of human T lymphocytes and CD34+ cells ; J Leukoc Biol. 2008,; 84(4):1130-40) (i) by direct effect on microglial chemotaxis (Bao J et al.; CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis; Biochem Biophys Res Coitimun. 2016 Jan 1; 469(1):1-7) (iii) by promoting remyelination through increased levels of CXCL12 that enhance CXCR4-mediated oligodendrocyte progenitor cell maturation (Williams JL). et al., Targeting CXCR7 / ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system, CXCR7 receptor activation promotes oligodendroglial cell maturation, Ann Neurol., 2010, 68 (6): 915 - 24) . Consequently, CXCR7 antagonism could therapeutically prevent inflammation and enhance myelin repair in the demyelinated adult CNS. Furthermore, CXCR7 antagonism has been shown to be effective in a mouse model for Guillain—Barré syndrome. Indeed, Brunn et al (Brunn A et al.; Differential effects of CXCR4-CXCL12- and GXCR7CXCL12-mediated immune reactions on murine P0106-125 -induced experimental autoimmune neuritis; Neuropathol Appl Neurobiol. 2013, 39(7):772- 87) teach that antagonization of CXCR7 reduced disease prevalence to 75% and impressively reduced disease activity in a murine model of experimental autoimmune neuritis. The authors conclude that the CXCR7 / CXCL12 interaction is an aaceous control for pathogenic cells. Specifically, the potential role of CXCR7 in rheumatoid arthritis is known from the literature. CXCR7 is reported to be expressed in IF-2019-79621737-APN-ANP#INPI Page 18 of 351 endothelial cells in the synovium. High levels of CXCL12 and CXCL11 mRNA were also found in the synovial tissue of patients with rheumatoid arthritis (Ueno et al.; The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis; Rheumatol Int. 2005, 25(5 ):361-7). CXCL12 was shown to play a central role in the accumulation of CD4 + T cells and monocytes in the synovium ((Nanki T et al.; Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4 + T cell accumulation in rheumatoid arthritis synovium; J Immunol. 2000, 165(11):6590-8; Mar; 46(3):824-36). Furthermore, CXCL12 participates in the process of rheumatoid arthritis through its proangiogenic functions and its action in the recruitment and differentiation of osteoclasts. CXCL12 pathway that includes CXCR7 modulators as possible therapeutic agents to treat rheumatoid arthritis Villalvilla et al (Villalvilla A et al.; SDF-1 signaling: a promising target in rheumatic diseases; Expert Opin Ther Targets. 2014, 18(9): 1077-87) recently discussed preclinical and clinical data supporting the potential use of anti-CXCL12 agents in rheumatoid arthritis treatments. Watanabe et al (Watanabe K et al.; Pathogenic role of CXCR7 in rheumatoid arthritis; Arthritis Rheum. 2010, 62(11):3211-20), teach that a CXCR7 inhibitor prophylactically and therapeutically reduces the clinical signs of the disease and angiogenesis in a mouse collagen-induced arthritis model. Specifically, CXCR7 is implicated in several inflammatory disorders. For example, CXCL12 and CXCL11 are involved in chronic pulmonary inflammatory processes (Petty JM et al.; Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury; J Immunol. 2007, 178(12):8148- 57; Porter JC et al. Page 19 of 351 localization of epithelial CXCL11 in chronic obstructive pulmonary disease and mechanisms of T cell egression; J Immunol. 2008, 180(3):1866-77). CXCL12 was found to be upregulated in the lung in human and animal models (Phillips RJ et al.; Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis; J Clin Invest. 2004, 114(3):438-46 ). Anti-CXCL12 agents have been shown to attenuate lung inflammation and airway hyperactivity in asthma models (Gasparik V et al.; Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo; ACS Med Chern Lett. 2012 Jan 12; 3(1): 10-4; AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperactivity; 160(4):1353-60). Petty et al. (Petty JM et al.; Pulmonary stromalderived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J Immunol. 2007, 178(12):8148-57) show that blockade of CXCL12 attenuates late neutrophilia in the injury acute pulmonary in mice. Cao et al (Cao Z et al.; Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis; Nat Med. 2016,; 22(2):154-62) show that the CXCR7 modulator after injury lung promotes alveolar repair and reduces fibrosis in a mouse model of pulmonary fibrosis. CXCL12 and CXCL11 are also reported to be upregulated in inflammatory bowel diseases (Koelink PJ et al.; Targeting chemokine receptors in chronic inflammatory diseases: an extensive review; Pharmacol Ther. 2012, 133(1):1-18). CXCR7 was found to be upregulated in peripheral blood T cells in inflammatory bowel diseases (Werner L et al.; Reciprocal regulation of CXCR4 and CXCR7 in intestinal mucosal homeostasis and inflammatory bowel disease; J Leukoc Biol. 2011, 90(3) :583-90). The author postulates increased expression of CXCR7 in the peripheral blood of patients with inflammatory bowel diseases. IF-2019-79621737-APN-ANP#INPI Page 20 of 351 may promote increased influx of T cells to sites of mucosal inflammation (Werner L et al.; Involvement of CXCR4 / CXCR7 / CXCL12 Interactions in Inflammatory bowel disease; Theranostics. 2013, 3(1):40 -6). In mouse models for inflammatory bowel diseases, modulators of the CXCL12 pathway can decrease T cell infiltration and reduce tissue damage (Mikami S et al.; Blockade of CXCL12 / CXCR4 axis ameliorates murine experimental colitis; J Pharmacol Exp Then 2008, 327(2):383-92; Xia XM et al.; CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis; Elevated levels of CXCL12 and CXCL11 have been found in skin with lesional psoriasis (Chen SC et al.; Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions; Arch Dermatol Res. 2010, 302(2): 113 -23; Zgraggen S et al.; An important role of the SDF-1 / CXCR4 axis in chronic skin inflammation. PLoS One. 2014, 9(4):e93665). Zgraggen et al show that CXCL12 blockade improved the course of chronic skin inflammation in two different models of psoriasis-type skin inflammation. Several other autoimmune disorders such as systemic lupus erythematosus (SLE) present altered expression of CXCR7 / CXCR4 correlated with a CXCL12-promoted migration of SLE B cells (Biajoux V et al.; Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic Lupus erythematosus; J Transí Med. 2012, 18; Furthermore, CXCL12 was significantly upregulated in nephritic kidneys in multiple murine models of lupus. Wang et al. (Wang A et al.; CXCR4 / CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus; J Immunol. 2009, 182(7):4448-58) show that acting on the CXCL12 axis is a good therapeutic target in lupus , since a CXCR4 antagonist significantly improves the disease, prolonging survival and reducing nephritis and lymphoproliferation. IF-2019-79621737-APN-ANP#INPI . twenty-one Page 21 of 351 CXCR7 modulators may also be useful in the treatment of fibrosis: Cao Z et al (Cao Z. et al; Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat Med. 2016, 22(2) :154-62) demonstrated that administration of a CXCR7 modulator after lung injury promotes alveolar repair and reduces fibrosis. A role for CXCR7 in liver fibrosis was also described (Ding BS et al.; Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis; Nature. 2014, 505(7481):97-102). The biological properties of CXCR7 modulators also include, but are not limited to, any physiological functions and / or cellular functions bound and / or controlled by their ligands CXCL11, CXCL12, BAM22 and their related peptides. Therefore, CXCL12 depletion sensitizes cancer cells to chemotherapy in vivo and CXCL12 treatment blocks colon carcinoma metastasis (Duda et al.; CXCL12 (SDF1alpha)-CXCR4 / CXCR7 pathway inhibition,: an emerging sensitizer for anticancer therapies?; Clin. Cancer Res. 2011 17(8) 2074-2080; CXCR7 function as a scavenger for CXCL12 and CXCL11; CXCR7 is also a receptor for CXCL11 (aka small inducible cytokine subfamily b, member 11, scyb11, alias interferon gamma inducible protein 9, ip9, alias small inducible cytokine subfamily b, member 9b, scyb9b) and therefore activity modulators CXCR7 can also be used in indications with CXCL11-associated pathology (Rupertus K et al.; Interaction of the chemokines l-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer; Clin Exp Metastasis . 2014, 31(4):447-59; Zohar Y et al.; CXCL11-dependent induction of FOXP3negative regulatory T cells suppresses autoimmune encephalomyelitis; .; Increase of interferon-y inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy. Page 22 of 351 9). CXCR7 also functions as a receptor for the opioid peptide BAM22 and its related peptides (peptide E, peptides BAM12, BAM14, BAM18) and therefore modulators of CXCR7 activity can possibly also be used in indications with pathologies associated with opioid peptides ( Ikeda et al.; Modulation of circadian glucocorticoid oscillation via adrenal opioid-CXCR7 signaling alters emotional behavior Cell. CXCR7 has also been shown to function as a scavenger receptor for CXCI11 and CXCL12. Consequently, targeting CXCR7 has been shown to alter the local concentration of CXCI11 and CXCL12 leading to a deregulation of CXCI11 and CXCL12 concentration gradients. Certain isoxazole compounds that are SMYD protein blockers are known from WO 2016 / 040515, where in the compounds of WO2016 / 040515, the isoxazole ring is substituted with certain (cyclo-)alkyl substituents instead of the present phenyl substituent Ar2 ; and the piperidine moiety does not carry a carboxamide substituent R1-CO- Certain pyrrole compounds are known as antibacterial agents from WO 2006 / 087543, WO 2005 / 026149 and J. Med. Chem. 2014, 57 (14), 6060 - 6082. Cyclic diamines as Factor Xa inhibitors are known from WO 2005 / 032490. WO 2004 / 050024 describes pyrrolidine compounds as chemokine receptor modulators. The present invention provides new trans-3,4-disubstituted piperidine derivatives of formula (I) that are modulators of the CXCR7 receptor, that is, they act as antagonists of the CXCR7 receptor and are useful for the prevention or treatment of diseases that respond to activation of CXCL12 receptors and / or CXCL11 receptors, especially cancer. In the prevention or treatment of cancers, IF-2019-79621737-APN-ANP#INPI Page 23 of 351 compounds of formula (I) may also be used in combination with one or more chemotherapeutic agents and / or radiotherapy and / or targeted therapy. 1) A first aspect of the invention relates to new piperidine derivatives of the formula (l). EITHER N Yo R2 Formula (I). where the two substituents of the piperidine ring: R1-CO- and -NH-CO-AH-Ar2, are in a relative trans configuration (i.e., the relative configuration of the two chiral carbon atoms in the 3 and 4 position of the piperidine ring is (3R*,4R*)); Ar1 represents a 5-membered heteroarylene group (especially a 5-membered heteroarylene containing one to a maximum of three heteroatoms, each independently selected from oxygen, nitrogen and sulfur; notably, oxazole diyl, isoxazole diyl, oxadiazol-diyl, triazole-diyl, isothiazol-diyl or thiadiazol-diyl), where the group -NH-CO- and Ar2 are linked in a meta arrangement with ring atoms of Ar1; wherein said 5-membered heteroarylene is unsubstituted or monosubstituted with RAr1; where RAr1 represents (C1-4)alkyl, (C1-4)alkoxy, halogen, fluoroalkyl (Ci-3) or fluoroalkoxy (C-i-3) (especially said 5-membered heteroarylene is unsubstituted); Ar2 represents phenyl (preferred) or 6-membered heteroaryl; wherein said phenyl or 6-membered heteroaryl is independently mono-, di- or trisubstituted, wherein the substituents are independently selected from fluoro, chloro, methyl, cyano, methoxy or fluoroalkyl (Ci). IF-2019-79621737-APN-ANP#INPI Page 24 of 351 [notably, one or two of said substituents are independently selected from fluoro, chloro and methyl and the others, if present, are fluoro; especially Ar2 represents phenyl which is mono-, di- or trisubstituted, wherein the substituents are, independently, fluoro or chloro; in particular Ar2 represents phenyl which is mono-, di- or trisubstituted with fluoro); R1represents RN1RN2N-, where • RN1represents > hydrogen; > (C^)alkyl (especially methyl, ethyl, isopropyl, sobutyl, tertbutyl, 1,2,2-trimethylpropyl); > alkyl (Ci-β) which is monosubstituted with hydroxy; alkoxy (Ci_3) (especially methoxy, ethoxy); 2-hydroxy-ethoxy; -CO-NH2! -SO2-alkyl (C1-3) (especially methanesulfonyl); cyano; fluoroalkoxy (Ci_3) (especially trifluoromethoxy); -NRN3RN4, where RN3and RN4 independently represent hydrogen or (C^)alkyl (especially NRN3RN4 represents dimethylamino); (especially where such RN1 group is monosubstituted, alkyl (ΟΊ_6) is 2-hydroxy-ethyl, 2-hydroxy-1-methyl-ethyl, 2-hydroxy-1,1-dimethyl-ethyl, . IF-2019-79621737-APN- ANP#INPI . Page 25 of 351 2-methoxy-ethyl, 3-methoxy-propyl, 2-ethoxy-ethyl, 2-ethoxy-1-methylethyl, 2-methoxy-1,1-dimethyl-ethyl, 3-methoxy-1,1-dimethyl-propyl, 2-(2hydroxy-ethoxy)-ethyl, carbamoyl-methyl, 2-methanesulfonyl-1,1-dimethyl-ethyl, 1-cyano-1-methyl-ethyl, 2-dimethylamino-ethyl, 2-trifluoromethoxyethyl); > alkynyl (C2-e) (especially 1-methyl-prop-2-ynyl); > fluoroalkyl (C2-5) (especially 2-fluoro-ethyl, 2,2-difluoro-ethyl, 2-fluoro-1-methyl-ethyl, 2-fluoro-1,1-dimethyl-ethyl, 2,2-difluoro- 1-methyl-ethyl, 3,3,3-trifluoro-1,1-dimethyl-propyl); > alkoxy (C-ι^ί) (especially methoxy); > 2—(2—oxo—pyrrolidin—1—yl)—ethyl; > a group -L1-Cy1; where L1 represents a direct bond, -(C1-3)alkylene- or (C3_5)cycloalkylene-; and Cy1 represents cycloalkyl (Cs-e); wherein said (C3-6)cycloalkyl optionally contains a ring oxygen atom; wherein said cycloalkyl (Cs-e) is independently unsubstituted; or monosubstituted with fluoro, methyl, hydroxy, CO-alkoxy (Ci-4) or cyano; or disubstituted with fluoro or trisubstituted with methyl and two fluoro; (especially such group -L1-Cy1es cyclopropyl, cyclopentyl, 1-methyl-cyclopropyl, 1-methyl-cyclobutyl, 1-cyclopropyl-cyclopropan-1-yl, 1-cyclobutyl-ethyl, 3-methyl-tetrahydrofuran-3-yl, tetrahydrofuran —3—I—methyl, tetrahydrofuran-2-yl-methyl, 1—tetrahydrofuran—2—yl—ethyl, oxetan-3-yl-methyl, 3,3-difluoro—1—methyl-cyclobutyl, 1(ethoxycarbonyl) -cyclopropyl or 1-cyano-cyclobutyl); ' IF-2019-79621737-APN-ANP#INPI Page 26 of 351 > a group -L2-Ar3, where L2 represents a direct link; -alkylene (Ci^)-¡ *cycloalkylene (C3_5)-alkylene (C0-2)- where said cycloalkylene (C3-5) optionally contains a ring oxygen atom, where the asterisk indicates the bond with which Ar3 is United; '-alkylene (Ci-2)-cycloalkylene (63-5) wherein said cycloalkylene (63-5) optionally contains a ring oxygen atom, where the asterisk indicates the bond with which Ar3 is attached; o -alkylene (Ci_3)—which is monosubstituted with hydroxy trifluoromethyl or -CO-alkoxy (C^); and Ar3 represents phenyl or 5- or 6-membered heteroaryl; wherein said independently 5- or 6-membered phenyl or heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci_4), alkoxy (Ci^), halogen, hydroxy, fluoroalkyl (C^) or fluoroalkoxy (61-3); wherein, in case Ar3 represents 6-membered heteroaryl which is pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective N-oxide (for the avoidance of doubt, the term 6-membered heteroaryl is understood to comprise the groups 1-oxy-pyridinyl and 1-oxy. (especially such group -L2-Ar3 is phenyl, benzyl, 1-phenyl-ethyl, 2-phenyl-ethyl, 2-(2-chloro-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 2-( 2-methyl-phenyl)-ethyl, 2-(3-methyl-phenyl)-ethyl, 2-(4-methyl-phenyl)-ethyl, 2-(2-methoxy-phenyl)-ethyl, 2-phenyl-propyl, 2- hydroxy-1-phenyl-ethyl, 2-, IF-2019-79621737-APN-ANP#INPI Page 27 of 351 hydroxy—2—phenyl—ethyl, 2—phenyl—cyclopropyl; or 1-(3-bromo-phenyl)-ethyl, 1-phenyl-cyclopropyl, 1-phenyl-cyclobutyl, 2-phenyl-cyclobutyl, 1-(3-chloro-phenyl)-cyclopropyl, 1-(4-fluoro-phenyl) —cyclopropyl, 1-(3-fluorophenyl)—cyclopropyl, 1—(2-fluoro-phenyl)—cyclopropyl, 1—(2-methyl-phenyl)—cyclopropyl, 1—(2-hydroxy-phenyl)—cyclopropyl, 1 -(2-methoxy-phenyl)-ethyl, 2-methyl-2-(2-chloro-phenyl)-propyl, 1-(4-chloro-phenyl)-cyclopropyl-methyl, 3-(3-chloro-phenyl) -oxetan-3-yl, 3-(4-fluoro-phenyl)-oxetan-3-yl, 3-(phenyl)-oxetan-3-yl-methyl, 3-(benzyl)-oxetan-3-yl, 1-( 2-methoxy-phenyl)-cyclopropyl, 1-(3-methoxy-phenyl)-cyclopropyl, 1-(2-trifluoromethyl-phenyl)-cyclopropyl, 2-ethoxy-2-oxo-1-phenylethyl; either 4,5-dimethyl-thiazol-2-yl, 1 H-imidazol-4-yl-methyl, thiazol-2-yl-methyl, 4-methyl-thiazol-5-yl-methyl, 4-methyl-thiazol-2 —yl-methyl, 5-methyl-thiazol- 2-yl-methyl, 2-methyl-thiazol-4-yl-methyl, oxazol-5-yl-methyl, 1-(2Hpyrazol-3-yl)-ethyl, ( 1—methyl—1 H—pyrazole—3—¡I)—methyl, 1- ([1,2,4]oxadiazol—3—yl)—ethyl, 1 —(isoxazol—3—yl)—ethyl, 3- methylisoxazol-5-yl-methyl, 5-methyl-isoxazol-3-yl-methyl, 1-(1 H[1,2,4]triazole—3—I)—ethyl, (1,5—dimethyl—1 H—pyrazol—3—yl)—methyl, (2,5—dimethyl—2H—pyrazol—3—yl)—methyl, (3—ethyl—([1,2,4]oxadiazol—5—yl)—methyl , 1—(5—methyl—([1,3,4]oxad iazol—2—¡I)—ethyl, 1 —methyl—1 —(1 —methyl— 1 H—pyrazol—4—yl)—ethyl, 1-methyl-1-(5-methyl-[1,2,4]oxadiazol-3-yl)-ethyl or 1-(4-methyl-thiazol-2-I)-cyclobutyl; , pindin-2-I-methyl, pyridin-3-yl-methyl, pyridin-4-yl-methyl, pyrimidin-2-yl-methyl, pyrimidin-4-yl-methyl, pyrazin-2-yl-methyl, 1—(pyridin—2—yl)—ethyl, 1—(pyridin—3—yl)—ethyl, 2—(pyridin—2—I)—ethyl, 1—methyl—1—(pyridin—2—yl) —ethyl, 1—(pyrazin—2—yl)-ethyl, 1(pyrimidin—4—yl)—ethyl, 1—(5-fluoro—pyrimidin- 2-yl)-ethyl, 1-(3-fluoropyridin—2 —yl)—ethyl, 1—(5—fluoro—pyridin—2—yl)—ethyl, 1—(6—methyl—pyridin—2—yl)—ethyl, 2—hydroxy—1—(pyridin—2—yl )—ethyl, 1—(1—oxy—pyridin—2—yl)—ethyl, 1—(pyridin—2—yl)—cyclopropyl, 1 —(pyridin-4—yl)—cyclopropyl, 1IF-2019-79621737- APN-ANP#INPI Page 28 of 351 (pyrazin-2-yl)-cyclopropyl, 1—(pyridazin—3-¡I)-cyclopropyl, 1(pyrimidin—2—¡I)—cyclopropyl, 1—(5—fluoro—pyridin—2— I)—cyclopropyl, 1(3,5—difluoro—pyridin—2—yl)—ethyl, 2,2,2—trifluoro—1—(pyridin—2—yl)—ethyl, 1 -(4,6- dimethyl-pyrimidin-2-yl)-cyclopropyl; or (6—methyl—pyridin—2—yl)—methyl, 1—(pyrimidin—2—¡I)—ethyl, 1—methyl—1—(pyrimidin—2—¡I)—ethyl, 1(pyrimidin—4 —yl)—cyclopropyl, 2—(pyrimidin—2—yl)—cyclobutyl, 2(pyrimidin—2—yl)—cyclopentyl, 1—(1—oxy—pyrimidin—2—yl)—cyclopropyl, 1(3—fluoro —pyridin—2—yl)—cyclopropyl, [1-(pyridin-2-yl)—cyclopropyl]—methyl, 1—(pyridin—2—I)—cyclobutyl, 1—(1—oxy—pyridin—2— I)—cyclopropyl, 2—methyl—2—(pyridin—2—yl)—propyl, 2—methyl—2—(3—methyl—pyridin—2—yl)—propyl); and RN2 represents, independently, hydrogen, (Ci~4) alkyl (especially methyl, ethyl, isopropyl) or (C2-3) fluoroalkyl (especially 2-fluoroethyl); • o RN1 and RN2 together with the nitrogen atom to which they are attached form a 4 to 6 membered ring selected from > azetidinyl, pyrrolidinyl or piperidinyl; each one, independently, not substituted; or monosubstituted with fluoro, methyl or hydroxy; or disubstituted with fluoro; or monosubstituted with Ar4, where Ar4 represents phenyl or 5- or 6-membered heteroaryl (especially pyridinyl); wherein said 5- or 6-membered phenyl or heteroaryl is, independently, (especially) unsubstituted or mono- or disubstituted; where the substituents are selected, IF-2019-79621737-APN-ANP#INPI Page 29 of 351 independently, of alkyl (Ci_4), alkoxy (C1-4), halogen, fluoroalkyl (C1-3) or fluoroalkoxy (Ci-s); or > morpholinyl; (especially such cyclic group RN1RN2N- is azetidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 3-fluoro-azetidin-1-yl, 3,3-difluoro-azetidin-1-yl , 3-hydroxy-pyrrolidin-1-yl, 3-phenyl-pyrrolidin-1-yl, 3-(pyrrolidin-2-yl)-pyrrolidin-1-yl); R2represents • hydrogen; • alkyl (Ci-e) (especially ethyl, isopropyl, isobutyl, tert-butyl, 2,2-dimethylpropyl, 3-methyl-butyl, 3,3-dimethylbutyl); • (C2-e) alkyl which is monosubstituted with (C1-3) alkoxy (especially methoxy) or hydroxy • (especially 2-hydroxyethyl, 2-methoxy-ethyl, 2-hydroxy-1-methyl-propyl); • alkenyl (C3_5) (especially allyl); • cyano-methyl; • fluoroalkyl (C2-3) (especially 3-fluoro-propyl); • cycloalkyl (C3_8)-alkyl (C0-3); wherein the cycloalkyl (C3-8) is unsubstituted or is mono- or disubstituted wherein the substituents are independently selected from alkyl (Ci_3) (especially methyl), fluoro, hydroxy, hydroxy-alkyl (Ci_3) (especially hydroxymethyl), alkoxy (Ci_3) (especially methoxy) or fluoroalkyl (Ci_3) (especially difluoromethyl); (especially cyclobutyl, 2-methylcyclobutyl, 2,2-dimethylcyclobutyl, 3,3-dimethylcyclobutyl, cyclopentyl, cyclohexyl, spiro[2,4]hept-4-yl IF-2019-79621737-APN-ANP#lNPI Page 30 of 351 spiro[3,3]hept-2-yl, bicyclo[2,2,1]hept-2-yl, 2-methylcyclopentyl, 2(hydroxymethyl)-cyclopentyl, 3,3-dimethylcyclopentyl, 2-ethylcyclopentyl , 3,3dimethylcyclohexyl, 2-fluoro-cyclohexyl, 4-fluoro-cyclohexyl, 4,4-difluorocyclohexyl, 2-hydroxy-cyclohexyl, 2-methoxycyclohexyl, 3-methoxycyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 1—cyclopropyl—ethyl , (1-methyl-cyclopropyl)-methyl, (1-methyl-cyclobutyl)-methyl, 2-cyclopropyl-ethyl; or (1-fluoro-cyclopropyl)-methyl, spiro[2,3]hex-5-yl, bicyclo[3,1,0]hex-3-yl, 3,3-difluorocyclobutyl, (2,2-difluorocyclopropyl) —methyl, (3,3-difluorocyclobutyl)-methyl, (1-difluoromethyl-cyclopropyl)-methyl); • thietan-3-yl; • cycloalkenyl (C3_8)-alkyl (C-|_3) (especially cyclopenten-1-yl-methyl); or • Ar5-CH2-, where Ar5 represents phenyl or 5- or 6-membered heteroaryl (especially pyrrolyl), wherein the independently 5- or 6-membered phenyl or heteroaryl is unsubstituted or mono- or disubstituted, wherein substituents are independently selected from alkyl (Ci_ 4), alkoxy (Ci_4), halogen, fluoroalkyl (C^s) or fluoroalkoxy (Ci_3); [especially such Ars-CH2- group is benzyl wherein the phenyl ring of said benzyl is unsubstituted or mono- or disubstituted, wherein the substituents are independently selected from alkyl (Ci4), alkoxy (Ci^ ), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci_3); in particular benzyl, wherein the phenyl ring of said benzyl is unsubstituted or monosubstituted with halogen (especially benzyl, 2-chloro-benzyl, 2-fluoro-benzyl, 4-fluoro-benzyl)]; and R3 represents hydrogen or methyl (especially hydrogen). The compounds of formula (I) contain at least two stereogenic centers which are located in the 3 and 4 position of the piperidine residue. It is understood that the two substituents of the piperidine ring: R1-CO- and -NHIF-2019-79621737-APN-ANP#INPI Page 31 of 351 CO-AH-Ar2, are in a relative trans configuration (that is, the relative configuration of said two chiral carbon atoms in the 3 and 4 position of the piperidine ring is In this way, a compound of formula (I) f represents a compound of the formula (Ir) or a compound of the formula (Is) or any of their mixtures:. OO0, O, J1 NR) ^ / -ArJ,|zTs)Arr1 r1 R3Γ I RAr1 r3 IRAr1 II R2R Formula (lR) Formula (Is) The relative configuration of stereoisomers is thus denoted as follows: for example [2-(2-chloro-phenyl)-ethyl]-acid acid (3R*,4R*)-1-cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperídine-3-carboxylic acid called [2—(2—chloro—phenyl)—ethyl]—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -peridine-3-carboxylic acid, [2-(2-chloro-phenyl)-ethyl]-amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4) — difluoro-phenyl)-soxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid, or any mixture of these two enantiomers that include the racemate. Furthermore, the compounds of formulas (I), (lR) and (ls) may contain one or more other stereogenic or asymmetric centers, such as one or more additional asymmetric carbon atoms. The compounds of the formulas (I), (Ir) and (ls) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers can be separated in a manner known to one skilled in the art. IF-2019-79621737-APN-ANP#INPI Page 32 of 351 In case a particular compound (or genetic structure) is designated as an (R) or (S) enantiomer because it has an absolute (R) or (S) configuration, this designation is to be understood as referring to the respective compound. (or generic structure) in enantiomerically enriched, especially essentially pure, form. Likewise, in the case that a specific asymmetric center in a compound is designated as in (R) or (S) configuration or as in a certain relative configuration, this designation is to be understood as referring to the compound that is in enriched form. , especially essentially pure, with respect to the respective configuration of said asymmetric center. Similarly, the c / s or trans designations (or (R*,R*) designations) are to be understood as referring to the respective stereoisomer of the respective relative configuration in the enriched form, especially in essentially pure form. The term "enriched", when used in the context of stereoisomers, is to be understood in the context of the present invention as meaning that the respective stereoisomer is present in a ratio of at least 70:30, especially at least 90:10. (i.e. in a purity of at least 70% by weight, especially at least 90% by weight), with respect to the respective other stereoisomer / the totality of the other respective stereoisomers. The term "essentially pure", when used in the context of stereoisomers, is to be understood in the context of the present invention as meaning that the respective stereoisomer is present in a purity of at least 95% by weight, in particular of at least 99% by weight, with respect to the other respective stereoisomer / the entirety of the other respective stereoisomer. In some instances, compounds of formula (I) may contain tautomeric forms. These tautomeric forms are within the scope of the present invention. For example, in the event that those present IF-2019-79621737-APN-ANP#INPI Page 33 of 351 compounds contain heteroaromatic aromatic rings containing unsubstituted ring nitrogen atoms having a free valence such as imidazole—2,4—diyl or [1,2,4]—triazole—3,5—diyl, these rings may be present in tautomeric forms. For example, the group imidazole—2,4—diyl represents the tautomeric forms 1 / 7—imidazole—2,4—diyl and 3 / 7—imidazole—2,4—diyl; and the [1,2,4]triazole—3,5—diyl group represents the tautomeric forms 1H[1,2,4]triazole—3,5—diyl, 2 / 7—[1,2,4]triazole— 3,5—diyl and 4 / 7—[ 1,2,4]triazole—3,5—diyl. The present invention also includes isotopically labeled compounds of the formula (I), especially labeled with 2H (deuterium), compounds that are the same as the compounds of the formula (I) except that one or more atoms have been replaced by an atom that It has the same atomic number but a different atomic mass from the atomic mass usually found in nature. Isotopically labeled compounds of formula (I), especially labeled with 2H (deuterium) and their salts are within the scope of the present invention. Substitution of hydrogen with the heavier 2H (deuterium) isotope may lead to greater metabolic stability, resulting, for example, in longer in vivo half-life or lower dose requirements, or may lead to less inhibition of cytochrome enzymes. P450, resulting, for example, in a higher safety profile. In one embodiment of the invention, the compounds of formula (I) are not isotopically labeled or are labeled with only one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labeled. Isotopically labeled compounds of formula (I) can be prepared analogously to the methods described hereinafter, but using the appropriate isotopic variation of appropriate reagents or starting materials. The deuterated groups are named as follows: for example the group (1,1,2,2,2-ds-ethyl) calls the residue IF-2019-79621737-APN-ANP#INPI Page 34 of 351 In this patent application, a bond drawn as a dotted line shows the attachment point of the traced radical. For example, the radical drawn below \ is an isoxazol-3,5-diyl group. When the plural form is used for compounds, salts, pharmaceutical compositions, diseases, and the like, it is also intended to mean a simple compound, salt, or the like. Any reference to compounds of formula (I) is to be understood as referring to salts (and especially pharmaceutically acceptable salts) of such compounds, as appropriate and appropriate. . The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. These salts include addition salts of inorganic or organic acids and / or bases depending on the presence of basic and / or acidic groups in the object compound. For reference, see, for example, Handbook of Pharmaceutical Salts. Properties, Selection and Use.”, P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and Pharmaceutical Salts and Co-crystals”, Johan Wouters and Luc Quéré (Eds.), RSC Publishing, 2012. The definitions provided herein are intended to apply uniformly to the compounds of formula (I), as defined in any of the embodiments 1) to 19) and 27), and, mutatis mutandis, throughout the description and claims, unless the definition IF-2019-79621737-APN-ANP#INPI Page 35 of 351 expressly stated otherwise provide a broader or narrower definition. It is to be understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of one or all of the other terms as defined herein. . If not otherwise explicitly defined in the respective embodiment or claim, the groups defined herein are not substituted. The term "halogen" means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine, especially fluorine. The term "alkyl", used alone or in combination, refers to a saturated straight or branched chain hydrocarbon group containing one to six (especially one to four) carbon atoms. The expression "alkyl (Cx_y)" (x and y each being an integer), refers to an alkyl group as defined above, containing x to y carbon atoms. For example, an alkyl group (Ci-e) contains one to six carbon atoms. Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, 1,1-dimethyl-propyl, 2,2-dimethyl-propyl. , 3-methyl-butyl and 1,1,2-trimethyl-propyl. Particular examples of (C-|_6) alkyl groups as used for R2 are ethyl, isopropyl, 2,2-dimethyl-propyl, 3-methyl-butyl and 3,3-dimethyl-butyl. Particular examples of alkyl groups (Ci-e) as used for RN1 are methyl, ethyl, isopropyl, isobutyl, tert-butyl and 1,1,2-trimethyl-propyl. Particular examples of alkyl groups (Ci_4) as used for RN2 are methyl, ethyl and isopropyl, especially methyl. Particular examples of alkyl groups (Ci_4) that are substituents of Ar1, Ar3 or Ar4 are methyl and ethyl, especially methyl. Examples of alkyl (Ci_6) that is monosubstituted with alkoxy (61-3) or hydroxy" as used for R2 are 2-hydroxy-ethyl, 2-hydroxy-propyl, 2-hydroxy-1-methyl-propyl and 2-methoxy-ethyl . IF-2019-79621737-APN-ANP#INPI Page 36 of 351 The term "-alkylene (Cx_y)-", used alone or in combination, refers to a bivalently linked alkyl group as defined above containing x to y carbon atoms. Preferably, the points? The attachment points of any bivalently bonded alkyl group are in the 1,1-diyl or 1,2-diyl arrangement. In the case of using an alkylene group (C0-y) in combination with another substituent, the term means that said substituent is linked directly to the rest of the molecule (that is, the alkyl group (Co) represents a direct bond that links said substituent. with the rest of the molecule) or is linked through an alkylene group (Ci_y) with the rest of the molecule. Examples of -alkylene (C-i-^)— are the groups -alkylene (Ci_3)methylene, ethylene, ethane-1,1-diyl, propane-1,2-diyl and propane-2,2-diyl, as well as the -alkylene (C4)-2-methyl-propan-1,2-diyl group. In the case where a linker group is a -alkylene (Co) group, such a group refers to a direct bond. Examples of -alkylene (C^)- that is monosubstituted with hydroxy or trifluoromethyl” as used for L2 are 1—trifluoromethyl—ethane—1,1—diyl, 2hydroxy-ethane-1,2-diyl, and 2-hydroxy-ethane -1,1-diyl. The term "alkynyl", used alone or in combination, refers to a straight-chain or branched hydrocarbon group containing one to six (especially one to four) carbon atoms wherein said hydrocarbon group contains at least one triple bond. carbon-carbon. The term "alkynyl (Cx_y)" (each x and y being an integer), refers to an alkynyl group as defined above, containing x to y carbon atoms. For example, an alkynyl group (C2-e) contains two to six carbon atoms. An example of an alkynyl group is 1-methyl-prop-2-ynyl. The term "alkenyl", used alone or in combination, refers to a straight or branched chain hydrocarbon group containing one to six (especially one to four) carbon atoms where said hydrocarbon group contains at least one double bond of carbon-carbon. The expression alkenyl (Cx_y)” (each x and y being an integer), refers to a . IF-2019-79621737-APN-ANP#INPI Page 37 of 351 alkenyl group as defined above, containing x to y carbon atoms. For example, an alkenyl group (C2-6) contains two to six carbon atoms. An example of an alkenyl group is allyl. The term "alkoxy", used alone or in combination, refers to an alkyl group -O-, where the alkyl group is as defined above. The term “alkoxy (Cx_y)” (each x and y being an integer) refers to an alkoxy group as defined above containing x to y carbon atoms. For example, a (C1-4)alkoxy group means a group of the formula (Ci-4)alkyl-O-, where the term “(C1-4)alkyl” has the meaning given previously. Examples of alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy. A preferred example is methoxy. The term "fluoroalkyl" refers to an alkyl group as defined above containing one to five carbon atoms wherein one or more (especially 1, 2 or 3; and possibly all) hydrogen atoms have been replaced with fluorine. The term “fluoroalkyl (Cx_y)” (each x and y being an integer) refers to a fluoroalkyl group as defined above containing x to y carbon atoms. For example a fluoroalkyl group (C^) contains one to three carbon atoms where one to seven hydrogen atoms were replaced with fluorine. Representative examples of fluoroalkyl groups include the (C1) fluoroalkyl groups difluoromethyl and trifluoromethyl, as well as the (C2-5) fluoroalkyl groups 2-fluoroethyl, 2,2-difluoro-ethyl, 2,2,2-trifluoroethyl, 2,2 —difluoropropyl, 3,3,3—trifluoropropyl, 2-fluoro-1—methyl—ethyl, 2—fluoro—1,1—dimethyl—ethyl, 2,2—difluoro—1—methyl—ethyl and 3,3,3 -trifluoro-1,1-dimethyl-propyl. The term "fluoroalkylene (Cx_y)", used alone or in combination, refers to a bivalently linked fluoroalkylene group as defined above containing x to y carbon atoms. Preferably, the points. IF-2019-79621737-APN-ANP#INPI Page 38 of 351 attachment of any bivalently linked fluoroalkyl group are in 1,1-diyl arrangement. An example is 2,2,2—trifluoro—ethane—1,1—diyl. The term "fluoroalkoxy" refers to an alkoxy group as defined above containing one to three carbon atoms wherein one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term fluoroalkoxy (Cx_y)” (each x and y being an integer) refers to a fluoroalkoxy group as defined above containing x to y carbon atoms. For example a fluoroalkoxy group (C1-3) contains one to three carbon atoms where one to seven hydrogen atoms were replaced with fluorine. Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy. A preferred example is trifluoromethoxy. The term "cyano" refers to a -CN group. The term "cycloalkyl", used alone or in combination, refers to a saturated mono- or bicyclic carbocyclic ring containing three to eight carbon atoms, where the term "bicyclic cycloalkyl" includes fused, bridged and spiro-bicyclic cycloalkyl groups. The term “cycloalkyl (Cx_y)” (each x and y being an integer), refers to a cycloalkyl group as defined above containing x to y carbon atoms. For example, a cycloalkyl group (Ca-e) contains three to eight carbon atoms. Examples of cycloalkyl groups are the monocyclic cycloalkyl groups cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; as well as bicyclic cycloalkyl groups such as spiro[2,4]hept4-yl, spiro[3,3]hept-2-yl, bicyclo[2,2,1 Jhept-2-yl, spiro[2,3]hex -5-yl and bicyclo[3,1,0]hex—3—yl. Preferred are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term -cycloalkylenep(Cx_y)-“, used alone or in combination, refers to a bivalently linked cycloalkyl group as defined above containing x to y carbon atoms. Preferably, the points IF-2019-79621737-APN-ANP#INPI 39 Page 39 of 351 attachment of any bivalently linked cycloalkyl group are in 1,1-diyl or 1,2-diyl arrangement. Examples are cyclopropan-1,1-diyl, cyclopropan-1,2-diyl, cyclobutan-1,1-diyl and cyclopentan-1,3-diyl; cyclopropan-1,1-diyl and cyclobutan-1,1-diyl are preferred. The term “cycloalkyl (Cx_y), wherein said cycloalkyl (Cx_y) optionally contains a ring oxygen atom”, refers to a cycloalkyl group (Cx_y) containing x to y carbon atoms, especially a monocyclic cycloalkyl group (C3_6). , as defined above. Furthermore, a carbon atom of the ring of said cycloalkyl (Cx_y) can be replaced by an oxygen atom. These groups are unsubstituted or substituted as explicitly defined. Examples are especially the (C3_6) cycloalkyl groups cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; as well as oxetanil, tetrahydrofuranyl and tetrahydropyranyl. A preferred “cycloalkylene (Cx_y), wherein said cycloalkylene (Cx_y) optionally contains a ring oxygen atom” is oxetan-3,3-diyl. The term “cycloalkyl (C3_8)-alkyl (Co_3)” refers to a cycloalkyl (C3_8) group as defined above (i.e. such group may optionally contain an oxygen atom as explicitly defined) whose group is linked with the rest of the molecule through an alkylene group (C0_3) as defined previously. The cycloalkyl (C3_8) group from cycloalkyl (C3_8)—alkyl (Co-3) is unsubstituted or substituted as explicitly defined. The alkylene group (Cq_3) portion of cycloalkyl (C3_8)-alkyl (Co-3) is unsubstituted or substituted as explicitly defined. The term "cycloalkenyl", used alone or in combination, refers to a non-aromatic, unsaturated (i.e. containing at least one carbon-carbon double bond of the ring) mono- or bicyclic carbocyclic ring containing three to eight atoms of carbon, wherein the term “bicyclic cycloalkenyl” includes fused, bridged and spiro cycloalkenyl groupsIF-2019-79621737-APN-ANP#INPI Page 40 of 351 bicyclics. The term “cycloalkenyl (Cx_y)” (each x and y being an integer), refers to a cycloalkenyl group as defined above containing x to y carbon atoms. For example, a cycloalkenyl group (C3e) contains three to eight carbon atoms. Examples of cycloalkenyl groups are cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl; especially cyclopenten-1-yl. The term "aryl", used alone or in combination, means phenyl or naphthyl, preferably phenyl. Similarly, an arylene group is an aryl group as defined above that has two attachment points with the respective moieties of the molecule. The aforementioned aryl / arylene groups are unsubstituted or substituted as explicitly defined. For the substituent Ar2que represents “phenyl, wherein said phenyl is mono-, di- or trisubstituted, wherein the substituents are independently selected from fluoro, chloro, methyl, cyano, methoxy or fluoroalkyl (€1)” , the particular groups are where one or two of said substituents are independently selected from fluoro, chloro and methyl and the others, if present, are fluoro. In particular, Ar2 represents phenyl that is mono-, di- or trisubstituted, wherein the substituents are independently fluoro or chloro; in particular Ar2 represents phenyl that is mono-, di- or trisubstituted with fluoro or phenyl that is mono-, di- or trisubstituted wherein one substituent is chloro and the other substituents, if present, are fluoro. Examples of Ar2 are 2-fluoro-phenyl, 4-fluoro-phenyl, 2,4-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-chloro-2-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl, 2,3,4-trifluoro-phenyl, 2,4-dimethylphenyl, 2-methylphenyl, 3,4-dimethylphenyl, 2,3-difluoro-phenyl, 3,4-difluoro-phenyl, 4- cyano-phenyl, 4-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 2-trifluoromethyl-phenyl and 2-fluoro-4-methoxy-phenyl. Preferred examples are 2,4-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 2,4-dichlorophenyl, 2,3,4-trifluoro-phenyl and 2,4-dimethylphenyl (especially 2,4- difluoro-phenyl). IF-2019-79621737-APN-ANP#INPI Page 41 of 351 For the substituent Ar3 representing phenyl, the phenyl is unsubstituted or substituted as explicitly defined. Examples are phenyl, 2-chlorophenyl, 4-fluoro-phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl and 2-methoxy-phenyl; as well as 3-bromo-phenyl, 3-chloro-phenyl, 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, 2-hydroxy-phenyl, 2-methoxy-phenyl, 4-chloro-phenyl, 3- methoxy-phenyl and 2-trifluoromethyl-phenyl. The term “aryl—alkyl (Cx_y)” refers to an aryl group as defined above that is linked to the rest of the molecule through an alkylene group (Cx_y), as defined above. The aryl group portion of aryl—alkyl (Cx_y) is unsubstituted or substituted as explicitly defined. The alkylene group (Cx_y) portion of aryl—alkyl (Cx_y) is unsubstituted or substituted as explicitly defined. . The term “aryl—cycloalkyl (Cx_y)” refers to an aryl group as defined above that is linked to the rest of the molecule through a cycloalkylene group (Cx_y) as defined above. The aryl group part aryl—cycloalkyl (Cx_y) is unsubstituted or substituted as explicitly defined. The cycloalkylene group (Cx_y) portion of aryl—cycloalkyl (Cx_y) is unsubstituted or substituted as explicitly defined. The term "heteroaryl", used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing one to a maximum of four heteroatoms (notably, containing one to a maximum of three heteroatoms), each selected , independently, of oxygen, nitrogen and sulfur. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, or benzothiophene. ilo , indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, IF-2019-79621737-APN-ANP#INPI Page 42 of 351 benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrrolopyrazinyl, imidazopyridinyl, imidazopyridazinyl and imidazothiazolyl. Similarly, a heteroarylene group is a heteroaryl group as defined above that has two attachment points with the respective moieties of the molecule. The aforementioned heteroaryl / heteroarylene groups are unsubstituted or substituted as explicitly defined. For the Ar1 group representing a 5-membered heteroarylene, the term means a 5-membered heteroarylene group as defined above (wherein said 5-membered heteroarylene notably contains one to a maximum of three heteroatoms); which is linked to the rest of the molecule as explicitly defined. The expression “meta arrangement in the context of a heteroarylene group such as Ar1 means that the respective substituents are linked in a relative 1,3 arrangement. Examples of Ar1 that represent 5-membered heteroarylene are especially 5-membered heteroarylene groups containing one to a maximum of three heteroatoms, each independently selected from oxygen, nitrogen and sulfur (especially 5-membered heteroarylene containing one to a maximum of three heteroatoms, each independently selected from oxygen and nitrogen; or 5-membered heteroarylene containing one sulfur ring atom and one to a maximum of two nitrogen ring atoms); notably, oxazole-diyl, isoxazole-diyl, oxadiazole-diyl or triazole-diyl; or thiadiazol-diyl or isothiazol-diyl; in particular oxazol-2,5-diyl, oxazol-2,4-diyl, isoxazol-3,5-diyl, [1,3,4]oxad iazol-2,5-diyl, [1,2,4]oxadiazol-3,5-diyl or 1 H-[1,2,3]triazol-1,4-diyl; or [1,3,4]thiadiazol-2,5diyl or isothiazol-3,5-diyl. Preferred examples of Ar1 that represent a 5-membered heteroarylene group are oxazol-2,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom at the 5-position; oxazolIF-2019-79621737-APN-ANP#INPI Page 43 of 351 2,4—diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 4-position; isoxazol-3,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 5-position; isoxazol-3,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 3-position; [1,3,4]oxadiazole-2,5-diyl; [1,2,4]oxadiazole-3,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 5-position; 1H—[1,2,3]triazole—1,4—diyl, wherein the Ar2 substituent is bonded to the nitrogen atom in the 1-position; [1,3,4]thiadiazol-2,5-diyl; and isothiazole-3,5-diyl, where the Ar2 substituent is bonded to the carbon atom in the 5-position. For the substituent Ar2que represents 6-membered heteroaryl, wherein said 6-membered heteroaryl is independently monodi- or trisubstituted, wherein two of said substituents are independently selected from fluoro, chloro, methyl, cyano, methoxy or fluoroalkyl (Ci)¡ and the remaining substituent, if present, is fluoro", examples are especially pyridinyl groups that are mono- or disubstituted with fluoro. An example is 5—fluoro—pyridin—2—ílo. . For the substituent Ar3 representing 5- or 6-membered heteroaryl, the term means 5- or 6-membered heteroaryl groups as defined above. Examples of Ar3 that represent 6-membered heteroaryl are pyrimidinyl, pyridinyl, pyridazinyl and pyrazinyl. For the avoidance of doubt, the term 6-membered heteroaryl as used for the Ar3 substituent further comprises the 1-oxy-pyridinyl and 1-oxy-pyrimidinyl groups. Particular examples are pyrazin—2—ílo, pyridazin—3—yl, pyrimidin—2—ílo, pyrimidin—4—ílo, pyridin—2—ílo, pyridin—3—ílo and pyridin—4—yl ; as well as the N-oxides 1-oxy-pyrimidin-2-yl and 1-oxy-pyridin-2-yl. The 6-membered heteroaryl groups as used for the Ar3 substituent are preferably unsubstituted: or said groups are substituted as explicitly defined (especially mono- or disubstituted where the substituents are independently selected from fluoro or methyl). The examples of IF-2019-79621737-APN-ANP#INPI Page 44 of 351 Ar3 representing 5-membered heteroaryl are oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxadiazolyl and triazolyl; in particular oxazol-5-yl, isoxazol-3-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-5-yl, thiazol-4-yl, imidazole-4-yl, 2H-pyrazole-3- yl, 1H—pyrazol—3—yl, 2H—pyrazol—3—yl, 1Hpyrazol—4—yl, [1,2,4]oxadiazol—3—yl, [1,2,4]oxadiazol—5—yl , [1,3,4]oxadiazol-2yl and 1H—[1,2,4]triazol—3—yl. The 5-membered heteroaryl groups as used for the Ar3no substituent are substituted; or said groups are substituted as explicitly defined (especially mono- or disubstituted where the substituents are independently selected from methyl or ethyl). An example of Ar4 representing 5- or 6-membered heteroaryl is pyridinyl. An example of Ar5-CH2- where Ar5 represents 5- or 6-membered heteroaryl is (1—methyl—pyrrole—3-yl)-methyl. The term “heteroaryl-alkyl (Cx_y)” refers to a heteroaryl group as defined above that is linked to the rest of the molecule through an alkylene group (Cx_y) as defined above. The heteroaryl group portion of heteroaryl-alkyl (Cx_y) is unsubstituted or substituted as explicitly defined. The alkylene group (Cx_y) portion of heteroaryl-alkyl (Cx_y) is unsubstituted or substituted as explicitly defined. The term “heteroaryl-cycloalkyl (Cx_y)” refers to a heteroaryl group as defined above that is linked to the rest of the molecule through a cycloalkylene group (Cx_y) as defined above. The heteroaryl group heteroaryl-cycloalkyl (Cx_y) portion is unsubstituted or substituted as explicitly defined. The cycloalkylene group (Cx_y) portion of heteroaryl-cycloalkyl (Cx_y) is unsubstituted or substituted as explicitly defined. Other embodiments of the invention are presented below in this document: IF-2019-79621737-APN-ANP#INPI Page 45 of 351 2) Another embodiment refers to the compounds of the formula (I) according to embodiment 1) which are also compounds of the formula (Ir), wherein the two substituents of the piperidine ring: R1-CO- and NH-CO-AH-Ar2, are in relative trans configuration, where the absolute configuration of the two chiral carbon atoms in position 3 and 4 of the piperidine ring is (3R,4R): EITHER Yo R2 Formula (Go). 3) Another embodiment refers to the compounds of the formula (I) according to embodiment 1) which are also compounds of the formula (Is), wherein the two substituents of the piperidine ring: R1-CO- and NH-CO-AP-Ar2, are in relative trans configuration, where the absolute configuration of the two chiral carbon atoms in position 3 and 4 of the piperidine ring is (3S,4S): EITHER Yo R2 Formula (ls). 4) Another embodiment refers to compounds according to any of embodiments 1) to 3), wherein R3 represents hydrogen. . IF-2019-79621737-APN-ANP#INPI Page 46 of 351 5) Another embodiment refers to the compounds of the formula (I) according to any of the embodiments 1) to 4), where Ar1 represents a 5-membered heteroarylene group (especially a 5-membered heteroarylene that contains one to a maximum of three heteroatoms, each independently selected from oxygen and nitrogen; notably, oxazole diyl, isoxazole diyl, oxadiazole diyl or triazole diyl or a 5-membered heteroarylene containing one atom; of the sulfur ring and one or two atoms of the nitrogen ring; notably, isothiazolyl or thiadiazol—diyl), where the -NH-CO- group and Ar2 are linked in a meta arrangement with ring atoms of Ar1; wherein said 5-membered heteroarylene is unsubstituted. 6) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 4), where Ar1 represents a 5-membered heteroarylene group selected from oxazole-diyl, isoxazole-diyl , oxadiazol-diyl or triazole-diyl, where the group -NH-CO- and Ar2 are linked in a meta arrangement with ring atoms of Ar1; wherein said 5-membered heteroarylene is unsubstituted or monosubstituted with RAr1; where RAr1 represents methyl, methoxy, fluorine, chlorine, trifluoromethyl or trifluoromethoxy (especially said 5-membered heteroarylene is unsubstituted). 7) Another embodiment relates to the compounds of formula (I) according to any of embodiments 1) to 4), where Ar1 represents a 5-membered heteroarylene group selected from oxazole-2,5diyl, oxazole -2,4-diyl, isoxazol—3,5—diyl, [1,3,4]oxadiazol—2,5—diyl, [1,2,4]oxadiazol—3,5—diyl, 1H—[1,2,3]triazole—1,4—diyl, [1,3,4]thiadiazol—2,5—diyl or isothiazol—3 ,5—say it; wherein said 5-membered heteroarylene is unsubstituted [especially Ar1 represents a 5-membered heteroarylene group selected from oxazole-2,5-diyl, wherein the substituent Ar2 is bonded to the carbon atom in the 5-position; oxazol-2,4-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 4-position; isoxazole- IF-2019-79621737-APN-ANP#INPI Page 47 of 351 3,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 5 position; isoxazol-3,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 3-position; [1,3,4]oxadiazole-2,5-diyl; [1,2,4]oxadiazol3,5-diyl, wherein the Ar2 substituent is bonded to the carbon atom in the 5-position; 1H—[1,2,3]triazole—1,4—diyl, wherein the Ar2 substituent is bonded to the nitrogen atom in the 1-position; [1,3,4]thiadiazol-2,5-diyl; or isothiazol-3,5-diyl, where the Ar2 substituent is bonded to the carbon atom in the 5-position], 8) Another embodiment relates to the compounds of formula (I) according to any of embodiments 1) to 4), where Ar1 represents (preferably) unsubstituted isoxazole-3,5-diyl, where the Ar2 substituent is bonded to the carbon atom in the 5 position; o Ar1 represents [1,3,4]thiadiazole—2,5—diyl. 9) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 8), wherein Ar2 represents phenyl which is mono-, di- or trisubstituted; wherein one or two of said substituents are independently selected from fluoro, chloro and methyl and the others, if present, are fluoro (especially 2,4difluoro-phenyl). In a sub-embodiment, Ar2 represents phenyl that is mono-, di- or tri-substituted, wherein the substituents are independently fluoro or chloro; in particular Ar2 represents phenyl which is mono-, di- or trisubstituted with fluoro (especially 2,4-difluoro-phenyl). 10) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 8), where Ar2 represents 2-fluoro-phenyl, 4-fluoro-phenyl, 2,4 —difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-chloro-2-fluoro-phenyl, 2-chloro-4-fluoro-phenyl, 2,4-dichlorophenyl, 2,3,4-trifluoro-phenyl , 2,4-dimethylphenyl, 2-methylphenyl, 3,4-dimethylphenyl, 2,3-difluoro-phenyl, 3,4-difluoro-phenyl, 4-cyano-phenyl, 4-trifluoromethyl-phenyl, 3 IF-2019-79621737-APN-ANP#INPI Page 48 of 351 trifluoromethyl-phenyl, 2-trifluoromethyl-phenyl or 2-fluoro-4-methoxy-phenyl. In a subembodiment, Ar2 represents 2-fluoro-phenyl, 4-fluoro-phenyl, 2,4-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-chloro-2-fluoro-phenyl or 2-chloro-4fluoro. -phenyl (especially Ar2 represents 2,4-difluoro-phenyl). 11) Another embodiment refers to the compounds of the formula (I) according to any of the embodiments 1) to 10), where R1 represents RN1RN2N-, where • RN1 represents > alkyl (Ci-θ) ( especially methyl, ethyl, isopropyl, sobutyl, tertbutyl, 1,2,2-trimethylpropyl); > alkyl (Ci-e) that is monosubstituted with hydroxy; alkoxy (Ci-3) (especially methoxy, ethoxy); 2-hydroxy-ethoxy; -CO-NH2; -SO2-alkyl (Ci_3) (especially methanesulfonyl); cyano; fluoroalkoxy (C-|_3) (especially trifluoromethoxy); -NRN3RN4, where RN3 and RN4 independently represent hydrogen or (C^)alkyl (especially NRN3RN4 represents dimethylamino); (especially where such group RN1 is monosubstituted, alkyl (Ci-e) is 2-hydroxy-ethyl, 2-hydroxy-1 -methyl-ethyl, 2-hydroxy-1,1-dimethyl-ethyl, 2-methoxy-ethyl, 3 -methoxy-propyl, 2-ethoxy-ethyl, 2-ethoxy-1-methyl IF-2019-79621737-APN-ANP#INPI Page 49 of 351 ethyl, 2-methoxy-1,1-dimethyl-ethyl, 3-methoxy-1,1-dimethyl-propyl, 2-(2-hydroxy-ethoxy)-ethyl, carbamoyl-methyl, 2-methanesulfonyl-1, 1-dimethyl-ethyl, 1-cyano-1-methyl-ethyl, 2-dimethylamino-ethyl, 2-trifluoromethoxyethyl); > (C2-6) alkynyl (especially 1-methyl-prop-2-ynyl); > fluoroalkyl (C2-5) (especially 2-fluoro-ethyl, 2,2-difluoro-ethyl, 2-fluoro-1-methyl-ethyl, 2-fluoro-1,1-dimethyl-ethyl, 2,2-difluoro- 1-methyl-ethyl, 3,3,3-trifluoro-1,1-dimethyl-propyl); ' > 2—(2—oxo—pyrrolidin—1—yl)—ethyl; > a group -L1-Cy1¡ where L1 represents a direct bond, -alkylene (C-|_3)- or cycloalkylene (C3_5)-¡ and Cy1 represents (C3-6)cycloalkyl, wherein said (C3_6)cycloalkyl optionally contains a ring oxygen atom; wherein said cycloalkyl (C3_e) is independently unsubstituted; or monosubstituted with fluoro, methyl, hydroxy, CO-alkoxy (C^) or cyano; or disubstituted with fluoro or trisubstituted with methyl and two fluoro; (especially such a group -L1-Cy1 is cyclopropyl, cyclopentyl, 1-methyl-cyclopropyl, 1-methyl-cyclobutyl, 1-cyclopropyl-cyclopropan-1-yl, 1-cyclobutyl-ethyl, 3-methyl-tetrahydrofuran-3-yl, tetrahydrofuran-3-ylmethyl, tetrahydrofuran-2-yl-methyl, 1-tetrahydrofuran-2-yl-ethyl, oxetan-3-yl-methyl, 3,3-difluoro-1-methyl-cyclobutyl, 1-(ethoxycarbonyl)-cyclopropyl or 1-cyano-cyclobutyl); > a group -L2-Ar3, where! IF-2019-79621737-APN-ANP#INPI Page 50 of 351 L2 represents a -(C 1-4)alkylene-; -(C3-5)cycloalkylene- wherein said cycloalkylene (63.5) optionally contains a ring oxygen atom; '-cycloalkylene (C3_5)-alkylene (Ci_2)-, wherein said cycloalkylene (C3-5) optionally contains a ring oxygen atom, where the asterisk indicates the bond with which Ar3 is attached; '-alkylene (ΟΊ_2)cycloalkylene (C3_5)- wherein said cycloalkylene (C3_5) optionally contains a ring oxygen atom, where the asterisk indicates the bond with which Ar3 is attached; or -(C1-3)alkylene- which is monosubstituted with hydroxy or trifluoromethyl; and Ar3 represents phenyl or 5-membered heteroaryl containing one oxygen atom and one or two nitrogen atoms or 6-membered heteroaryl containing one or two nitrogen atoms; wherein said independently 5- or 6-membered phenyl or heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci_4), alkoxy (Ci_4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci_ 3); wherein, in case Ar3 represents 6-membered heteroaryl which is pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective N-oxide; (especially such a group -L2-Ar3 is benzyl, 1—phenyl-ethyl, 2—phenyl—ethyl, 2—(2—chloro—phenyl)—ethyl, 2—(4—fluoro—phenyl)—ethyl, 2—( 2-methyl-phenyl)-ethyl, 2-(3-methyl-phenyl)-ethyl, 2-(4-methyl-phenyl)-ethyl, 2-(2-methoxyphenyl)-ethyl, 2-phenyl-propyl, 2 -hydroxy-1-phenyl-ethyl, 2-hydroxy-2-phenylethyl, 2-phenyl-cyclopropyl or 1-(3-bromo-phenyl)-ethyl, 1-phenyl-; IF-2019-79621737-APN-ANP#INPI Page 51 of 351 cyclopropyl, 1—phenyl—cyclobutyl, 2—phenyl—cyclobutyl, 1-(3-chloro-phenyl)cyclopropyl, 1 —(4—f I or gold—phe n i I)—ci cl op rop i I or, 1 -(3-fluoro-phenyl)cyclopropyl, 1 -(2-fluoro-phenyl)-cyclopropyl, 1 —(2-methyl I—phen i I )— cyclopropyl, 1—(2-hydroxy-phenyl)— cyclopropyl, 1-(2-methoxy-phenyl)-ethyl, 2-methyl-2-(2-chloro-phenyl)-propyl, 1-(4-chloro-phenyl)-cyclopropyl-methyl, 3-(3-chloro -phenyl)-oxetan-3-yl, 3-(4-fluoro-phenyl)-oxetan-3. yl, 3-(phenyl)-oxetan-3-yl-methyl, 3-(benzyl)-oxetan-3-yl, 1-(2methoxy-phenyl)-cyclopropyl, 1-(3-methoxy-phenyl)-cyclopropyl, 1-(2trifluoromethyl-phenyl)-cyclopropyl; or, oxazol-5-yl-methyl, 1-([1,2,4]oxad iazol-3-yl)-ethyl, 1-(isoxazol-3-yl)ethyl, 3-methyl-isoxazol-5-yl -methyl, 5-methyl-isoxazol-3-yl-methyl, (3ethyl—([1,2,4]oxadiazol-5-yl)-methyl, 1 —(5—methyl—([1,3,4] oxadiazol-2¡I)-ethyl, 1-methyl-1-(5-methyl-[1,2,4]oxadiazol-3-yl)-ethyl; pyridin-2-yl-methyl, pyridin-3-I-methyl, pyridin-4-yl-methyl, pyrimidin-2-yl-methyl, pyrimidin-4-yl-methyl, pyrazin-2-I-methyl, 1—(pyridin—2—yl)—ethyl, 1—(pyridin—3—yl)—ethyl, 2—(pyridin—2—yl)—ethyl, 1—methyl—1—(pyridin—2—yl)— ethyl, 1—(pyrazin—2—yl)—ethyl, 1—(pyrimidin—4—yl)—ethyl, 1—(5—fluoro—pyrimidin—2—yl)—ethyl, 1—(3—fluoro—pyridin —2—yl)—ethyl, 1-(5-fluoropyridin—2—yl)—ethyl, 1—(6—methyl—pyridin—2—I)—ethyl, 2—hydroxy—1—(pyridin— 2— ¡I)—ethyl, 1-(1-oxy-pyridin-2-¡I)-ethyl, 1—(pyridin-2-yl)—cyclopropyl, 1—(pyridin-4-yl)—cyclopropyl, 1—( pyrazin—2—I)—cyclopropyl, 1(pyrimid azi n—3—i I)—ci cl op rop i Io, 1 -(pyrimid i n—2—i I)—ci cl op rop i I o, 1-(5fluoro-pyridin-2-yl)-cyclopropyl, 1-(3,5-difluoro-pyridin-2-yl)-ethyl, 2,2,2-trifluoro-1-(pyridin-2-yl)-ethyl, 1-(4,6-dimethyl-pyrimidin-2-yl)-cyclopropyl; or (6—methyl—pyridin—2—yl)—methyl, 1—(pyrimidin—2—yl)—ethyl, 1—methyl—1—(pyrimidin—2—yl)—ethyl, 1—(pyrimidin—4— yl)—cyclopropyl, 2-(pyrimidin-2-yl)—cyclobutyl, 2-(pyrimidin-2-yl)—cyclopentyl, 1—(1—oxy—pyrimidin—2—¡I)—cyclopropyl, 1—(3— fluoro—pyridin—2—I)—cyclopropyl, [1(pyridin—2—yl)—cyclopropyl]—methyl, 1—(pyridin—2—yl)—cyclobutyl, 1-(1IF-2019-79621737-APN- ANP#INPI Page 52 of 351 oxy—pyridin—2—yl)—cyclopropyl, 2—methyl—2—(pyridin—2—yl)—propyl, 2methyl—2—(3—methyl—pyridin—2—yl)—propyl); and RN2 represents, independently, hydrogen or alkyl (Ci_4) (especially methyl, ethyl, isopropyl). 12) Another embodiment relates to the compounds of formula (I) according to any of embodiments 1) to 10), wherein R1 represents RN1RN2N-, wherein • RN1 represents > (C3-6) cycloalkyl, wherein said cycloalkyl (C3_g) optionally contains a ring oxygen atom; wherein said cycloalkyl (Cs-e) is independently unsubstituted or monosubstituted with fluoro, methyl or hydroxy or disubstituted with fluoro or trisubstituted with methyl and two fluoro (especially cyclopropyl, cyclopentyl, 1—methyl—cyclopropyl, 1— methyl-cyclobutyl, 3-methyl-tetrahydrofuran-3-yl, 3,3-difluoro-1-methyl-cyclobutyl); > cycloalkyl (C3_6)-alkylene (Ci_3)—, wherein said cycloalkyl (Ο3_β) optionally contains a ring oxygen atom (especially 1—cyclobutyl-ethyl, tetrahydrofuran-3-yl-methyl, tetrahydrofuran-2- ylmethyl, 1-tetrahydrofuran-2-yl-ethyl, oxetan-3-yl-methyl); > cycloalkyl (C3^)-cycloalkylene (C3_5)- (especially 1—cyclopropyl—cyclopropan-1-yl); > phenyl—alkylene (C^)- wherein said phenyl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (C^), alkoxy (Ci_ 4), halogen, fluoroalkyl (C-|_3) or fluoroalkoxy (Ci_3); (especially such a group is benzyl, 1-phenyl-ethyl, 2-phenyl-ethyl, 2-(2-chloro-phenyl)-ethyl, 2-(4-fluoro-phenylj-ethyl, 2-(2-methyl- phenyl)-ethyl, 2-(3-methyl-phenyl) IF-2019-79621737-APN-ANP#INPI Page 53 of 351 ethyl, 2-(4-methyl-phenyl)-ethyl, 2-(2-methoxy-phenyl)-ethyl, 2-phenyl-propyl; or 1-(3-bromo-phenyl)-ethyl, 1-(2-methoxy-phenyl)-ethyl, 2-methyl-2-(2-chloro-phenyl)-propyl); > phenyl—alkylene (C-i-a)- wherein said -alkylene (C-i-a)— is monosubstituted with hydroxy (especially 2-hydroxy-2-phenyl-ethyl, 2-hydroxy-1-phenyl-ethyl); > phenyl—(C3-5)cycloalkylene—wherein said (C3_5)cycloalkylene optionally contains a ring oxygen atom and wherein said phenyl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (61-4), alkoxy (Ci_4), halogen, hydroxy, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci-3) (especially 2-phenyl-cyclopropyl, 1 —phenyl—cyclopropyl, 1—phenyl—cyclobutyl, 2—phenyl—cyclobutyl, 1—(3—chloro—phenyl)— cyclopropyl, 1—(4—fluoro—phenyl)—cyclopropyl, 1—(3—fluoro—phenyl) — cyclopropyl, 1-(2-fluoro-phenyl)-cyclopropyl, 1-(2-methyl-phenyl)-cyclopropyl, 1-(2-hydroxy-phenyl)-cyclopropyl, 3-(3-chloro-phenyl)oxetan- 3-yl, 3-(4-fluoro-phenyl)-oxetan-3-yl, 1-(2-methoxy-phenyl)cyclopropyl, 1-(3-methoxy-phenyl)-cyclopropyl, 1—(2—trifluoromethyl— phenyl)—cyclopropyl); > phenyl—cycloalkylene (C3_5)-alkylene (61-2)-, wherein said cycloalkylene (63-5) optionally contains a ring oxygen atom and wherein said phenyl is unsubstituted or is monosubstituted with halogen (especially 1 —(4-chloro-phenyl)-cyclopropyl-methyl, 3-(phenyl)-oxetan-3-yl-methyl); > phenyl—(Ci_2)alkylene-(C3-5)cycloalkylene—wherein said (C3_5)cycloalkylene optionally contains a ring oxygen atom (especially 3-(benzyl)-oxetan-3-yl); IF-2019-79621737-APN-ANP#INPI Page 54 of 351 > 5-membered heteroaryl-alkylene (Ci_3)-, wherein said 5-membered heteroaryl contains one oxygen atom and one or two nitrogen atoms; and wherein said 5-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (C^), alkoxy (Ci-4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci_3); (especially oxazol-5-yl-methyl, 1-([1,2,4]oxadiazol-3-yl)-ethyl, 1-(isoxazol-3-yl)-ethyl, 3-methyl-isoxazol-5- yl-methyl, 5-methyl-isoxazol-3-yl-methyl, (3ethyl—([1,2,4]oxadiazol-5-yl)-methyl, 1 —(5—methyl—([1,3,4 ]oxadiazol-2-yl)—ethyl, 1 —methyl—1 —(5—methyl—[1,2,4]oxadiazol-3-yl)-ethyl)¡ > 6-membered heteroaryl-alkylene (C-i-^) —, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci_4); , alkoxy (Ci_4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci_3); —yl—methyl, pyridin—3—yl—methyl, pyridin—4—I—methyl, pyrimidin—2—yl—methyl, pyrimidin—4—yl—methyl, pyrazin—2—yl—methyl, 1—(pyridin —2—yl)—ethyl, 1—(pyridin—3—yl)—ethyl, 2(pyridin—2—yl)—ethyl, 1—methyl—1—(pyridin—2—yl)—ethyl, 1—( pyrazin—2—yl)—ethyl, 1—(pyrimidin—4—yl)—ethyl, 1—(5—fluoro—pyrimidin—2—yl)—ethyl, 1—(3—fluoro—pyridin—2—yl) —ethyl, 1-(5-fluoro-pyridin-2-yl)-ethyl, 1-(6-methylpyridin-2-yl)-ethyl, 1-(3,5-difluoro-pyridin-2-yl)-ethyl , (6—methyl—pyridin—2—yl)—methyl, 1—(pyrimidin—2—yl)—ethyl, 1—methyl—1—(pyrimidin—2—yl)—ethyl, 2-methyl-2-( pyridin-2-yl)-propyl, 2-methyl-2-(3-methyl-pyridin-2-yl)propyl); IF-2019-79621737-APN-ANP#INPI Page 55 of 351 > 6-membered heteroaryl-alkylene (61-3)-, wherein said alkylene (Ci_3)- is monosubstituted with hydroxy or trifluoromethyl; wherein said 6-membered heteroaryl contains one or two nitrogen atoms; (especially 2-hydroxy-1-(pyridin-2-yl)-ethyl, 2,2,2trifluoro-1-(pyridin-2-yl)-ethyl); > 6-membered heteroaryl-cycloalkylene (C3_5)—, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci^), alkoxy (Ci_ 4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (C-|_3); where, in case Ar3 represents pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective N-oxide (especially 1—(pyridin—2—yl)—cyclopropyl, 1(pyridin—4—I )—cyclopropyl, 1—(pyrazin—2-I)-cyclopropyl, 1—(pyridazin—3—yl)—cyclopropyl, 1—(pyrimidin—2-yl)-cyclopropyl, 1—(5—fluoro—pyridin— 2-yl)-cyclopropyl, 1-(4,6-dimethyl-pyrimidin-2-yl)-cyclopropyl, 1-(pyrimidin-4-yl)-cyclopropyl, 2-(pyrimidin-2-yl)-cyclobutyl, 2 (pyrimidin—2—I)—cyclopentyl, 1—(1—oxy—pyrimidin-2-yl)-cyclopropyl, 1—(3—fluoro—pyridin—2—I)—cyclopropyl, 1—(pyridin—2— yl)—cyclobutyl, 1-(1oxy—pyridin—2—¡I)—cyclopropyl); > 6-membered heteroaryl-cycloalkylene (C3_5)-alkylene (Ci_2)—, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted; (especially [1-(pyridin-2-I)—cyclopropyl]—methyl); oN2 and R independently represent hydrogen (preferred) or (Ci-4) alkyl (especially methyl, ethyl, isopropyl); IF-2019-79621737-APN-ANP#INPI Page 56 of 351 or RN1 represents (C^) alkyl (especially methyl, ethyl); and RN2 represents hydrogen or methyl. 13) Another embodiment refers to the compounds of the formula (I) according to any of the embodiments 1) to 10), where R1 represents RN1RN2N-, where • RN1 represents > cycloalkyl (C3_6)-alkylene ( Ci_3)—, wherein said cycloalkyl (C3_6) optionally contains a ring oxygen atom (especially 1—cyclobutyl—ethyl, tetrahydrofuran-3-yl-methyl, tetrahydrofuran-2-ylmethyl, 1—tetrahydrofuran—2—yl— ethyl, oxetan-3-yl-methyl)¡ > phenyl-alkylene (Ci_4)- wherein said phenyl is unsubstituted or mono- or disubstituted; wherein the substituents are selected, independently, from alkyl (Ci-4), alkoxy (C^ 4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci_3); (especially such a group is benzyl, 1-phenyl-ethyl, 2-phenyl-ethyl, 2-(2-chloro-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 2-(2-methyl —phenyl)-ethyl, 2-(3-methyl-phenyl)-ethyl, 2-(4-methyl-phenyl)-ethyl, 2-(2-methoxy-phenyl)-ethyl, 2-phenyl-propyl or 1; -(3-bromo-phenyl)-ethyl, 1-(2-methoxy-phenyl)-ethyl, 2-methyl-2-(2-chloro-phenyl)-propyl); > phenyl—(C3_5)cycloalkylene—wherein said (C3_5)cycloalkylene optionally contains a ring oxygen atom and wherein said phenyl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci_4), alkoxy (C·^), halogen, hydroxy, fluoroalkyl (Ci_3) or fluoroalkoxy (Ci_3); (especially 2-phenyl-cyclopropyl, 1-phenyl-cyclopropyl, 1-phenyl-cyclobutyl, 2-phenyl-cyclobutyl, 1-(3-chloro-phenyl)-cyclopropyl, 1-(4-fluoro-phenyl)-cyclopropyl , 1—(3—fluoro—phenyl)— IF-2019-79621737-APN-ANP#INPI Page 57 of 351 cyclopropyl, —(2—fl u oro—phen i I)—cycloprop i lo, 1 — (2—methi I—phen i I)— cyclopropyl, 1—(2—hydroxy—phenyl)—cyclopropyl, 3-(3-chloro-phenyl)oxetan-3-yl, 3-(4-fluoro-phenyl)-oxetan-3-yl, 1-(2-methoxy-phenyl)cyclopropyl, 1-(3-methoxy-phenyl )-cyclopropyl, 1—(2-trifluoromethyl-phenyl)-cyclopropyl); > 6-membered heteroaryl-alkylene (Ci^)-, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci^), alkoxy (Ci4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (C-|_3); where, in case Ar3 represents pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective dioxide; (especially pyridin-2-I-methyl, pyridin-3-yl-methyl, pyridin-4-yl-methyl, pyrimidin-2-yl-methyl, pyrimidin-4-yl-methyl, pyrazin-2-yl- methyl, 1—(pyridin—2—yl)—ethyl, 1—(pyridin—3—yl)—ethyl, 2(pyridin—2—yl)—ethyl, 1—methyl—1—(pyridin-2-yl) -ethyl, 1—(pyrazin—2—yl)—ethyl, 1—(pyrimidin—4—yl)—ethyl, 1—(5—fluoro—pyrimidin—2—yl)—ethyl, 1-(3fluoro—pyridin— 2-yl)-ethyl, 1-(5-fluoro-pyridin-2-yl)-ethyl, 1-(6-methyl-pyridin-2-I)-ethyl, 1-(3,5-difluoro-pyridin —2—yl)—ethyl, (6—methyl—pyridin—2—yl)—methyl, 1—(pyrimidin—2—I)—ethyl, 1—methyl—1—(pyrimidin—2—yl)—ethyl , 2-methyl-2-(pyridin-2-yl)-propyl, 2-methyl-2-(3-methyl-pyridin-2-I)-propyl); > 6-membered heteroaryl-(C3_5)cycloalkylene-, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (C^), alkoxy (C^ IF-2019-79621737-APN-ANP#INPI Page 58 of 3514), halogen, fluoroalkyl (C1-3) or fluoroalkoxy (61-3); where, in case Ar3 represents pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective N-oxide (especially 1—(pyridin—2-¡I)-cyclopropyl, 1(pyridin—4—yl )—cyclopropyl, 1—(pyrazin—2-I)-cyclopropyl, 1—(pyridazin—3—yl)—cyclopropyl, 1—(pyrimidin—2-yl)-cyclopropyl, 1—(5—fluoro—pyridin— 2-yl)-cyclopropyl, 1-(4,6-dimethyl-pyrimidin-2-I)-cyclopropyl, 1-(pyrimidin-4-yl)-cyclopropyl, 2-(pyrimidin-2-yl)-cyclobutyl, 2 (pyrimidin-2-yl)-cyclopentyl, 1-(1-oxy-pyrimidin-2-I)-cyclopropyl, 1-(3-fluoro-pyridin-2-yl)-cyclopropyl, 1-(pyridin-2-! I)—cyclobutyl, 1-(1oxy—pyridin—2—yl)—cyclopropyl); and RN2 represents, independently, hydrogen or (C·^) alkyl (especially methyl, ethyl, isopropyl). 14) Another embodiment relates to the compounds of formula (I) according to any of embodiments 1) to 10), wherein R1 represents RN1RN2N-, wherein • RN1 represents > 6-membered heteroaryl-alkylene ( C^)-, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (C^), alkoxy (Ci~ 4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (C^); where, in case Ar3 represents pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective dioxide; (especially pyridin-2-yl-methyl, pyridin-3-yl-methyl, pyridin-4-yl-methyl, pyrimidin-2-yl-methyl, pyrimidin-4-I-methyl, pyrazin-2-yl- methyl, 1—(pyridin—2—yl)—ethyl, 1—(pyridin—3—yl)—ethyl, 2IF-2019-79621737-APN-ANP#INPI 59 Page 59 of 351 (pyridin—2—I)—ethyl, 1—methyl—1—(pyridin—2—yl)—ethyl, 1—(pyrazin—2—I)—ethyl, 1—(pyrimidin—4 —yl)—ethyl, 1—(5—fluoro—pyrimidin—2—yl)—ethyl, 1—(3fluoro—pyridin—2—yl)—ethyl, 1—(5—fluoro—pyridin—2—yl)— ethyl, 1-(6-methylpyridin—2—yl)—ethyl, 1-(3,5—difluoro—pyridin—2—yl)—ethyl, (6—methyl—pyridin—2—yl)—methyl, 1— (pyrimidin—2—yl)—ethyl, 1—methyl—1—(pyrimidin—2—yl)—ethyl, 2—methyl—2—(pyridin—2—yl)—propyl, 2—methyl—2—(3 —methyl—pyridin—2—yl)—propyl); > 6-membered heteroaryl-cycloalkylene (63.5)-, wherein said 6-membered heteroaryl contains one or two nitrogen atoms; and wherein said 6-membered heteroaryl is unsubstituted or mono- or disubstituted; wherein the substituents are independently selected from alkyl (Ci^), alkoxy (Ci_ 4), halogen, fluoroalkyl (61.3) or fluoroalkoxy (61-3); where, in case Ar3 represents pyridyl or pyrimidinyl, such pyridyl or pyrimidinyl may additionally be present in the form of the respective N-oxide (especially 1-(pyridin-2-yl)—cyclopropyl, 1(pyridin—4—I )—cyclopropyl, 1—(pyrazin—2—¡I)—cyclopropyl, 1—(pyridazin—3—yl)—cyclopropyl, 1—(pyrimidin—2—yl)—cyclopropyl, 1—(5—fluoro—pyridin— 2-yl)-cyclopropyl, 1-(4,6-dimethyl-pyrimidin-2-yl)-cyclopropyl, 1-(pyrimidin-4-yl)-cyclopropyl, 2-(pyrimidin-2-yl)-cyclobutyl, 2 (pyrimidin-2-yl)-cyclopentyl, 1-(1-oxy-pyrimidin-2-yl)-cyclopropyl, 1-(3-fluoro-pyridin-2-yl)-cyclopropyl, 1-(pyridin-2-yl) )-cyclobutyl, 1-(1-oxy-pyridin-2-yl)-cyclopropyl); and R represents, independently, hydrogen or methyl. 15) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 10), where R1 represents RN1RN2N-, where IF-2019-79621737-APN-ANP#INPI Page 60 of 351 RN1represents > hydrogen; > methyl, ethyl, isopropyl, isobutyl, tert-butyl or 1,2,2-trimethyl-propyl; > 2-hydroxy-ethyl, 2-hydroxy-1-methyl-ethyl, 2-hydroxy-1,1-dimethyl-ethyl, 2-methoxy-ethyl, 3-methoxy-propyl, 2-ethoxy-ethyl, 2-ethoxy -1-methylethyl, 2-methoxy-1,1-dimethyl-ethyl, 3-methoxy-1,1-dimethyl-propyl, 2-(2-hydroxy-ethoxy)-ethylcarbamoyl-methyl, 2-methanesulfonyl-1,1- dimethylethyl, 1-cyano-1-methyl-ethyl, 2-dimethylamino-ethyl or 2-trifluoromethoxyethyl; > 1—methyl—prop—2—ynyl; > 2-fluoro-ethyl, 2,2-difluoro-ethyl, 2-fluoro-1-methyl-ethyl, 2-fluoro1,1-dimethyl-ethyl, 2,2-difluoro-1-methyl-ethyl or 3,3 ,3-trifluoro-1,1-dimethyl-propyl; > methoxy; > 2—(2—oxo—pyrrolidin—1—yl)—ethyl; > cyclopropyl, cyclopentyl, 1-methyl-cyclopropyl, 1-methyl-cyclobutyl, 1-cyclopropyl-cyclopropan-1-yl, 1-cyclobutyl-ethyl, 3-methyl-tetrahydrofuran-3-yl, tetrahydrofuran-3-yl-methyl, tetrahydrofuran-2-yl-methyl, 1-tetrahydrofuran-2-l-ethyl, oxetan-3-yl-methyl or 3,3-difluoro-1-methyl-cyclobutyl, > 1-(ethoxycarbonyl)-cyclopropyl or 1 — cyanocyclobutyl; > phenyl, benzyl, 1—phenyl—ethyl, 2—(2—chloro—phenyl)—ethyl, 2-(4-fluorophenyl)—ethyl, 2-(2-methyl-phenyl)-ethyl, 2-(3- methyl-phenyl)-ethyl, 2-(4-methyl-phenyl)-ethyl, 2-(2-methoxy-phenyl)-ethyl, 2-phenyl-propyl, 2-hydroxy-1-phenyl-ethyl, 2-hydroxy-2 —phenyl-ethyl or 2-phenyl-cyclopropyl IF-2019-79621737-APN-ANP#INPI Page 61 of 351 > 1—(3—bromo—phenyl)—ethyl, 1—phenyl—cyclopropyl, 1-phenyl-cyclobutyl, 2-phenyl—cyclobutyl, 1—(3—chloro—phenyl)—cyclopropyl, 1—(4— fluoro—phenyl)— cyclopropyl, 1—(3—fluoro—phenyl)—cyclopropyl, 1—(2—fluoro—phenyl)— cyclopropyl, 1—(2—methyl—phenyl)—cyclopropyl, 1—(2—hydroxy— phenyl)—cyclopropyl, 1-(2-methoxy-phenyl)-ethyl, 2-methyl-2-(2-chloro-phenyl)propyl, 1—(4-chloro-phenyl)—cyclopropyl—methyl, 3-(3 -chloro-phenyl)oxetan-3-yl, 3-(4-fluoro-phenyl)-oxetan-3-yl, 3-(phenyl)-oxetan-3-ylmethyl, 3-(benzyl)-oxetan-3-yl , 1-(2-methoxy-phenyl)-cyclopropyl, 1-(3-methoxy-phenyl)-cyclopropyl, 1-(2-trifluoromethyl-phenyl)-cyclopropyl or 2-ethoxy-2-oxo-1-phenylethyl; > 4,5-dimethyl-thiazol-2-yl, 1H-imidazol-4-yl-methyl, thiazol-2-yl-methyl, 4-methyl-thiazol-5-yl-methyl, 4-methyl-thiazol-2 -yl-methyl, 5-methyl-thiazol2—I—methyl, 2—methyl—thiazol—4—I—methyl, oxazol-5-yl-methyl, 1-(2Hpyrazol—3—yl)—ethyl, ( 1—methyl—1 H—pyrazol—3—yl)—methyl, 1-([1,2,4]oxad iazol—3—yl)—ethyl, 1 —(isoxazol—3—yl)—ethyl, 3- methylisoxazol-5-yl-methyl, 5-methyl-isoxazol-3-yl-methyl, 1-(1 H[1,2,4]triazol—3—yl)—ethyl, (1,5—dimethyl—1 H —pyrazole—3—I)—methyl, (2,5—dimethyl—2H—pyrazol—3—yl)—methyl, (3—ethyl—([1,2,4]oxadiazol—5—yl)—methyl or 1-methyl-1-(5-methyl-[1,2,4]oxadiazol-3-yl)-ethyl; or > pyridin-3-yl, pyridin-2-yl-methyl, pyridin-3-yl-methyl , pyridin—4—¡I— methyl, pyrimidin—2—yl—methyl, pyrimidin—4—I—methyl, pyrazin—2—I— methyl, 1—(pyridin—2—yl)—ethyl, 1— (pyridin—3—I)—ethyl, 2—(pyridin—2—yl)—ethyl, 1—methyl—1—(pyridin—2—yl)—ethyl, 1—(pyrazin—2—yl)—ethyl , 1-(pyrimidin-4-yl)-ethyl, 1-(5-fluoro-pyrimidin-2-yl)-ethyl, 1-(3-fluoropyridin-2-yl)-ethyl, 1-(5-fluoro-pyridin —2—yl)—ethyl, 1—(6—methyl—pyridin—2—yl)—ethyl, 2—hydroxy—1—(pyridin—2—yl)—ethyl, 1—(1—oxy—pyridin—2 —il)— IF-2019-79621737-APN-ANP#INPI < 62 Page 62 of 351 ethyl, 1—(pyridin—2-¡I)-cyclopropyl, 1—(pyridin—4-yl)-cyclopropyl, 1—pyrazin—2—yl)—cyclopropyl, 1—(pyridazin—3-¡ I)-cyclopropyl, . 1(pyrimidin—2—yl)—cyclopropyl, 1—(5—fluoro—pyridin—2—yl)—cyclopropyl, 1(3,5—difluoro—pyridin—2—yl)—ethyl, 2,2,2- trifluoro-1-(pyridin-2-yl)-ethyl or 1-(4,6-dimethyl-pyrimidin-2-yl)-cyclopropyl; or > (6—methyl—pyridin—2—yl)—methyl, 1—(pyrimidin—2—yl)—ethyl, 1—methyl—1— (pyrimidin—2—yl)—ethyl, 1—(pyrimidin—4 —yl)—cyclopropyl, 2—(pyrimidin—2—yl)—cyclobutyl, 2-(pyrimidin-2-I)—cyclopentyl, 1—(1—oxy—pyrimidin—2—yl)—cyclopropyl, 1—( 3—fluoro—pyridin—2—yl)—cyclopropyl, [1—(pyridin—2—yl)—cyclopropyl]—methyl, 1—(pyridin—2—yl)—cyclobutyl, 1—(1—oxy—pyridin— 2-yl)-cyclopropyl, 2-methyl-2-(pyridin-2-yl)-propyl or 2-methyl-2-(3-methylpyridin-2-I)-propyl; and RN2 represents, independently, hydrogen, methyl, ethyl, isopropyl or 2-fluoro-ethyl; • o RN1and RN2 together with the nitrogen atom to which they are attached form a 4 to 6 membered ring selected from azetidin—1—yl, pyrrolidin—1—yl, morpholin-4-yl, 3—fluoro—azetidin—1—yl , 3,3—difluoro—azetidin—1—ílo, 3-hydroxy—pyrrolidin—1—yl, 3—phenyl—pyrrolidin—1—ílo, 3—(pyridin—2—íI)—pyrrolidin—1— ilo. 16) Another embodiment relates to the compounds of formula (I) according to any of embodiments 1) to 15), wherein R2 represents • hydrogen; • (C^)alkyl (especially ethyl, isopropyl, isobutyl, tert-butyl, 2,2-dimethylpropyl, 3-methyl-butyl, 3,3-dimethylbutyl); • (C2-6) alkyl which is monosubstituted with (Ci_3) alkoxy (especially methoxy) or hydroxy; IF-2019-79621737-APN-ANP#INPI Page 63 of 351 (especially 2-hydroxyethyl, 2-methoxy-ethyl, 2-hydroxy-1-methyl-propyl): • cycloalkyl (C3_8)-alkyl (Ci_3), where the cycloalkyl (C3_8) is unsubstituted; or monosubstituted wherein the substituent is alkyl (Ci_3) (especially methyl), fluoro or fluoroalkyl (Ci_3) (especially difluoromethyl); or disubstituted with fluoro; (especially cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 1-cyclopropyl-ethyl, (l-methyl-cyclopropyl)-methyl, (1-methyl-cyclobutyl)-methyl, 2-cyclopropyl-ethyl, (l-fluoro-cyclopropyl)-methyl, (2, 2—difluorocyclopropyl)—methyl, (3,3—difluorocyclobutyl)—methyl, (l-difluoromethyl-cyclopropyl)-methyl); • (C3_8)cycloalkyl, wherein the (C3_8)cycloalkyl is unsubstituted or mono- or disubstituted wherein the substituents are independently selected from (Ci_3)alkyl (especially methyl), fluoro, hydroxy, hydroxy— alkyl (Ci-3) (especially hydroxymethyl) or alkoxy (Ci_3) (especially methoxy); (especially cyclobutyl, 2-methylcyclobutyl, 2,2-dimethylcyclobutyl, 3,3-dimethylcyclobutyl, cyclopentyl, cyclohexyl, spiro[2,4]hept-4-yl, spiro[3,3]hept-2-yl, bicyclo [2,2,1]hept—2-yl, 2-methylcyclopentyl, 2(hydroxymethyl)—cyclopentyl, 3,3—dimethylcyclopentyl, 2—ethylcyclopentyl, 3,3—dimethylcyclohexyl, 2-fluoro-cyclohexyl, 4-fluoro- cyclohexyl, 4,4-difluoro-cyclohexyl, 2-hydroxy-cyclohexyl, 2-methoxy-cyclohexyl, 3-methoxy-cyclohexyl, spiro[2,3]hex-5-yl, bicyclo[3,1,0]hex -3-yl, 3,3-difluorocyclobutyl); • cycloalkenyl (C3_8)-alkyl (C-|_3) (especially cyclopenten-1-ylmethyl); or • benzyl, wherein the phenyl ring of said benzyl is unsubstituted or monosubstituted with halogen (especially benzyl, 2-chloro-benzyl, 2-fluoro-benzyl, 4-fluoro-benzyl). IF-2019-79621737-APN-ANP#INPI Page 64 of 351 17) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 15), wherein R2 represents • cycloalkyl (Cs-ej-alkyl (Ci-3), in where the cycloalkyl (Cs-e) is unsubstituted; or monosubstituted where the substituent is (C1-3) alkyl (especially methyl), fluoro or fluoroalkyl (Ci_3) (especially difluoromethyl); special cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 1-cyclopropyl-ethyl, (1-methyl-cyclopropyl)-methyl, (1-methyl-cyclobutyl)-methyl, 2-cyclopropyl-ethyl, (l-fluoro-cyclopropyl)-methyl, ( 2,2difluorocyclopropyl)-methyl, (3,3-difluorocyclobutyl)-methyl, (1-difluoromethylcyclopropyl)-methyl); or • cycloalkyl (Cs-e), wherein the (C3_8) cycloalkyl is unsubstituted or mono- or disubstituted wherein the substituents are independently selected from alkyl (Ci_3) (especially methyl) or fluoro (especially cyclobutyl, 2-methylcyclobutyl, 2,2-dimethylcyclobutyl, 3,3-dimethylcyclobutyl, cyclopentyl, cyclohexyl, spiro[2,4]hept-4-yl, spiro[3,3]hept-2-yl, bicyclo[2,2,1]hept-2-yl, 2-methylcyclopentyl, 3,3-dimethylcyclopentyl, 2 —ethylcyclopentyl, 3,3-dimethylcyclohexyl, 2-fluorocyclohexyl, 4-fluoro-cyclohexyl, 4,4-difluoro-cyclohexyl, spiro[2,3]hex-5yl, bicyclo[3,1,0]hex-3-yl , 3,3-difluorocyclobutyl). 18) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 15), wherein R2 represents • unsubstituted cycloalkyl (Cs-b)—alkyl (C-i-s) ( especially cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 1-cyclopropyl-ethyl, 2-cyclopropyl-ethyl); or • unsubstituted (C3_6) cycloalkyl (especially cyclobutyl, cyclopentyl, cyclohexyl); either IF-2019-79621737-APN-ANP#INPI Page 65 of 351 • (C3-8)cycloalkyl, wherein the (C3-8)cycloalkyl is disubstituted with fluoro (especially 3,3-difluorocyclobutyl); or • cycloalkyl (Cs-eJ-(61-3)alkyl); wherein the (C3_8)cycloalkyl is monosubstituted with methyl, fluoro or fluoro(C1)alkyl (especially difluoromethyl); or disubstituted with fluoro (especially (1—methyl —cyclopropyl)—methyl, (1—methyl—cyclobutyl)—methyl, (l-fluoro-cyclopropyl)-methyl, (2,2—difluorocyclopropyl)—methyl, (3,3—difluorocyclobutyl)—methyl, (1—difluoromethyl — cyclopropyl)-methyl). 19) Another embodiment refers to the compounds of formula (I) according to any of embodiments 1) to 15), wherein R2 represents • hydrogen; • ethyl, isopropyl, 2,2-dimethylpropyl, 3-methyl-butyl, 3,3-dimethylbutyl; • sobutyl, ter.—butyl; • 2-hydroxyethyl, 2-methoxy-ethyl, 2-hydroxy-1-methyl-propyl; • allyl; • cyano-methyl; • 3-fluoro-propyl; • cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 1-cyclopropyl-ethyl, (1-methyl-cyclopropyl)-methyl, (1-methyl-cyclobutyl)-methyl, 2-cyclopropyl-ethyl; • (l-fluoro-cyclopropyl)-methyl, (2,2-difluorocyclopropyl)-methyl, (3,3-difluorocyclobutyl)-methyl, (l-difluoromethyl-cyclopropyl)-methyl; • cyclobutyl, cyclopentyl, cyclohexyl; • 2—methylcyclobutyl, 2,2—dimethylcyclobutyl, 3,3—dimethylcyclobutyl; IF-2019-79621737-APN-ANP#INPI Page 66 of 351 • 2—methylcyclopentyl, 2-(hydroxymethyl)—cyclopentyl, 3,3-dimethylcyclopentyl, 2-ethylcyclopentyl, 3,3-dimethylcyclohexyl, 2-fluoro-cyclohexyl, 4-fluorocyclohexyl, 4,4-difluoro-cyclohexyl, 2 -hydroxy-cyclohexyl, 2-methoxycyclohexyl, 3-methoxy-cyclohexyl; • 3,3—difluorocyclobutyl; • spiro[2,4]hept—4—yl, spiro[3,3]hept—2—yl, bicyclo[2,2,1 ]hept—2—yl, • spiro[2,3]hex-5- yl, bicyclo[3,1,0]hex-3-yl; • tietan—3—ilo; • cyclopenten-1-ylmethyl; or • benzyl, 2-chloro-benzyl, 2-fluoro-benzyl or 4-fluoro-benzyl. IF-2019-79621737-APN-ANP#INPI Page 67 of 351 20) The invention thus especially relates to compounds of formula (I) as defined in embodiment 1) and to such compounds also limited by the characteristics of any of the embodiments 2) to 19), taking into account their respective dependencies; to its pharmaceutically acceptable salts; and to the use of such compounds as medicaments especially in the prevention / prophylaxis or treatment of disorders referring to the CXCR7 receptor or its ligands as described herein, alone or, as for example in the case of cancer (especially in malignant glioma, in particular glioblastoma multiforme; pancreatic ductal adenocarcinoma; head and neck), optionally in combination with one or more therapeutic agents and / or radiotherapy and / or targeted therapy. For the avoidance of doubt, in particular the following embodiments relating to the compounds of the formula (I) are also possible and intended and are thereby specifically disclosed on an individual basis: 1, 3+1, 4+1, 4+3+1, 5+1, 5+3+1, 5+4+1, 5+4+3+1, 7+1, 7+3+1, 7+4+1, 7+4+3+1, 8+1, 8+3+1, 8+4+1, 8+4+3+1, 9+1, 9+3+1, 9+ 4+1, 9+4+3+1, 9+5+1, 9+5+3+1, 9+5+4+1, 9+5+4+3+1, 9+7+1, 9+7+3+1, 9+7+4+1, 9+7+4+3+1, 9+8+1, 9+8+3+1, 9+8+4+1, 9+ 8+4+3+1, 10+1, 10+3+1, 10+4+1, 10+4+3+1, 10+5+1, 10+5+3+1, 10+5+ 4+1, 10+5+4+3+1, 10+7+1, 10+7+3+1, 10+7+4+1, 10+7+4+3+1, 10+8+ 1, 10+8+3+1, 10+8+4+1, 10+8+4+3+1, 11+1, 11+3+1, 11+4+1, 11+4+3+ 1, 11+5+1, 11+5+3+1, 11+5+4+1, 11+5+4+3+1, 11+7+1, 11+7+3+1, 11+ 7+4+1, 11+7+4+3+1, 11+8+1, 11+8+3+1, 11+8+4+1, 11+8+4+3+1, 11+ 9+1, 11+9+3+1, 11+9+4+1, 11+9+4+3+1, 11+9+5+1, 11+9+5+3+1, 11+ 9+5+4+1, 11+9+5+4+3+1, 11+9+7+1, 11+9+7+3+1, 11+9+7+4+1, 11+ 9+7+4+3+1, 11+9+8+1, 11+9+8+3+1, 11+9+8+4+1, 11+9+8+4+3+1, 11+10+1, 11+10+3+1, 11+10+4+1, 11+10+4+3+1,11+10+5+1, IF-2019-79621737-APN-ANP#INPI Page 68 of 351 11+10+5+3+1, 11+10+5+4+1, 11+10+5+4+3+1, 11+10+7+1, 11+10+7+3+1, 11+10+7+4+1, 11+10+7+4+3+1, 11+10+8+1, 11+10+8+3+1, 11+10+8+4+1, 11+10+8+4+3+1, 12+1, 12+3+1, 12+4+1, 12+4+3+1, 12+5+1, 12+5+3+1, 12+5+4+1, 12+5+4+3+1, 12+7+1, 12+7+3+1, 12+7+4+1, 12+7+4+3+1, 12+8+1, 12+8+3+1, 12+8+4+1, 12+8+4+3+1, 12+9+1, 12+9+3+1, 12+9+ 4+1, 12+9+4+3+1, 12+9+5+1, 12+9+5+3+1, 12+9+5+4+1, 12+9+5+4+ 3+1, 12+9+7+1, 12+9+7+3+1, 12+9+7+4+1, 12+9+7+4+3+1, 12+9+8+1, 12+9+8+3+1, 12+9+8+4+1, 12+9+8+4+3+1, 12+10+1, 12+10+3+1,12+10+ 4+1, 12+10+4+3+1, 12+10+5+1, 12+10+5+3+1, 12+10+5+4+1, 12+10+5+4+ 3+1, 12+10+7+1, 12+10+7+3+1, 12+10+7+4+1, 12+10+7+4+3+1, 12+10+8+ 1, 12+10+8+3+1, 12+10+8+4+1, 12+10+8+4+3+1, 13+1, 13+3+1, 13+4+1, 13+4+3+1, 13+5+1, 13+5+3+1, 13+5+4+1, 13+5+4+3+1, 13+7+1, 13+7+ 3+1, 13+7+4+1, 13+7+4+3+1, 13+8+1, 13+8+3+1, 13+8+4+1, 13+8+4+ 3+1, 13+9+1, 13+9+3+1, 13+9+4+1, 13+9+4+3+1, 13+9+5+1, 13+9+5+ 3+1, 13+9+5+4+1, 13+9+5+4+3+1, 13+9+7+1, 13+9+7+3+1, 13+9+7+ 4+1, 13+9+7+4+3+1, 13+9+8+1, 13+9+8+3+1, 13+9+8+4+1, 13+9+8+ 4+3+1, 13+10+1, 13+10+3+1, 13+10+4+1, 13+10+4+3+1, 13+10+5+1, 13+10+ 5+3+1, 13+10+5+4+1, 13+10+5+4+3+1, 13+10+7+1, 13+10+7+3+1, 13+10+ 7+4+1, 13+10+7+4+3+1, 13+10+8+1, 13+10+8+3+1, 13+10+8+4+1, 13+10+ 8+4+3+1, 14+1, 14+3+1, 14+4+1, 14+4+3+1, 14+5+1, 14+5+3+1, 14+5+ 4+1, 14+5+4+3+1, 14+7+1, 14+7+3+1, 14+7+4+1, 14+7+4+3+1, 14+8+ 1, 14+8+3+1, 14+8+4+1, 14+8+4+3+1, 14+9+1, 14+9+3+1, 14+9+4+1, 14+9+4+3+1, 14+9+5+1, 14+9+5+3+1, 14+9+5+4+1, 14+9+5+4+3+1, 14+9+7+1, 14+9+7+3+1, 14+9+7+4+1, 14+9+7+4+3+1, 14+9+8+1, 14+9+8+3+1, 14+9+8+4+1, 14+9+8+4+3+1, 14+10+1, 14+10+3+1, 14+10+4+1, 14+10+4+3+1, 14+10+5+ 1, 14+10+5+3+1, 14+10+5+4+1, 14+10+5+4+3+1, 14+10+7+1, 14+10+7+3+ 1, 14+10+7+4+1, 14+10+7+4+3+1, 14+10+8+1, 14+10+8+3+1, 14+10+8+4+ 1, 14+10+8+4+3+1, 15+1, 15+3+1, 15+4+1, 15+4+3+1, 15+5+1, 15+5+3+ 1, 15+5+4+1, 15+5+4+3+1, 15+7+1, 15+7+3+1, 15+7+4+1, 15+7+4+3+ 1, 15+8+1, IF-2019-79621737-APN-ANP#INPI Page 69 of 351 15+8+3+1, 15+8+4+1, 15+8+4+3+1, 15+9+1, 15+9+3+1, 15+9+4+1, 15+ 9+4+3+1, 15+9+5+1, 15+9+5+3+1, 15+9+5+4+1, 15+9+5+4+3+1, 15+9+7+1, 15+9+7+3+1, 15+9+7+4+1, 15+9+7+4+3+1, 15+9+8+1, 15+9+8+3+1, 15+9+8+4+1, 15+9+8+4+3+1, 15+10+1,15+10+3+1,15+10+ 4+1, 15+10+4+3+1, 15+10+5+1, 15+10+5+3+1, 15+10+5+4+1, 15+10+5+4+ 3+1, 15+10+7+1, 15+10+7+3+1, 15+10+7+4+1, 15+10+7+4+3+1, 15+10+8+ 1, 15+10+8+3+1, 15+10+8+4+1, 15+10+8+4+3+1, 17+1, 17+3+1, 17+4+1, 17+4+3+1, 17+5+1, 17+5+3+1, 17+5+4+1, 17+5+4+3+1, 17+7+1, 17+7+ 3+1, 17+7+4+1, 17+7+4+3+1, 17+8+1, 17+8+3+1, 17+8+4+1, 17+8+4+ 3+1, 17+9+1, 17+9+3+1, 17+9+4+1, 17+9+4+3+1, 17+9+5+1, 17+9+5+ 3+1, 17+9+5+4+1, 17+9+5+4+3+1, 17+9+7+1, 17+9+7+3+1, 17+9+7+ 4+1, 17+9+7+4+3+1, 17+9+8+1, 17+9+8+3+1, 17+9+8+4+1, 17+9+8+ 4+3+1, 17+10+1, 17+10+3+1, 17+10+4+1, 17+10+4+3+1, 17+10+5+1, 17+10+ 5+3+1, 17+10+5+4+1, 17+10+5+4+3+1, 17+10+7+1, 17+10+7+3+1, 17+10+ 7+4+1, 17+10+7+4+3+1, 17+10+8+1, 17+10+8+3+1, 17+10+8+4+1, 17+10+ 8+4+3+1, 17+11+1, 17+11+3+1, 17+11+4+1, 17+11+4+3+1, 17+11+5+1, 17+ 11+5+3+1, 17+11+5+4+1, 17+11+5+4+3+1, 17+11+7+1, 17+11+7+3+1, 17+11+7+4+1, 17+11+7+4+3+1, 17+11+8+1, 17+11+8+3+1, 17+11+8+4+1, 17+11+8+4+3+ 1, 17+11+9+1, 17+11+9+3+1, 17+11+9+4+1, 17+11+9+4+3+1, 17+11+9+5+ 1, 17+11+9+5+3+1, 17+11+9+5+4+1, 17+11+9+5+4+3+1, 17+11+9+7+1, 17+11+9+7+3+1, 17+11+9+7+4+1, 17+11+9+7+4+3+1, 17+11+9+8+1, 17+11+9+8+3+1, 17+11+9+8+4+1, 17+11+9+8+4+3+1, 17+11+10+1, 17+11+10+3+1, 17+11+10+4+1, 17+11+10+4+3+1, 17+11+10+5+1, 17+11+10+5+3+1, 17+11+10+5+4+1, 17+11+10+5+4+3+1, 17+11+10+7+1, 17+ 11+10+7+3+1, 17+11+10+7+4+1, 17+11+10+7+4+3+1, 17+11+10+8+1, 17+11+ 10+8+3+1, 17+11+10+8+4+1, 17+11+10+8+4+3+1, 17+12+1, 17+12+3+1, 17+12+4+1, 17+12+4+3+1, 17+12+5+1, 17+12+5+3+1, 17+12+5+4+1, 17+12+5+4+3+1, 17+12+7+1, 17+12+7+3+1, 17+12+7+4+1, 17+12+7+4+3+1, 17+12+8+1, 17+12+8+3+1, 17+12+8+4+1, 17+12+8+4+3+ 1, IF-2019-79621737-APN-ANP#INPI Page 70 of 351 17+12+9+1, 17+12+9+3+1, 17+12+9+4+1, 17+12+9+4+3+1, 17+12+9+5+1, 17+12+9+5+3+1, 17+12+9+5+4+1, 17+12+9+5+4+3+1, 17+12+9+7+1, 17+12+9+7+3+1, 17+12+9+7+4+1, 17+12+9+7+4+3+1, 17+12+9+8+1, 17+12+9+8+3+1, 17+12+9+8+4+1, 17+12+9+8+4+3+1, 17+12+10+1, 17+12+10+3+1, 17+12+10+4+1, 17+12+10+4+3+1, 17+12+10+5+1, 17+12+10+5+3+1, 17+12+10+5+4+1, 17+12+10+5+4+3+1, 17+12+10+7+1, 17+ 12+10+7+3+1, 17+12+10+7+4+1, 17+12+10+7+4+3+1, 17+12+10+8+1, 17+12+ 10+8+3+1, 17+12+10+8+4+1, 17+12+10+8+4+3+1, 17+13+1, 17+13+3+1, 17+13+4+1, 17+13+4+3+1, 17+13+5+1, 17+13+5+3+1, 17+13+5+4+1, 17+13+5+4+3+1, 17+13+7+1, 17+13+7+3+1, 17+13+7+4+1, 17+13+7+4+3+1, 17+13+8+1, 17+13+8+3+1, 17+13+8+4+1, 17+13+8+4+3+ 1, 17+13+9+1, 17+13+9+3+1, 17+13+9+4+1, 17+13+9+4+3+1, 17+13+9+5+ 1, 17+13+9+5+3+1, 17+13+9+5+4+1, 17+13+9+5+4+3+1, 17+13+9+7+1, 17+13+9+7+3+1, 17+13+9+7+4+1, 17+13+9+7+4+3+1, 17+13+9+8+1, 17+13+9+8+3+1, 17+13+9+8+4+1, 17+13+9+8+4+3+1, 17+13+10+1, 17+13+10+3+1, 17+13+10+4+1, 17+13+10+4+3+1, 17+13+10+5+1, 17+13+10+5+3+1, 17+13+10+5+4+1, 17+13+10+5+4+3+1, 17+13+10+7+1, 17+ 13+10+7+3+1, 17+13+10+7+4+1, 17+13+10+7+4+3+1, 17+13+10+8+1, 17+13+ 10+8+3+1, 17+13+10+8+4+1, 17+13+10+8+4+3+1, 17+14+1, 17+14+3+1, 17+14+4+1, 17+14+4+3+1, 17+14+5+1, 17+14+5+3+1, 17+14+5+4+1, 17+14+5+4+3+1, 17+14+7+1, 17+14+7+3+1, 17+14+7+4+1, 17+14+7+4+3+1, 17+14+8+1, 17+14+8+3+1, 17+14+8+4+1, 17+14+8+4+3+ 1, 17+14+9+1, 17+14+9+3+1, 17+14+9+4+1, 17+14+9+4+3+1, 17+14+9+5+ 1, 17+14+9+5+3+1, 17+14+9+5+4+1, 17+14+9+5+4+3+1, 17+14+9+7+1, 17+14+9+7+3+1, 17+14+9+7+4+1, 17+14+9+7+4+3+1, 17+14+9+8+1, 17+14+9+8+3+1, 17+14+9+8+4+1, 17+14+9+8+4+3+1, 17+14+10+1, 17+14+10+3+1, 17+14+10+4+1, 17+14+10+4+3+1, 17+14+10+5+1, 17+14+10+5+3+1, 17+14+10+5+4+1, 17+14+10+5+4+3+1, 17+14+10+7+1, 17+ 14+10+7+3+1, 17+14+10+7+4+1, 17+14+10+7+4+3+1, 17+14+10+8+1, IF-2019-79621737-APN-ANP#INPI Page 71 of 351 17+14+10+8+3+1, 17+14+10+8+4+1, 17+14+10+8+4+3+1, 17+15+1, 17+15+3+ 1, 17+15+4+1, 17+15+4+3+1, 17+15+5+1, 17+15+5+3+1, 17+15+5+4+1, 17+ 15+5+4+3+1, 17+15+7+1, 17+15+7+3+1, 17+15+7+4+1, 17+15+7+4+3+1, 17+15+8+1, 17+15+8+3+1, 17+15+8+4+1, 17+15+8+4+3+1, 17+15+9+1, 17+ 15+9+3+1, 17+15+9+4+1, 17+15+9+4+3+1, 17+15+9+5+1, 17+15+9+5+3+ 1, 17+15+9+5+4+1, 17+15+9+5+4+3+1, 17+15+9+7+1, 17+15+9+7+3+1, 17+15+9+7+4+1, 17+15+9+7+4+3+1, 17+15+9+8+1, 17+15+9+8+3+1, 17+ 15+9+8+4+1, 17+15+9+8+4+3+1, 17+15+10+1, 17+15+10+3+1, 17+15+10+4+ 1, 17+15+10+4+3+1, 17+15+10+5+1, 17+15+10+5+3+1, 17+15+10+5+4+1, 17+ 15+10+5+4+3+1, 17+15+10+7+1, 17+15+10+7+3+1, 17+15+10+7+4+1, 17+15+ 10+7+4+3+1, 17+15+10+8+1, 17+15+10+8+3+1, 17+15+10+8+4+1, 17+15+10+ 8+4+3+1, 18+1, 18+3+1, 18+4+1, 18+4+3+1, 18+5+1, 18+5+3+1, 18+5+ 4+1, 18+5+4+3+1, 18+7+1, 18+7+3+1, 18+7+4+1, 18+7+4+3+1, 18+8+ 1, 18+8+3+1, 18+8+4+1, 18+8+4+3+1, 18+9+1, 18+9+3+1, 18+9+4+1, 18+9+4+3+1, 18+9+5+1, 18+9+5+3+1, 18+9+5+4+1, 18+9+5+4+3+1, 18+9+7+1, 18+9+7+3+1, 18+9+7+4+1, 18+9+7+4+3+1, 18+9+8+1, 18+ 9+8+3+1, 18+9+8+4+1, 18+9+8+4+3+1, 18+10+1, 18+10+3+1,18+10+4+ 1, 18+10+4+3+1, 18+10+5+1, 18+10+5+3+1, 18+10+5+4+1, 18+10+5+4+3+ 1, 18+10+7+1, 18+10+7+3+1, 18+10+7+4+1, 18+10+7+4+3+1, 18+10+8+1, 18+10+8+3+1, 18+10+8+4+1, 18+10+8+4+3+1, 18+11+1, 18+11+3+1, 18+11+ 4+1, 18+11+4+3+1, 18+11+5+1, 18+11+5+3+1, 18+11+5+4+1, 18+11+5+4+ 3+1, 18+11+7+1, 18+11+7+3+1, 18+11+7+4+1, 18+11+7+4+3+1, 18+11+8+ 1, 18+11+8+3+1, 18+11+8+4+1, 18+11+8+4+3+1, 18+11+9+1, 18+11+9+3+ 1, 18+11+9+4+1, 18+11+9+4+3+1, 18+11+9+5+1, 18+11+9+5+3+1, 18+11+ 9+5+4+1, 18+11+9+5+4+3+1, 18+11+9+7+1, 18+11+9+7+3+1, 18+11+9+ 7+4+1, 18+11+9+7+4+3+1, 18+11+9+8+1, 18+11+9+8+3+1, 18+11+9+8+ 4+1, 18+11+9+8+4+3+1, 18+11+10+1, 18+11+10+3+1, 18+11+10+4+1, 18+11+ 10+4+3+1, 18+11+10+5+1, 18+11+10+5+3+1, 18+11+10+5+4+1, IF-2019-79621737-APN-ANP#INPI Page 72 of 351 18+11+10+5+4+3+1, 18+11+10+7+1, 18+11+10+7+3+1, 18+11+10+7+4+1, 18+ 11+10+7+4+3+1, 18+11+10+8+1, 18+11+10+8+3+1, 18+11+10+8+4+1, 18+11+ 10+8+4+3+1, 18+12+1, 18+12+3+1, 18+12+4+1, 18+12+4+3+1, 18+12+5+1, 18+12+5+3+1, 18+12+5+4+1, 18+12+5+4+3+1, 18+12+7+1, 18+12+7+3+1, 18+12+7+4+1, 18+12+7+4+3+1, 18+12+8+1, 18+12+8+3+1, 18+12+8+4+1, 18+12+8+4+3+1, 18+12+9+1, 18+12+9+3+1, 18+12+9+4+1, 18+12+9+4+3+ 1, 18+12+9+5+1, 18+12+9+5+3+1, 18+12+9+5+4+1, 18+12+9+5+4+3+1, 18+12+9+7+1, 18+12+9+7+3+1, 18+12+9+7+4+1, 18+12+9+7+4+3+1, 18+12+9+8+1, 18+12+9+8+3+1, 18+12+9+8+4+1, 18+12+9+8+4+3+1, 18+12+10+1, 18+12+10+3+1, 18+12+10+4+1, 18+12+10+4+3+1, 18+12+10+5+1, 18+12+10+5+3+1, 18+12+10+5+4+1, 18+12+ 10+5+4+3+1, 18+12+10+7+1, 18+12+10+7+3+1, 18+12+10+7+4+1, 18+12+10+ 7+4+3+1, 18+12+10+8+1, 18+12+10+8+3+1, 18+12+10+8+4+1, 18+12+10+8+ 4+3+1, 18+13+1, 18+13+3+1, 18+13+4+1, 18+13+4+3+1, 18+13+5+1, 18+13+ 5+3+1, 18+13+5+4+1, 18+13+5+4+3+1, 18+13+7+1, 18+13+7+3+1, 18+13+ 7+4+1, 18+13+7+4+3+1, 18+13+8+1, 18+13+8+3+1, 18+13+8+4+1, 18+13+ 8+4+3+1, 18+13+9+1, 18+13+9+3+1, 18+13+9+4+1, 18+13+9+4+3+1, 18+ 13+9+5+1, 18+13+9+5+3+1, 18+13+9+5+4+1, 18+13+9+5+4+3+1, 18+13+9+7+1, 18+13+9+7+3+1, 18+13+9+7+4+1, 18+13+9+7+4+3+1, 18+13+9+8+1, 18+13+9+8+3+1, 18+13+9+8+4+1, 18+13+9+8+4+3+1, 18+13+10+1, 18+13+10+3+1, 18+13+10+4+1, 18+13+10+4+3+1, 18+13+10+5+1, 18+13+10+5+3+1, 18+13+10+5+4+1, 18+13+ 10+5+4+3+1, 18+13+10+7+1, 18+13+10+7+3+1, 18+13+10+7+4+1, 18+13+10+ 7+4+3+1, 18+13+10+8+1, 18+13+10+8+3+1, 18+13+10+8+4+1, 18+13+10+8+ 4+3+1, 18+14+1, 18+14+3+1, 18+14+4+1, 18+14+4+3+1, 18+14+5+1, 18+14+ 5+3+1, 18+14+5+4+1, 18+14+5+4+3+1, 18+14+7+1, 18+14+7+3+1, 18+14+ 7+4+1, 18+14+7+4+3+1, 18+14+8+1, 18+14+8+3+1, 18+14+8+4+1, 18+14+ 8+4+3+1, 18+14+9+1, 18+14+9+3+1, 18+14+9+4+1, 18+14+9+4+3+1, 18+ 14+9+5+1, 18+14+9+5+3+1, 18+14+9+5+4+1, IF-2019-79621737-APN-ANP#INPI Page 73 of 351 18+14+9+5+4+3+1, 18+14+9+7+1, 18+14+9+7+3+1, 18+14+9+7+4+1, 18+ 14+9+7+4+3+1, 18+14+9+8+1, 18+14+9+8+3+1, 18+14+9+8+4+1, 18+14+ 9+8+4+3+1, 18+14+10+1, 18+14+10+3+1, 18+14+10+4+1, 18+14+10+4+3+1, 18+14+10+5+1, 18+14+10+5+3+1, 18+14+10+5+4+1, 18+14+10+5+4+3+1, 18+ 14+10+7+1, 18+14+10+7+3+1, 18+14+10+7+4+1, 18+14+10+7+4+3+1, 18+14+ 10+8+1, 18+14+10+8+3+1, 18+14+10+8+4+1,' 18+14+10+8+4+3+1, 18+15+1 , 18+15+3+1, 18+15+4+1, 18+15+4+3+1, 18+15+5+1, 18+15+5+3+1, 18+15+5 +4+1, 18+15+5+4+3+1, 18+15+7+1, 18+15+7+3+1, 18+15+7+4+1, 18+15+7 +4+3+1, 18+15+8+1, 18+15+8+3+1, 18+15+8+4+1, 18+15+8+4+3+1, 18+15 +9+1, 18+15+9+3+1, 18+15+9+4+1, 18+15+9+4+3+1, 18+15+9+5+1, 18+15 +9+5+3+1, 18+15+9+5+4+1, 18+15+9+5+4+3+1, 18+15+9+7+1, 18+15+9 +7+3+1, 18+15+9+7+4+1, 18+15+9+7+4+3+1, 18+15+9+8+1, 18+15+9+8 +3+1, 18+15+9+8+4+1, 18+15+9+8+4+3+1, 18+15+10+1, 18+15+10+3+1, 18 +15+10+4+1, 18+15+10+4+3+1, 18+15+10+5+1, 18+15+10+5+3+1, 18+15+10+5 +4+1, 18+15+10+5+4+3+1, 18+15+10+7+1, 18+15+10+7+3+1, 18+15+10+7+4 +1, 18+15+10+7+4+3+1, 18+15+10+8+1, 18+15+10+8+3+1, 18+15+10+8+4+1 , 18+15+10+8+4+3+1, 19+1, 19+3+1, 19+4+1, 19+4+3+1, 19+5+1, 19+5+3 +1, 19+5+4+1, 19+5+4+3+1, 19+7+1, 19+7+3+1, 19+7+4+1, 19+7+4+3 +1, 19+8+1, 19+8+3+1, 19+8+4+1, 19+8+4+3+1, 19+9+1, 19+9+3+1, 19 +9+4+1, 19+9+4+3+1, 19+9+5+1, 19+9+5+3+1, 19+9+5+4+1, 19+9+5 +4+3+1, 19+9+7+1, 19+9+7+3+1, 19+9+7+4+1, 19+9+7+4+3+1, 19+9 +8+1, 19+9+8+3+1, 19+9+8+4+1, 19+9+8+4+3+1, 19+10+1, 19+10+3+1 , 19+10+4+1, 19+10+4+3+1, 19+10+5+1, 19+10+5+3+1, 19+10+5+4+1, 19+10 +5+4+3+1, 19+10+7+1, 19+10+7+3+1, 19+10+7+4+1, 19+10+7+4+3+1, 19 +10+8+1, 19+10+8+3+1, 19+10+8+4+1, 19+10+8+4+3+1, 19+11+1, 19+11+3 +1, 19+11+4+1, 19+11+4+3+1, 19+11+5+1, 19+11+5+3+1, 19+11+5+4+1, 19 +11+5+4+3+1, 19+11+7+1, 19+11+7+3+1, 19+11+7+4+1, 19+11+7+4+3+1 , 19+11+8+1, 19+11+8+3+1, 19+11+8+4+1, 19+11+8+4+3+1, 19+11+9+1, IF-2019-79621737-APN-ANP#INPI Page 74 of 351 19+11+9+3+1, 19+11+9+4+1, 19+11+9+4+3+1, 19+11+9+5+1, 19+11+9+5+3+1, 19+11+9+5+4+1, 19+11+9+5+4+3+1, 19+11+9+7+1, 19+11+9+7+3+1, 19+11+9+7+4+1, 19+11+9+7+4+3+1, 19+11+9+8+1, 19+11+9+8+3+1, 19+11+9+8+4+1, 19+11+9+8+4+3+1, 19+11+10+1, 19+11+10+3+1, 19+11+10+4+1, 19+11+10+4+3+1, 19+11+10+5+1, 19+11+10+5+3+1, 19+11+10+5+4+1, 19+11+10+5+4+3+1, 19+11+10+7+1, 19+ 11+10+7+3+1, 19+11+10+7+4+1, 19+11+10+7+4+3+1, 19+11+10+8+1, 19+11+ 10+8+3+1, 19+11+10+8+4+1, 19+11+10+8+4+3+1, 19+12+1, 19+12+3+1, 19+12+4+1, 19+12+4+3+1, 19+12+5+1, 19+12+5+3+1, 19+12+5+4+1, 19+12+5+4+3+1, 19+12+7+1, 19+12+7+3+1, 19+12+7+4+1, 19+12+7+4+3+1, 19+12+8+1, 19+12+8+3+1, 19+12+8+4+1, 19+12+8+4+3+ 1, 19+12+9+1, 19+12+9+3+1, 19+12+9+4+1, 19+12+9+4+3+1, 19+12+9+5+ 1, 19+12+9+5+3+1, 19+12+9+5+4+1, 19+12+9+5+4+3+1, 19+12+9+7+1, 19+12+9+7+3+1, 19+12+9+7+4+1, 19+12+9+7+4+3+1, 19+12+9+8+1, 19+12+9+8+3+1, 19+12+9+8+4+1, 19+12+9+8+4+3+1, 19+12+10+1, 19+12+10+3+1, 19+12+10+4+1, 19+12+10+4+3+1, 19+12+10+5+1, 19+12+10+5+3+1, 19+12+10+5+4+1, 19+12+10+5+4+3+1, 19+12+10+7+1, 19+ 12+10+7+3+1, 19+12+10+7+4+1, 19+12+10+7+4+3+1, 19+12+10+8+1, 19+12+ 10+8+3+1, 19+12+10+8+4+1, 19+12+10+8+4+3+1, 19+13+1, 19+13+3+1, 19+13+4+1, 19+13+4+3+1, 19+13+5+1, 19+13+5+3+1, 19+13+5+4+1, 19+13+5+4+3+1, 19+13+7+1, 19+13+7+3+1, 19+13+7+4+1, 19+13+7+4+3+1, 19+13+8+1, 19+13+8+3+1, 19+13+8+4+1, 19+13+8+4+3+ 1, 19+13+9+1, 19+13+9+3+1, 19+13+9+4+1, 19+13+9+4+3+1, 19+13+9+5+ 1, 19+13+9+5+3+1, 19+13+9+5+4+1, 19+13+9+5+4+3+1, 19+13+9+7+1, 19+13+9+7+3+1, 19+13+9+7+4+1, 19+13+9+7+4+3+1, 19+13+9+8+1, 19+13+9+8+3+1, 19+13+9+8+4+1, 19+13+9+8+4+3+1, 19+13+10+1, 19+13+10+3+1, 19+13+10+4+1, 19+13+10+4+3+1, 19+13+10+5+1, 19+13+10+5+3+1, 19+13+10+5+4+1, 19+13+10+5+4+3+1, 19+13+10+7+1, 19+ 13+10+7+3+1, 19+13+10+7+4+1, 19+13+10+7+4+3+1, 19+13+10+8+1, IF-2019-79621737-APN-ANP#INPI Page 75 of 351 19+13+10+8+3+1, 19+13+10+8+4+1, 19+13+10+8+4+3+1, 19+14+1, 19+14+3+1, 19+14+4+1, 19+14+4+3+1, 19+14+5+1, 19+14+5+3+1, 19+14+5+4+1, 19+14+5+4+3+1, 19+14+7+1, 19+14+7+3+1, 19+14+7+4+1, 19+14+7+4+3+1, 19+14+8+1, 19+14+8+3+1, 19+14+8+4+1, 19+14+8+4+3+ 1, 19+14+9+1, 19+14+9+3+1, 19+14+9+4+1, 19+14+9+4+3+1, 19+14+9+5+ 1, 19+14+9+5+3+1, 19+14+9+5+4+1, 19+14+9+5+4+3+1, 19+14+9+7+1, 19+14+9+7+3+1, 19+14+9+7+4+1, 19+14+9+7+4+3+1, 19+14+9+8+1, 19+14+9+8+3+1, 19+14+9+8+4+1, 19+14+9+8+4+3+1, 19+14+10+1, 19+14+10+3+1, 19+14+10+4+1, 19+14+10+4+3+1, 19+14+10+5+1, 19+14+10+5+3+1, 19+14+10+5+4+1, 19+14+10+5+4+3+1, 19+14+10+7+1, 19+ 14+10+7+3+1, 19+14+10+7+4+1, 19+14+10+7+4+3+1, 19+14+10+8+1, 19+14+ 10+8+3+1, 19+14+10+8+4+1, 19+14+10+8+4+3+1, 19+15+1, 19+15+3+1, 19+15+4+1, 19+15+4+3+1, 19+15+5+1, 19+15+5+3+1, 19+15+5+4+1, 19+15+5+4+3+1, 19+15+7+1, 19+15+7+3+1, 19+15+7+4+1, 19+15+7+4+3+1, 19+15+8+1, 19+15+8+3+1, 19+15+8+4+1, 19+15+8+4+3+ 1, 19+15+9+1, 19+15+9+3+1, 19+15+9+4+1, 19+15+9+4+3+1, 19+15+9+5+ 1, 19+15+9+5+3+1, 19+15+9+5+4+1, 19+15+9+5+4+3+1, 19+15+9+7+1, 19+15+9+7+3+1, 19+15+9+7+4+1, 19+15+9+7+4+3+1, 19+15+9+8+1, 19+15+9+8+3+1, 19+15+9+8+4+1, 19+15+9+8+4+3+1, .19+15+10+1, 19+15+10+3+1, 19+15+10+4+1, 19+15+10+4+3+1, 19+15+10+5+1, 19+15+10+5+3+1, 19+15+10+5+4+1, 19+15+10+5+4+3+1, 19+15+10+7+1, 19+ 15+10+7+3+1, 19+15+10+7+4+1, 19+15+10+7+4+3+1, 19+15+10+8+1, 19+15+ 10+8+3+1, 19+15+10+8+4+1,19+15+10+8+4+3+1. In the above list, numbers refer to embodiments according to their numbering provided herein above, while “+” indicates dependence on another embodiment. The different individualized embodiments are separated with commas. In other words, “18+14+8+1 for example refers to an embodiment 18) according to embodiment 14), according to embodiment 8), according to IF-2019-79621737-APN-ANP# INPI 76 Page 76 of 351 embodiment 1), i.e. embodiment 18+14+8+1” corresponds to the compounds of formula (I) according to embodiment 1) also limited by all the characteristics of embodiments 8), 14) and 18). 21) Another embodiment refers to compounds according to embodiment 1) which are selected from the following compounds: (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-p¡perídin-3-carboxylic¡ (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-p¡perídin-3-carboxylic¡ (1—methyl—1—pyridin—2—yl—ethyl) —(3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide; (1—pyrimidin—2—yl—cyclopropyl)—amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-am no}-piperidine-3-carboxylic ¡(1—pyrimidin—2—yl—cyclopropyl)—amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—amide (3S,4S)—1—Cyclohexyl—4—{[5—(2I4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidn -3-carboxylic acid cyclopentylamide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazole-3-carbonyl]-amino}-piperidine --3-carboxylic; 5-(2,4-Difluoro-phenyl)-isoxazole-3-carboxylic acid [(3R*,4R*)-1-cyclohexyl-3-(pyrrolidin-1-carbonyl)-piperidin-4-yl]-amide ; Acid (2-hydroxy-ethyl)-methyl-amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidín-3-carboxylic acid; ' (3R*,4R*)-1-C¡clohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol-3-carbonyl]amino}-piper¡din-3-carboxylic ( 2-methoxy-ethyl)-amide; acid isobutyl-amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperídine-3- carboxylic! IF-2019-79621737-APN-ANP#INPI Page 77 of 351 (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid isopropylamide; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]aminoJ-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid methylamide; (2-fluoro-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol3-carbonyl]-amino}-piperidine-3-carboxylic acid ethylamide! cyclopropyl-methyl-amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid carbamoylmethyl-amide; (2-hydroxy-ethyl)-amide (3R*,4R*)-1-CyclohexiM-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid ; 5-(2,4-Difluoro-phenyl)-isoxazole-3-carboxylic acid [(3R*,4R*)-1-cyclohexyl-3-(morpholine-4-carbonyl)-piperidin-4-yl]-amide ; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid isopropyl-methyl-amide; (2-dimethylamino-ethyl)-methyl-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (2-ethoxy-ethyl)-methyl-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine -3-carboxylic; (5-methyl-thiazol-2-ylmethyl)-acid acid (3R*,4R*)-1-CyclohexiM-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-pipendin -3-carboxylic; (2-methoxy-ethyl)-methyl-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-pipendin -3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 78 of 351 (5—methyl—isoxazol—3—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (2-dimethylamino-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidin-3 -carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid ethyl-methyl-amide; (pyridin—2—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (2,2-difluoro-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine -3-carboxylic; Acid (3-methoxy-propyl)-methyl-amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; 5-(2,4-Difluoro-phenyl)-isoxazole-3-carboxylic [(3R*,4R*)-1-cyclohexyl-3-(3hydroxy—pyrrolidin—1—carbonyl)—piperidin-4-yl]-amide ; (3-methyl-isoxazol-5-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic; 5-(2,4-Difluoro-phenyl)-isoxazole-3-carboxylic acid [(3R*,4R*)-3-(azetidin-1-carbonyl)-1-cyclohexyl-piperidin-4-yl]-amide ; (2-methyl-thiazol-4-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (pyrimidin—2—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (4-methyl-thiazol-5-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -pipendin-3-carboxylic; (pyrimidin—4—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol-3-carbonyl]amino}-piperidine-3-carboxylic (oxazol-5-ylmethyl)- amide; . · IF-2019-79621737-APN-ANP#INPI Page 79 of 351 5-(2,4—Difluoro—phenyl)—isoxazole—3—carboxylic [(3R*,4R*)-1-cyclohexyl-3-(3fluoro—azetidin—1—carbonyl)—piperidine—4—¡I]— amide; (pyrazin-2-ylmethyl)-amide (3R*,4R*)-1-CyclohexiM-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid ; (2-trifluoromethoxy-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; methyl-oxetan-3-ylmethyl-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidin-3 -carboxylic; (1—pyridin—2—I—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [2—(2—oxo—pyrrolidin—1—yl)—ethyl]—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole- 3-carbonyl]-amino}-piperidine-3-carboxylic; (1-methyl-1H-pyrazol-3-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (1H-imidazol-4-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; (tetrahydro-furan-2-ylmethyl)-acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1,5-dimethyl-1H-pyrazol-3-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((1S,2R)-2-phenyl-cyclopropyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((1R,2S)-2-phenyl-cyclopropyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((1S,2R)-2-phenyl-cyclopropyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((1R,2S)-2-phenyl-cyclopropyl)-acid acid (3S,4S)—1—Cyclohexyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 80 of 351 (3—ethyl—[1,2,4]oxadiazol—5—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (pyridin—3—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid methyl-phenethyl-amide; (pyridin—4—ylmethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (thiazol-2-ylmethyl)-acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidin-3 -carboxylic; [(3R*,4R*)—1—cyclohexyl—3—(3,3—difluoro—azetidin—1—carbonyl)—piperidin—4—yl]— 5-(2,4-Difluoro-phenyl) acid amide -isoxazole-3-carboxylic acid (tetrahydro-furan-3-ylmethyl)-amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; (2,5-dimethyl-2H-pyrazol-3-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; Acid [2-(2-hydroxy-ethoxy)-ethyl]-isopropyl-amide (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (2—o—tolyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; [2-(2-methoxy-phenyl)-ethyl]-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [2-(2-chloro-phenyl)-ethyl]-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [2—(4—fluoro—phenyl)—ethyl]—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (2-phenyl-propyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; IF-2019-79621737-APN-ANP#INPI Page 81 of 351 ((1 R*,2S*)—2—phenyl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-am¡no}-p¡peridín-3-carboxylic¡ ((1S*,2R*)-2-phenyl-cyclopropyl)-acid acid amide (3R*,4R*)- 1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (2—p—tolyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; (1—(pyrimidin—4—¡I)—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid phenylamide; (4,5—dimethyl—thiazol—2—yl)—(3R*,4R*)-1-CyclohexiM-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-amide piperidine-3-carboxylic; (2-m-tolyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine -3-carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid pyridine-3-ylamide; (4-methyl-thiazol-2-ylmethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (2,2,2—trifluoro—1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(3R*,4R*)—1—cyclohexyl—3—(3—phenyl—pyrrolidin—1—carbonyl)—piperidin—4—yl]—acid amide 5-(2,4-Difluoro-phenyl)-isoxazole -3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—2—hydroxy—2—phenyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidin-3-carboxylic acid: ((S)-2-hydroxy-2-phenyl-ethyl)-amide (3R*,4R*)-1-Cyclohexyl-4-{[5 (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; IF-2019-79621737-APN-ANP#INPI Page 82 of 351 (2—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; methyl—(2—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (2-hydroxy-1-methyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (2,2-difluoro-1-methyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—cyclobutyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (2—fluoro—1,1—dimethyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendine-3-carboxylic acid; (3,3,3—trifluoro—1,1—dimethyl—propyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole- 3-carbonyl]-amino}-piperidine-3-carboxylic; (2-methanesulfonyl-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (2-fluoro-1-methyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (2-ethoxy-1-methyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (3-methyl-tetrahydro-furan-3-yl)-acid acid (3R*,4R*)-1-CyclohexiM-{[5(2,4-difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic; [1—(5—methyl—[1,3,4]oxadiazol—2—yl)—ethyl]—acid amide (3R*,4R*)-1Cyclohexyl-4-{[5-(2,4-difluoro -phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3carboxylic; [1-(3,5-difluoro-pyridin-2-yl)-ethyl]-acid acid amide (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (3,3—difluoro—1—methyl—cyclobutyl)—acid amide (3R*,4R*)-1-CyclohexiM{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 83 of 351 (2—hydroxy—1,1—dimethyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole- 3-carbonyl]-amino}-piperidine-3-carboxylic; [(3R*,4R*)—1—cyclohexyl—3—(3—pyridin—2—yl—pyrrolidin—1—carbonyl)—piperidin—4—yl]-acid amide 5-(2,4-Difluoro- phenyl)-isoxazole-3-carboxylic acid. ((R)-1-pyrazin-2-¡I-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1-cyclobutyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; [(R)—1—(3—fluoro—pyridin—2—yl)—ethyl]—acid amide (3R*,4R*)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; . ((R)-1,2,2-trimethyl—propyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-¡soxazole-3- carbonyl]-am¡no}-p¡perídin-3-carboxylic¡ [(R)—1—(5—fluoro—pyrimidin—2—yl)—ethyl]—acid amide (3R*,4R*)-1-Cyclohexyl4-{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; acid dimethylamide (3R,4R)—1—Cyclohexyl—4—{[1—(2,4—difluoro—phenyl)—1H— [1,2,3]triazole-4-carbonyl]-amino}-piperidin- 3-carboxylic; acid dimethylamide (3S,4S)—1—Cyclohexyl—4—{[1—(2,4—difluoro—phenyl)—1H— [1,2,3]triazole-4-carbonyl]-amino}-piperidine-3-carboxylic acid; acid dimethylamide (3R*,4R*)-1-CiclopentiM-{[1-(2,4-difluoro-phenyl)-1H[1,2,3]triazol-4-carbonyl]-amino}-piperidin-3 -carboxylic; acid dimethylamide (3R*,4R*)-1-CyclopropylmetiM-{[1-(2,4-difluoro-phenyl)1 H-[1,2,3]triazol-4-carbonyl]-amino}-piperidin- 3-carboxylic; acid dimethylamide (3R*,4R*)-4-{[1-(2,4-Difluoro-phenyl)-1H-[1,2,3]triazol4-carbonyl]-amino}-1-(2-methyl -cyclopentyl)-piperidine-3-carboxylic; (3R*,4R*)-1-CiclopentiM-{[5-(2,4,6-trifluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-1-Cyclopropylmethyl-4-{[5-(2,4,6-trifluorophenyl)-isoxazol-3-carbonyl]-amino}-p¡peridine-3-carboxylic acid dimethylamide IF-2019-79621737-APN-ANP#INPI Page 84 of 351 acid dimethylamide (3R*,4R*)-1-(2-Methyl-cyclopentyl)-4-{[5-(2,4,6-trifluorophenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (3R*,4R*)-1-Cyclohexyl-4-{[3-(2,4-difluoro-phenyl)isoxazol-5-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-1-Cyclopentyl-4-{[3-(2,4-difluoro-phenyl)isoxazol-5-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; [(3R*,4R*)-3-(azetidin-1-carbonyl)-1-cyclohexyl-piperidin-4-yl]-acid acid 1-(2,4—Difluoro—phenyl)—1 H-[1 ,2,3]triazole-4-carboxylic acid; [(3R*,4R*)-3-(azetidin-1-carbonyl)-1-cyclohexyl-piperidin-4-yl]-5-(2,4,6-Trifluoro-phenyl)-isoxazole-3 acid amide -carboxylic; [(3R*,4R*)-3-(azetidin-1-carbonyl)-1-cyclopentyl-piperidin-4-yl]-5-(2,4,6-Trifluoro-phenyl)-isoxazole-3 acid amide -carboxylic; [(3R*,4R*)-3-(azetidin-1-carbonyl)-1-cyclopropylmethyl-piperidin-4-yl]-amide 5-(2,4,6-Trifluoro-phenyl)-isoxazole-3 -carboxylic; 5-(2,4,6-Trifluoro-phenyl) [(3R*,4R*)-3-(azetidin-1-carbonyl)-1-(2-methyl-cyclopentyl)-piperidin-4-yl]amide )-isoxazole-3-carboxylic acid (2-methoxy-1,1-dimethyl-ethyl)-amide (3R*,4R*)-1-Cyclopentyl-4-{[1(2,4—difluoro—phenyl )—1 H—[1,2,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[1—(2,4—difluoro—phenyl)—1 H—[1, 2,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-Cyclopentyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 85 of 351 (2—methoxy—1,1—dimethyl—ethyl)—acid amide (3R,4R)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-(2-Methyl-cyclopentyl)4-{[5-(2,4,6-trifluoro-phenyl) )-isoxazole-3-carbonyl]-amino}-piperidine-3carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl] -amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-Cyclopentyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl] -amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2-yl-ethyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[1-(2,4difluoro-phenyl)-1H-[1,2, 3]triazol-4-carbonyl]-amino}-pipendine-3-carboxylic acid; ((R)—1—pyridin—2—¡I—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[1-(2,4difluoro-phenyl)-1H-[1,2 ,3]triazol-4-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclopentyl—4—{[1—(2,4—difluoro—phenyl)—1 H—[1 ,2,3]triazole-4-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopentyl-4—{[1—(2,4—difluoro-phenyl)—1 H-[1 ,2,3]triazol-4-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[1(2,4-difluoro-phenyl)-1H-[1 ,2,3]triazol-4-carbonyl]-amino}-piperidine-3carboxylic acid; ((R)—1— pyridin-2-I-ethyl)-acid acid amide (3R*,4R*)-4-{[1-(2,4-Difluoro-phenyl)1 H—[1,2 ,3]triazole—4—carbonyl]—amino}—1—(2—methyl—cyclopentyl)—piperidine—3—carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclohexyl—4—{[5—(2,4,6— trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-pipendine-3-carboxylic; ((R)—1—pyridin—2—¡I—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3- carbonyl]-amino}-pipendine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 86 of 351 ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclopentyl—4—{[5—(2,4,6— trifluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3S,4S)-1-Cyclopentyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—¡I—ethyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-pipendine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3R*,4R*)-1-(2-Methyl-cyclopentyl)-4{[5-(2,4,6-trifluoro -phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—I—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl] -amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—I—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[3—(2,4— difluoro-phenyl)-isoxazole-5- carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; . ((R)—1—pyrazin—2—I—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[1-(2,4difluoro—phenyl)—1H—[1 ,2,3]triazole-4-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R*,4R*)—1—Cyclopentyl—4—{[1 -(2,4difluoro—phenyl)—1 H—[1 ,2,3]triazol-4-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R*,4R*)-1-CyclohexiM-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—(3R,4R)-1-Cyclohexyl—4—{[5-(2,4,6— trifluoro-phenyl)-isoxazole-3 acid amide -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4,6—trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; , · IF-2019-79621737-APN-ANP#INPI Page 87 of 351 ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R*,4R*)-1-(2-Methyl-cyclopentyl)-4{[5-(2,4,6-trifluoro -phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)-1-pyrazin-2-yl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[1-(2,4difluoro—phenyl)—1 H—[1,2,3 ]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; ((R)-1-cyclobutyl-ethyl)-acid acid (3R*,4R*)-1-Cyclopentyl-4-{[1-(2,4difluoro-phenyl)-1H-[1,2,3] triazole-4-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—cyclobutyl—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[1(2,4—difluoro—phenyl)—1 H—[1,2, 3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; ((R)—1—cyclobutyl—ethyl)—acid amide (3R*,4R*)-4-{[1-(2,4-Difluoro-phenyl)1 H—[1,2,3]triazole— 4-carbonyl]-amino}-1-(2-methyl-cyclopentyl)-piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)—acid amide (3R,4R)—1—Cyclopentyl—4—{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; ((R)-1-cyclobutyl-ethyl)-acid acid (3S,4S)-1-Cyclopentyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carboyl]-amino} -piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)—(3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; ((R)-1—Cyclobutyl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl-4—{[5—(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 88 of 351 ((R)—1—cyclobutyl—ethyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—í—cyclobutyl—ethyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl]-amino} -pipendin-3-carboxylic; [1-(5-fluoro-pyridin-2-yl)—cyclopropyl]—acid amide (3R*,4R*)-1-Cid°hexyl4—{[1—(2,4—difluoro—phenyl)—1 H—[1,2,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; [1—(5—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3R*,4R*)-1-Cyclohexyl4-{[5-(2,4,6-trifluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3carboxylic; [1—(5—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3R*,4R*)-1Cyclopropylmethyl-4-{[5-(2,4,6-trifluoro-phenyl)-isoxazole -3-carbonyl]-amino}piperidine-3-carboxylic; ((1R*,2S*)-2-phenyl-cyclopropyl)-acid acid amide (3R*,4R*)-1-Cyclohexyl-4-{[1(2,4—difluoro—phenyl)—1 H-[ 1,2,3]triazol-4-carbonyl]-amino}-piperidine-3carboxylic; . ((1S*,2R*)-2-phenyl-cyclopropyl)-acid acid amide (3R*,4R*)-1-CyclohexiM-{[1(2,4-difluoro-phenyl)-1H—[1,2 ,3]triazol-4-carbonyl]-amino}-piperidine-3carboxylic; ((1R*,2S*)-2-phenyl-cyclopropyl)-acid acid (3R*,4R*)-1-Cyclopentyl-4-{[1(2,4-difluoro-phenyl)-1H-[1 ,2,3]triazol-4-carbonyl]-amino}-pipendine-3carboxylic; ((1R*,2S*)-2-phenyl-cyclopropyl)-acid acid amide (3R*,4R*)-1-CiclopentiM-{[1(2,4—difluoro—phenyl)—1 H—[1, 2,3]triazole-4-carbonyl]-amino}-piperidine-3-carboxylic; ((1S*,2R*)-2-phenyl-cyclopropyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5- carbonyl]-amino}-piperidine-3-carboxylic; ((1R*,2S*)-2-phenyl-cyclopropyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[3(2,4-difluoro-phenyl)-ísoxazole-5 -carbonyl]-am¡no}-p¡perídin-3-carboxylic¡ IF-2019-79621737-APN-ANP#INPI Page 89 of 351 ((1 S*,2R*)—2—phenyl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[3(2,4-difluoro-phenyl) -isoxazole-5-carbonyl]-amino}-piperidine-3-carboxylic; ((1R*,2S*)-2-phenyl-cyclopropyl)-acid acid (3R*,4R*)-1-CiclopentiM-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl] -amino)-piperidine-3-carboxylic; (3R*,4R*)-1-Cyclopropylmethyl-4-{[3-(2,4-difluoro-phenyl)isoxazol-5-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-4-{[3-(2,4-Difluoro-phenyl)-isoxazole-5carbonyl]-amino}-1-(2-methyl-cyclopentyl)-piperidine-3-carboxylic acid dimethylamide ; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-CyclopropylmetiM{[3-(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-[1,2,4 ]oxadiazol-3-carbonyl]-amino}-piperidine-3carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-[1,2,4 ]oxadiazol-3-carbonyl]-amino}-piperidine-3carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl] -amino}-pipendine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[3— (2,4-difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; .((R)—1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-4-{[3-(2,4-Difluoro-phenyl)isoxazole-5-carbonyl]- amino}-1-(2-methyl-cyclopentyl)-piperidine-3-carboxylic; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3R,4R)-1—Cyclohexyl-4—{[5—(2,4— difluoro-phenyl)-[1,2, 4]oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-[1,2,4] oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3R*,4R*)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-[1,2, 4]oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; - IF-2019-79621737-APN-ANP#INPI Page 90 of 351 ((R)—1—pyridin—2—¡I—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl) -[1,2,4]oxadiazol-3-carbonyl]-amino}-piperidine-3carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5- carbonyl]-amino}-piperidine-3-carboxylic; ((R)-1-pyrazin-2-yl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-[1,2, 4]oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—cyclobutyl—ethyl)-acid acid (3R*,4R*)-1-Cyclopropylmethyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino}-piperidine-3-carboxylic; ((R)-1-cyclobutyl-ethyl)-acid acid (3R*,4R*)-4-{[3-(2,4-Difluoro-phenyl)isoxazol-5-carbonyl]-amino}-1- (2-methyl-cyclopentyl)-piperidine-3-carboxylic; [1—(5—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3R*,4R*)-1Cyclopropylmethyl-4-{[3-(2,4-difluoro-phenyl)-isoxazole-5 -carbonyl]-amino}piperidine—3—carboxylic; ((1S*,2R*)-2-phenyl-cyclopropyl)-acid acid (3R*,4R*)-1-Cyclopropylmethyl4-{[3-(2,4-difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; ((1R*,2S*)-2-phenyl-cyclopropyl)-acid acid (3R*,4R*)-1-Cyclopropylmethyl-4{[3-(2,4-difluoro-phenyl)-isoxazole-5- carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[1-(2,4d!fluoro-phenyl)-1 H-[1,2 ,3]triazole—4-carbonyl]—amino}-piperidine-3-carboxylic acid; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1—Cyclohexyl—4—{[1—(2,4—difluoro—phenyl)—1 H—[1,2,3 ]triazol-4-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1—Cyclohexyl-4—{[1—(2,4—difluoro—phenyl)—1 H—[1,2,3 ]triazol-4-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R*,4R*)-1-CiclopentiM-{[1(2,4-difluoro-phenyl)-1H-[1,2,3] triazole-4-carbonyl]-amino}-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI Page 91 of 351 (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-CyclopropylmetiM{[ 1 -(2,4—difluoro—phenyl)—1H—[1,2 ,3]triazol-4-carbonyl]-amino}-piperidine-3carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R*,4R*)-4-{[1-(2,4-Difluorophenyl)—1 H—[1,2,3]triazole— 4-carbonyl]-amino}-1-(2-methyl-cyclopentyl)-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R,4R)-1-Cyclopentyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic acid: (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-(2-Methyl-cyclopentyl)4—{[5-(2,4,6-trifluoro-phenyl)- isoxazol-3-carbonyl]-amino}-piperidine-3carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[3-(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R*,4R*)-4-{[3-(2,4-Difluorophenyl)-isoxazole-5-carbonyl]-amino}-1- (2-methyl-cyclopentyl)-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3R,4R)-1-Cyclopentyl-4-{[5(2,4>6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 92 of 351 (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-pipendine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (1—pyrimidin—2—I—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1-pyrazin-2-yl-cyclopropyl)-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyridazine—3-I-cyclopropyl)-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrazin—2-yl-cyclopropyl)-acid acid (3S,4S)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; (1—pyridazin—3—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (cyano-dimethyl-methyl)-acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; [1—(4,6—dimethyl—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopentyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine3-carboxylic; [1-(4,6—dimethyl—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}piperidine-3-carboxylic; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; ((S)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclohexyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((S)—1—pyridin—2—yl-ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 93 of 351 ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [(R)—1—(6—methyl—pyridin—2—yl)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(R)—1 —(6—methyl—pyridin—2—yl)—ethyl]—acid amide (3R,4R)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(S)—1—(6—methyl—pyridin—2—yl)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(S)—1— (6-methyl-pyridin-2-yl)-ethyl]-acid acid (3R,4R)—1—Cyclohexy1—4—{[5— (2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-isopropyl-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-4-{[5-(214-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-ethyl-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-isopropyl-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-ethyl-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3R*,4R*)-1-Cyclopentyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3R*,4R*)-1-Cyclopropylmethyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino}-1- isopropyl-piperidine-3-carboxylic; (1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino}-1- et¡l-p¡perídine-3-carboxylic¡ IF-2019-79621737-APN-ANP#INPIλ94 Page 94 of 351 (1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[5-(2l4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- pipendin-3-carboxylic; [(R)—1—(1—oxy—pyridin—2—yl)—ethyl]—acid amide (3R*,4R*)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (3R*,4R*)-1-(1-Cyclopropyl-ethyl)-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide ; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-hydroxymethyl-cyclopentyl)-piperidine-3-carboxylic acid dimethylamide ; acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1--(2-ethyl-cyclopentyl)-piperidin-3- carboxylic; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-methyl-cyclobutyl)-piperidine-3-carboxylic acid dimethylamide ; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-methyl-cyclobutyl)-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2,2-dimethyl-cyclobutyl)-piperidin-3 acid dimethylamide -carboxylic; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl-aminoJ-l-ÍS.S-dimethyl-cyclopentiQ-piperidine-S-carboxylic acid dimethylamide; (3R,4R)-1-CiclopentiM-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-p¡perídin-3-carboxylic acid dimethylamide ( 3S,4S)-1-Cyclopentyl-4-{[5-(2,4-difluoro-phenyl)¡soxazol-3-carbonyl]-amino}-pi¡perid¡n-3-carboxylic acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2,2-dimethyl-propyl)-piperidine-3-carboxylic acid; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(3-methyl-butyl)-piperidine-3-carboxylic acid dimethylamide ; IF-2019-79621737-APN-ANP#INPI Page 95 of 351 acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-(3,3-dimethyl-butyl) -piperidine-3-carboxylic; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-methyl-cyclopentyl)-piperidine-3-carboxylic acid dimethylamide ; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-methyl-cyclopentyl)-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(3,3-dimethyl-cyclohexyl)-pipendin-3 acid dimethylamide -carboxylic; acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-spiro[3,3]hept-2-yl-piperidin -3-carboxylic; acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbon¡l]-amino}-1-(4-fluoro-cyclohex¡l) -piperidine-3-carboxylic acid dimethylamide (3R*,4R*)-1-(4,4-Difluoro-cyclohexyl)-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; . (3R*,4R*)—1—Cyclobutyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-1-Cyclopentylmethyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(3,3-dimethyl-cyclobutyl)-pipendin-3 acid dimethylamide -carboxylic; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(3-methoxy-cyclohexyl)-piperidine-3-carboxylic acid dimethylamide ; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-methoxy-cyclohexyl)-piperidine-3-carboxylic acid dimethylamide ; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(1-methyl-cyclopropylmethyl)-pipendine-3-carboxylic acid dimethylamide ; IF-2019-79621737-APN-ANP#INPI Page 96 of 351 acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(1-methyl-cyclobutylmethyl)-piperidine -3-carboxylic; (3R*,4R*)-1-Ciclopent-1-enylmethyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid dimethylamide: acid dimethylamide (3R*,4R*)-1-Bicyclo[2,2,1]hept-2-yl-4-{[5-(2,4-difluorophenyl)-¡soxazol-3-carbon¡l] -amino}-piperidine-3-carboxylic acid dimethylamide (3R*,4R*)-1-Cyclobutylmethyl-4-{[5-(2,4-difluoro-phenyl)isoxazole-3-carbonyl]-amino}-pipendin-3-carboxylic; (3R*,4R*)-1-(2-Cyclopropyl-ethyl)-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide ; λ acid dimethylamide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-fluoro-cyclohexyl)-piperidin-3- carboxylic; (3R,4R)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4R)—1—(1—Cyclopropyl—ethyl)-4—{[5—(2I4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-spiro[2,4]hept-4-yl-pipendin-3 acid dimethylamide -carboxylic; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-hydroxy-cyclohexyl)-piperidine-3-carboxylic acid dimethylamide ; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-hydroxy-1-methyl-propyl)-piperidine acid dimethylamide -3-carboxylic; acid methyl-phenethyl-amide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-(2-hydroxy-cyclohexyl)-piperidine -3-carboxylic; methyl-phenethyl-acid acid (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazoí-3carbonyl]-amino}-1-(2-hydroxy-1- methyl-propyl)-pyridine-3-carboxylic; acid methyl-phenethyl-amide (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-(2-hydroxy-ethyl)-pipendin -3-carboxylic; IF-2019-79621737-APN-ANP#INPI Page 97 of 351 (1—pyridin—2—yl—ethyl)—(3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide}-1-(2-hydroxy-cyclohexyl)-piperidine-3-carboxylic¡ (1—pyridin—2—yl—ethyl)—acid amide (3R*,4R*)-4-{[5-( 2,4-Difluoro-phenyl)isoxazol-3-carbonyl]-amino}-1-(2-hydroxy-1-methyl-propyl)-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(2- methoxy-ethyl)-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1-ethyl acid amide -pipenden-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)—isoxazole—3—carbonyl]—amino acid amide)—1-(1, 1,2,2,2—c / s—ethyl)—piperidine—3—carboxylic; (3R*,4R*)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide ; (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,6-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R*,4R*)-1-CyclohexiM-{[5-(4-fluoro-phenyl)-isoxazol3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; acid dimethylamide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)[1,3,4]oxadiazol-2-carbonyl]-amino}-piperidin-3 -carboxylic; acid dimethylamide (3S,4S)-1—Cyclohexyl-4—{[5-(2,4—difluoro-phenyl)— [1,3,4]oxadiazol-2-carbonyl]-amino}-piperidine-3-carboxylic acid; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)[1,3,4]oxadiazol-2-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide ; (3R*,4R*)-4-{[5-(2-chloro-4-fluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-cyclohexyl-piperidine-3-carboxylic acid dimethylamide; IF-2019-79621737-APN-ANP#INPI ' 98 Page 98 of 351 acid dimethylamide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4,6-trifluoro-phenyl)¡soxazol-3-carbonyl]-amino}-peridin -3-carboxylic; (3R*,4R*)-4-{[5-(4-chloro-2-fluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-cyclohexyl-piperidine-3-carboxylic acid dimethylamide; acid dimethylamide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)[1,2,4]oxadiazol-3-carbonyl]-amino}-piperidin-3 -carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2fluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-[1,2,4]oxadiazol- 3-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-oxazol-2-carbonyl]-am! no}-p¡perídin-3-carboxylic¡ (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2 ,4difluoro-phenyl)-[1,3,4]oxadiazol-2-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2-fluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(4-fluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-[1,3,4]oxadiazol-2 -carbonyl]-amino}-piperidine-3carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-[1,3,4]oxadiazol- 2-carbonyl]-amino}-piperidine-3carboxylic; (3R*,4R*)-1-Cyclopentyl-4-{[5-(2,4-difluoro-phenyl)oxazol-2-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; . IF-2019-79621737-APN-ANP#INPI Page 99 of 351 (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)oxazol-2-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; acid dimethylamide (3R*,4R*)-1-Cyclohexyl-4-{[3-(2,4-difluoro-phenyl)[1,2,4]oxadiazol-5-carbonyl]-amino}-piperidin-3 -carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-pipendin-3-carboxylic; (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid (l-methyl-cyclopropyl)-amide ; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (3-methoxy-1,1-dimethyl-propyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [1—(5—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid (l-methyl-cyclobutyl)-amide ; (1—[1,2,4]oxadiazol—3—I—ethyl)—(3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-acid amide 3-carbonyl]-amino}-piperidine-3-carboxylic; [1—(5—fluoro—pyridin—2—¡I)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—Cyclobutyl—ethyl)-amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; ((R)-1-phenyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine -3-carboxylic; IF-2019-79621737-APN-ANP#INPI 100 Page 100 of 351 ((S)—2—hydroxy—1—phenyl—ethyl)—(3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3 acid amide -carbonyl]-amino}-piperidine-3-carboxylic; (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol3-carbonyl]-amino]-piperidine-3-carboxylic acid benzylamide; (2-hydroxy-1—pyridin—2-yl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)-acid acid (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid tert-butylamide; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid (l-methyl-cyclobutyl)-amide ; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3carbonyl]-amino]-piperidine-3-carboxylic acid amide; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid (l-methyl-cyclopropyl)-amide ; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid (cyano-dimethyl-methyl)-amide ; ((S)—2—hydroxy—1—phenyl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)-2-hydroxy-1-phenyl-ethyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)-1-phenyl-ethyl)-acid acid (3R,4R)—1—Cyclohexyl-4—{[5-(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; [1—(2H—pyrazole—3-¡I)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic acid¡ ((R)-1-pyridin-3-yl-ethyl)-amide (3S,4S)-1-CyclopropylmethiM-{[5(2,4-difluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 101 Page 101 of 351 (1-pyrimidin—2-¡I-cyclopropyl)—(3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-piperidine-3-carboxylic¡(1—pyridin—4—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyridin—4—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopentyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—methyl—1 —pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; [1—methyl—1—(1—methyl—1 H—pyrazol—4—yl)—ethyl]—acid amide (3S,4S)-1Cyclopentyl-4-{[5-(2,4-difluoro-phenyl )-isoxazole-3-carbonyl]-amino}-pipendine3-carboxylic acid; [1-methyl-1-(5-methyl-[1,2,4]oxadiazol-3-yl)-ethyl]-amide (3S,4S)-1Cyclopentyl-4-{[5-(2,4 -difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine3-carboxylic; bicyclopropyl—1—(3S,4S)-1—Cyclopentyl—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide: [1-(tetrahydro-furan-2-yl)-ethyl]-acid amide (3S,4S)-1-Cyclopentyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 102 Page 102 of 351 [1—(1 Η—[1,2,4]triazol—3—yl)—ethyl]—acid amide (3S,4S)—1—Cyclopentyl-4—{[5— (2,4-difluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1-methyl-prop-2-ynyl)-acid acid (3S,4S)-1-CiclopentiM-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidin-3 -carboxylic; (1-soxazol-3-yl-ethyl)-acid acid (3S,4S)—1—Cyclopentyl-4—{[5—(214—difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; [1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)—1—pyridin-3-I-ethyl)-acid amide (3S,4S)—1—Cyclopentyl-4—{[5—(2,4— difluorophenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [1—methyl—1—(1—methyl—1 H—pyrazol—4—yl)—ethyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl )-isoxazole-3-carbonyl]-amino}pi perid i n-3-ca rboxy I ¡co; [1—methyl—1—(5—methyl—[1,2,4]oxadiazol—3—yl)—ethyl]—acid amide (3S,4S)-1Ciclop.roylmethyl-4-{[5-(2 ,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}piperidine-3-carboxylic; (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid bicyclopropyl-1-ylamide; [1—(tetrahydro—furan-2-yl)—ethyl]—(3S,4S)-1-CyclopropylmethiM{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; [1—(1 H—[1,2,4]triazol—3—yl)—ethyl]—acid amide (3S.4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (1-methyl-prop-2-ynyl)-acid acid (3S,4S)-1—Cyclopropylmethyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1-isoxazol-3-yl-ethyl)-acid acid (3S,4S)—1—Cyclopropylmethyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-3-methyl-piperídine-3-carboxylic; and IF-2019-79621737-APN-ANP#INPI 103 Page 103 of 351 acid dimethylamide (3R*,4R*)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-3-methyl-piperidin- 3-carboxylic; 22) In addition to the compounds of embodiment 21), other compounds according to embodiment 1) are selected from the following compounds: (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2,4-dichloro-phenyl)-isoxazole-3-carbonyl]-amino}-p¡períd¡n-3-carboxylic; (1—pyrimidin—2—I—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4-dichloro-phenyl)-isoxazole-3-carboníl]- amino}-piperidine-3-carboxylic; (1—pyrimidin—2—I—cyclopropyl)—acid amide (3S,4S)-1-Cíclopropylmethyl-4{[5-(2,4-dichloro-phenyl)-ísoxazole-3-carbonyl] -amino}-p¡perídine-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4{[5-(2,3 ,4-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino}-perídine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,3,4-trifluoro-phenyl)-isoxazole-3-carbon¡l] -amino}-piper¡din-3-carboxylic; (1—pyridin—2—yl—cyclobutyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [1-(2-methoxy-phenyl)-cyclopropyl]-acid acid (3R*,4R*)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidín-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-4-{[5-(2,4-Difluorophenyl)- isoxazol-3-carbonyl]-amino}-1-(2-hydroxy¡-cyclohexyl)-piperid¡n-3carboxylic; [1—(1—oxy—pyridin-2-I)-cyclopropyl]- acid amide (3R*,4R*)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)- isoxazol-3-carbon¡l]-amino}piperidine-3-carboxylic; [1—(1—oxy—pyridin—2—I)—cyclopropyl]—acid amide (3R*,4R*)-1-Cyclopentyl-4{[5-(2,4-difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-p¡per¡din-3-carboxylic; [1—(1—oxy—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1-CiclopentiM{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 104 Page 104 of 351 (1—cyano—cyclobutyl)—acid amide (3R*,4R*)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopentylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(1-Difluoromethylcyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}piperidine-3-carboxylic; (1—pyrimidin—2—I—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazbl-3-carbonyl]-amino acid amide}-1-(4 -fluoro-benzyl)-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino acid amide}-1-(2, 2-dimethyl-propyl)-pipendin-3-, carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1-isobutyl-piperidin -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Benzyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclobutylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-([5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1-isopropyl-piperidin acid amide -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclobutyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -pipendin-3-carboxylic; (3R,4R)-1-Cyclopentyl-4-{[5-(2,4-difliioro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid ethyl-methyl-amide; methyl—(2—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclopentyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; methyl—(2—pyridin—2—yl-ethyl)—(3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 105 Page 105 of 351 (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—(2,2—Difluoro—cyclopropylmethyl)-4-{[5-(2,4-difluoro- phenyl)-isoxazole-3-carbonyl]-amino}piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(3- fluoro-propyl)-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclobutyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-p¡per¡din-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole -3-carbonyl]-amino}-1-(1-methyl-c¡clopropylmethyl)-piper¡dine-3carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[1— (2,4—difluoro—phenyl)—1H—[1,2,3] triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3S,4S) acid amide—1—Cyclopentyl—4-{[1-(2,4d ifluoro—phenyl)—1 H-[1,2,3] triazol-4-carbonyl]-amino}-p¡peridín-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Allyl—4—{[5 —(2,4—difluoro-phenyl)-isoxazol-3-carbon¡l]-am¡no}-piper¡din-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Bicyclo[3,1,0]hex-3<l—4—{[5—(2,4-difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piper din-3carboxylic; (1—pyrimidin—2-yl-cyclopropyl)—acid amide (3S,4S)-4—{[5-(2,4—Difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-1-prop ¡l-piper¡din-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino} -piper¡din-3-carboxylic¡; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(3,3-Difluorocyclobutylmethyl)-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 acid amide -carbonyl]-amino}piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 106 Page 106 of 351 (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1 acid amide -spiro[2,3]hex-5-l-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclobutyl—4—{[5—(2,4—difluoro-phenyl)-[1,3,4] thiadiazol-2-carbon¡l]-amino}-p¡peridine-3-carboxylic acid; (1—pyrimidin—2—¡l—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-difluorophenyl)—[1,3,4]thiadiazole—2—carbonyl]— amino}—1—(1—fluoro—cyclopropylmethyl)—piperidine—3—carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-(Cyclopropyl-(d2methyl))-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-p¡peridine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[4-fluoro-5-(4-fluoro-phenyl)-isoxazole-3-carbonyl] -am¡no}-p¡peridine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-4-fluoro-isoxazole-3- carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-4-fluoro-isoxazole-3-carbonyl] -amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-4-fluoro-¡soxazole-3-carbon ¡l]-amino}-piperidine-3carboxylic; [1-(1 —oxy—pyridin-2-yl)—cyclopropyl]—acid amide (3S,4S)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic acid (1—pyrimidin—2—yl-cyclopropyl)-amide (3S,4S)-4—{[5-(2,4—Difluoro—phenyl)- isoxazol-3-carbonyl]-amino}-1-(1-fluoro-cyclopropylmethyl)-piperidine-3carboxylic; tIF-2019-79621737-APN-ANP#INPI 107 Page 107 of 351 (1—phenyl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; [1—(3—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}piperidine—3—carboxylic; (1—Pyrimidin—4-I-cyclopropyl)-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; 1—[((3S,4S)—1—Cyclopropylmethyl-4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidin-3-carbonyl acid ethyl ester -amino]cyclopropanecarboxylic; (1—phenyl—cyclobutyl)—(3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide ; (3S,4S)-1—Cyclopropylmethyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid benzyl-(2-fluoro-ethyl)-amide -3-carboxylic; (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid [1-(3-methoxy-phenyl)-cyclopropyl]-amide}-piperidine-3-carboxylic; [1—(2—trifluoromethyl—phenyl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} p i perid i n-3-ca rboxy I ico; [1-(2-fluoro-phenyl)-cyclopropyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-pipendin-3-carboxylic; [2-(2-chloro-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; [(3S.4S)-1—cyclopropylmethyl—3-((R)-2-phenyl—azetidin-1-carbonyl)—piperidin—4yl]-amide 5-(2,4-Difluoro-phenyl)-isoxazole -3-carboxylic; [(3S,4S)-1-cyclopropylmethyl—3-((S)—2—phenyl—azetidin—1-carbonyl)-piperidin—4—yl]—5-(2,4-difluoro-phenyl) acid amide -isoxazole-3-carboxylic; [1—(3—chloro—phenyl)—cyclopropyl]—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2.4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 108 Page 108 of 351 [1-(4-methyl-thiazol-2-I)—cyclobutyl]—acid amide (3S,4S)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [1-(2-methoxy-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid [1-(2-methoxy-phenyl)-cyclopropyl]-amide}-pipendin-3-carboxylic; [(R)-1-(3-bromo-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [1—(2—hydroxy—phenyl)—cyclopropyl]—(3S,4S)-1-Cyciopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic acid ¡[1-(1-oxy-pyrimidin—2-¡I)-cyclopropyl]-amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro -phenyl)-isoxazol-3-carbonyl]-amino}p i perid i n-3-ca rboxí I ¡co; [(3S,4S)—1—cyclopropylmethyl—3—(2—pyrimidin—2—I—pyrrolidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-Difluoro-phenyl) acid amide )-isoxazole-3-carboxylic; [(3S.4S)—1—cyclopropylmethyl—3—((R)—2—pyrimidin—2—yl—azetidin—1—carbonyl)— piperidin—4—yl]—5-(2,4-) acid amide Difluoro-phenyl)-isoxazole-3-carboxylic acid; [(3S,4S)—1 —cyclopropylmethyl—3—((S)—2—pyrimidin—2—yl—azetidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-) acid amide difluoro-phenyl)-isoxazole-3-carboxylic; (1—pyrimidin—2—yl—ethyl)—(3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; [1—(3—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)—1—Cyclobutyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; (1-methyl-1-pyrimidin-2-yl-ethyl)-acid acid (3S,4S)-1-CyclobutiM-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1.—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)-1—Cyclobutyl-4—{[5—(2,4— difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((S)-1-pyrimidin-2-yl-ethyl)-acid acid (3S,4S)-1-Cyclobutyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 109 Page 109 of 351 (3-benzyl-oxetan-3-yl)-acid amide (3R,4R)—1—Cyclobutyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylicp; (3-Phenyl-oxetan-3-ylmethyl)-acid acid (3R,4R)—1—Cyclobutyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; [(R)—1—(6—methyl—pyridin—2—yl)—ethyl]—(3S,4S)-4-{[5-(2,4Difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-1-ethyl-piperidine-3-carboxylic; (1-methyl-1-pyrimidin-2-yl-ethyl)-acid acid (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1 -ethyl-piperidine-3-carboxylic; [3-(3-chloro-phenyl)-oxetan-3-yl]-acid acid (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino)-piperidine-3-carboxylic; [1—(3—fluoro—pyridin—2—yl)—ethyl]—acid amide (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [(R)—1—(3—fluoro—pyridin—2—yl)—ethyl]—acid amide (3S,4S)—1—Cyclobutyl—4— {[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(S)—1— (3-fluoro-pyridin-2-¡I)-ethyl]-acid acid (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-tert-Butyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R*,4R*)-1-tert-Butyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic acid (enantiomer 1); (1—methyl—1—pyrimidin—2—yl—ethyl)—(3S,4S)-1-CyclopropylmethiM{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyrimidin—2—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl-4— {[4-fluoro-5-(4-fluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidin-3-. carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl acid amide—4{[1 —(2,4—difluoro—phenyl)—1 H—[1,2,3] triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; IF-2019-79621737-APN-ANP#INPI 110 Page 110 of 351 (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-dimethyl-phenyl)-isoxazole-3-carbonyl] acid amide -amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[3-(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-[1,2,4]oxadiazol-3 -carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[4-(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino}- piperidine-3-carboxylic; and (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5—(2,4—difluoro—phenyl)—[1,3,4]thiadiazole— 2—carbonyl]—amino}—piperidine—3— carboxylic. 23) Another embodiment refers to preferred compounds according to embodiment 1) which are selected from the following compounds: (1—methyl—1—pyridin—2—I—ethyl)—acid amide (3S,4S)-1—Cyclohexyl-4—{[5—(2,4— difluorophenyl)-isoxazole-3- carbonyl]-amino}-p¡perídin-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidín-3-carboxylic acid; (3R,4R)-1-CyclohexiM-{[5-(2,4-difluoro-phenyl)¡soxazol-3-carbonyl]-amino}-piper¡dine-3-carboxylic acid dimethylamide; (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-¡soxazol3-carbonyl]-amino}-piperidine-3-carboxylic acid methylamide¡ (3S, 4S)-1-Cyclohex¡M-{[5-(2,4-difluoro-phen¡l)-¡soxazol3-carbonyl]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 111 Page 111 of 351 (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol-3carbonyl]-amino}-piperidine-3-carboxylic acid ethylamide; (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol-3carbonyl]-amino}-piperidine-3-carboxylic acid ethylamide; (pyridin—2—ylmethyl)—(3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide ; (pyridin—2—ylmethyl)—(3S,4S)M acid amide —Cyclohexyl—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3- carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclohexyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-pipendine-3-carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidin-3“Carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; [2-(2-oxo-pyrrolidin—1—yl)—ethyl]—acid amide (3R,4R)-1-CyclohexiM-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; [2—(2—oxo—pyrrolidin—1—yl)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3S,4S)-1-CyclohexiM-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (thiazol-2-ylmethyl)-acid acid (3R,4R)—1—Cyclohexyl—4—{[5—(2,4—difluoro—phenyl)-isoxazol-3-carbonyl]-amino}-piperidin-3 -carboxylic! (thiazol-2-ylmethyl)-(3S,4S)-1-CyclohexiM-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide; IF-2019-79621737-APN-ANP#INPI · 112 Page 112 of 351 (2—o—tolyl—ethyl)—acid amide (3R,4R)-1-CyclohexiM-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-pipendine -3-carboxylic; (2-o-tolyl-ethyl)-acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(214-difluorophenyl)-isoxazole-3-carbon¡l]-amino}-p peridin-3-carboxylic; [2-(2-methoxy-phenyl)-ethyl]-acid acid (3R,4R)—1—Cyclohexyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-p¡peridine-3-carboxylic acid; [2-(2-methoxy-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piper¡din-3-carboxylic; [2-(2-chloro-phenyl)-ethyl]-acid acid (3R,4R)—1—Cyclohexyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; [2-(2-chloro-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-¡soxazol-3-carbonyl]-amino}-piper¡din-3-carboxylic; ((1R,2S)-2-phenyl-cyclopropyl)-acid acid (3R,4R)-1-C¡clohex¡l-4-{[5(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidín-3-carboxylic acid¡ ((1S,2R)-2-phenyl-cycloprop¡l)-amide (3R,4R)-1-Cyclohexyl-4-{[5 (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((1R,2S)-2-phenyl-cyclopropyl)-acid acid (3S,4S)—1—Cyclohexyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-p¡peridine-3-carboxylic acid; ((1S,2R)-2-phenyl-cyclopropyl)-acid acid (3S,4S)—1—Cyclohexyl—4—<[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (2-p-tolyl-ethyl)-acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-¡soxazol-3-carbonyl]-amino}- piperidine-3-carboxylic¡(2-p-tolyl-ethyl)-acid amide (3S,4S)-1-Cyclohex¡M-{[5-(2,4-difluorophenyl)-isoxazole-3 -carbonyl]-amino}-piper¡din-3-carboxylic¡ (2-m-tolyl-ethyl)-acid acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4 -difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperídine-3-carboxylic; (2-m-tolyl-ethyl)-acid amide (3S,4S)-1-CyclohexiM-{[5-(214-difluorophenyl)-¡soxazol-3-carbonyl]-amino}-piperidin- 3-carboxylic IF-2019-79621737-APN-ANP#INPI 113 Page 113 of 351 (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isdxazol-3-carbonyl]- amino}-pipendin-3-carboxylic acid; (1—pyridin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; ((R)-2-hydroxy-2-phenyl-ethyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)—2—hydroxy—2—phenyl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (2—pyridin—2—yl—ethyl)—(3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; (2—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; methyl—(2—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; methyl—(2—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Gyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; ((1R)-2-ethoxy-1-methyl-ethyl)-acid acid (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendin-3-carboxylic acid; ((1S)-2-ethoxy-1-methyl-ethyl)-acid acid (3R,4R)—1—Cyclohexyl-4—{[5—(2,4— difluorophenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((1R)-2-ethoxy-1-methyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((1S)-2-ethoxy-1-methyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R>—1—pyrazin—2—¡I—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-pipendine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 114 Page 114 of 351 ((R)—1—cyclobutyl—ethyl)-acid acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)—1—cyclobutyl—ethyl)—(3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; [(R)—1—(3—fluoro—pyridin—2—yl)—ethyl]—acid amide (3R,4R)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(R)—1— (3-fluoro-pyridin-2-¡I)-ethyl]-acid acid (3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(R)—1—(5—fluoro—pyrimidin—2—yl)—ethyl]—acid amide (3R,4R)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(R)—1—(5—fluoro—pyrimidin—2—¡I)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (3R,4R)-1-((1R,2R)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6tnfluoro-phenyl)-isoxazok3-carbonyl]-amino}-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-1-((1S,2S)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide} -piperidine-3-carboxylic; (3R,4R)-1-((1R,2S)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide -piperidine-3-carboxylic; (3R,4R)-1-((1S,2R)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide -piperidine-3-carboxylic; (3S,4S)-1-((1R,2R)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide} -piperidine-3-carboxylic; (3S,4S)-1-((1S,2S)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide} -piperidine-3-carboxylic; (3S,4S)-1-((1R,2S)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide -piperidine-3-carboxylic; (3S,4S)-1-((1S,2R)-2-Methyl-cyclopentyl)-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid dimethylamide} -piperidine-3-carboxylic; , IF-2019-79621737-APN-ANP#INPI 115 Page 115 of 351 (2—methoxy—1,1—dimethyl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[1-(2,4difluoro—phenyl)—1 H—[1,2 ,3]triazol-4-carbonyl]-amino}-pipendine-3-carboxylic acid; ((R)-1-pyridin-2-yl—ethyl)—(3S,4S) acid amide—1—Cyclohexyl—4—{[1—(2,4—difluoro—phenyl)—1 H—[1 ,2,3]triazole-4-carbonyl]-amino}-piperidine-3-carboxylic; ((R)-1-pyridin-2-yl-ethyl)-acid acid (3R,4R)-1-Cyclopentyl-4-{[1-(2,4difluoro-phenyl)-1H-[1,2, 3]triazol-4-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclopentyl-4-{[1-(2,4difluoro-phenyl)-1H-[1,2, 3]triazol-4-carbonyl]-amino}-piperidín-3-carboxylic; ((R)—1—pyridin-2-yl—ethyl)—(3S,4S)-1-Cyclohexyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4,6— trifluorop-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin-2-yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-(2-Methyl-cyclopentyl)-4{[5-(2,4,6-trifluoro-phenyl )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—(2—Methyl—cyclopentyl)-4— {[5-(2,4,6-trifluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl]- amino)-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[3—(2,4— difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopentyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl]- amino}-piperidine-3-carboxylic; . IF-2019-79621737-APN-ANP#INPI 116 Page 116 of 351 ((R)—1—pyridin—2—¡I—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[3—(2,4— difluoro-phenyl)- isoxazole-5-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyrazin-2-yl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyrazin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((R)-1-cyclobutyl-ethyl)-acid acid (3S,4S)—1—Cyclopentyl—4—{[5—(2,4,6—trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)-1-cyclobutyl-ethyl)-acid acid (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl] -amino}-piperidine-3-carboxylic; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3S,4S)—1—Cyclopropylmethyl—4—{[3— (2,4-difluoro-phenyl)-isoxazole-5-carbonyl ]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-[1,2,4] oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin-2-yl-ethyl)-acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2>4— difluoro-phenyl)-[1,2, 4]oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin-2-yl-ethyl)-acid acid (3R,4R)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-[1,2, 4]oxadiazol-3-carbonyl]-amino}-piperidine-3carboxylic; ((R)—1—pyridin—2—yl—ethyl)—(3S,4S) acid amide—1—Cyclopropylmethyl—4—{[5— (2,4—difluoro—phenyl)—[1,2, 4]oxadiazol-3-carbonyl]-amino}-piperidine-3carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclohexyl-4—{[1—(2,4—difluoro-phenyl)-1H-[1,2,3] triazole-4-carbonyl]-amino}-piperidine-3-carboxylic acid; kIF-2019-79621737-APN-ANP#INPI 117 Page 117 of 351 (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)—1—Cyclopentyl—4—{[1-(2,4difluoro—phenyl)—1 H—[1,2 ,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic acid; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[1—(2,4—difluoro-phenyl)-1H-[1,2,3] triazole-4-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3R,4R)-1-Cyclopentyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic;. (1—pyridin—2—I—cyclopropyl)—acid amide (3R,4R)-1-((1R,2R)-2-Methylcyclopentyl)-4-{[5--(2,4,6- trifluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin<. . 3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-((1R,2S)-2-Methylcyclopentyl)-4-{[5-(2,4,6-trifluoro- phenyl)-isoxazole-3-carbonyl]-amino}-pipendine3-carboxylic acid; (1—pyridin—2—yl-cyclopropyl)—acid amide (3R,4R)-1-((1S,2R)-2-Methylcyclopentyl)-4-{[5-(2,4,6-trifluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3R,4R)-1-((1S,2S)-2-Methylcyclopentyl)-4-{[5-(2,4,6-trifluoro -phenyl)-isoxazole-3-carbonyl]-amino}-piperidine3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-((1R,2R)-2-Methylcyclopentyl)-4-{[5-(2,4,6-trifluoro- pheníl)-isoxazol-3-carbonyl]-amino}-píperidine3-carboxylic acid; IF-2019-79621737-APN-ANP#INPI 118 Page 118 of 351 (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-((1R,2S)-2-Methylcyclopentyl)-4-{[5-(2,4, 6-tnfluoro-phenyl)-isoxazole-3-carbonyl]-amino}-pipendin3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3S,4S)-1-((1S,2R)-2-Methylcyclopentyl)-4-{[5-(2,4,6--trifluoro)acid amide -phenyl)-isoxazole-3-carbonyl]-amino}-piperidine3-carboxylic; (1—pyridin—2—I—cyclopropyl)—(3S,4S)-1-((1S,2S)-2-Methylcyclopentyl)-4-{[5-(2,4,6-tnfluoro) acid amide -phenyl)-isoxazole-3-carbonyl]-amino}-pipendin3-carboxylic; , (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[3— (2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2-yl-cyclopropyl)-acid acid (3R,4R)-1-Cyclopentyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendin-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—(3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic acid: (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4,6-trifluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrazine—2-I-cyclopropyl)-acid acid (3S,4S)—1—Cyclopropylmethyl-4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (1-pyrazin-2-yl-cyclopropyl)-acid acid (3S,4S)—1—Cyclopentyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 119 Page 119 of 351 (cyano-dimethyl-methyl)-acid acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine -3-carboxylic; (cyano-dimethyl-methyl)-acid acid (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro-pheryl)-¡soxazol-3-carbon¡l]-am ¡no}-p¡peridin-3-carboxylic¡ [1-(4,6—dimethyl—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Giclopentyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine3-carboxylic; [1—(4,6—dimethyl—pyrimidin—2—¡I)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluorophenyl)-isoxazole- 3-carbonyl]-amino}piperidine-3-carboxylic; (3R,4R)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; ((R)—1—pyridin—2-yl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [(R)—1—(6—methyl—pyridin—2—yl)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-isopropyl-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-isopropyl-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3R,4R)—1—Cyclopentyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3S,4S)—1—Cyclopentyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid methikphenethyl-amide; (3R,4R)-1-Cyclopropylmethyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid methyl-phenethyl-amide; IF-2019-79621737-APN-ANP#INPI 120 Page 120 of 351 ((1 R)—1—pyridin—2—yl—ethyl)—(3R,4R)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl acid amide ]-amino}-1-isopropyl-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—(3R,4R)-4-{[5-(2,4-Difluoro-phenyl)isoxazol-3-carbonyl]-amino acid amide} -1-isopropyl-piperidine-3-carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide} -1-isopropyl-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—4—([5—(2,4—DifliJoro—phenyl)— isoxazole-3-carbonyl]-amino}-1-isopropyl-piperidine-3-carboxylic acid; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopentyl-4—{[5—(2,4— difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-CyclopropylmethiM-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—([5— (2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (3R,4R)—1—((1R)—1—Cyclopropyl—ethyl)—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-1-((1S)-1-Cyclopropyl-ethyl)-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidin-3 acid dimethylamide -carboxylic; . IF-2019-79621737-APN-ANP#INPI 121 Page 121 of 351 acid dimethylamide (3S,4S)—1-((1 R)—1—Cyclopropyl—ethyl)—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (3S,4S)—1—((1S)—1—Cyclopropyl—ethyl)—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-((1R,2R)-2-ethyl-cyclopentyl) acid dimethylamide -piperídin-3-carboxylic acid dimethylamide (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-((1R, 2S)-2-ethyl-cyclopentyl)-pipendin-3-carboxylic acid; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)-2-ethyl-cyclopentyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2S)-2-ethyl-cyclopentyl)-piperidine acid dimethylamide -3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1R,2R)-2-ethyl-cyclopentyl)-acid dimethylamide piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3-carbonyl]amino}—1-((1 R,2S)—2—ethyl—cyclopentyl acid dimethylamide —piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1S,2R)-2-ethyl-cyclopentyl)-acid dimethylamide pipendin-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difliioro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1S,2S)-2-ethyl-cyclopentyl)-acid dimethylamide piperidine-3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2R)-2-methyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-((1S,2S)-2-methyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2S)-2-methyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4—([5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)-2-methyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; IF-2019-79621737-APN-ANP#INPI 122 Page 122 of 351 acid dimethylamide (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]aminoJ-1-((1R,2R)-2-methyl- cyclobutyl)-piperidine-3-carboxylic; (3S,4S)-4-([5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]aminoJ-1-((1S,2S)-2-methyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1R,2S)-2-methyl-cyclobutyl)-acid dimethylamide piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1S,2R)-2-methyl-cyclobutyl)-acid dimethylamide piperidine-3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-(1R)-1-(2,2-dimethyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-(1S)-1-(2,2-dimethyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]aminoJ-(1R)-1-(2,2-dimethyl-cyclobutyl)-piperidine acid dimethylamide -3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3-carbonyl]amino}-(1 S)—1-(2,2-dimethyl-cyclobutyl) acid dimethylamide —piperidine-3-carboxylic acid; (3R,4R)-1-Cyclopentyl-4-{[5-(2,4-difluoro-phenyl)isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2R)-2-methyl-cyclopentyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2S)-2-methyl-cyclopentyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)-2-methyl-cyclopentyl)-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2S)-2-methyl-cyclopentyl)-piperidine acid dimethylamide -3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1R,2R)-2-methyl-cyclopentyl)-acid dimethylamide piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 123 Page 123 of 351 (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3-carbonyl]amino}-1-((1R,2S)-2-methyl acid dimethylamide -cyclopentyl)-piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3-carbonyl]amino}-1^((1S,2R)-2-methyl-c acid dimethylamide Clopentyl)-piperidin-3-carboxylic acid dimethylamide (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl ]amino}-1-((1S,2S)-2-methyl-cyclopentyl)-piperidine-3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R)-3,3-dimethyl-cyclohexyl) acid dimethylamide -p¡pendin-3-carboxylic acid dimethylamide (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-((1S)-3 ,3-dimethyl-cyclohexyl)-piperidine-3-carboxylic acid; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1R)-3,3-dimethyl-cyclohexyl)-acid dimethylamide piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3-carbonyl]amino}-1-((1S)-3,3-dimethyl-cyclohexyl)-acid dimethylamide piperidine-3-carboxylic; (3R,4R)—1—Cyclobutyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3S,4S)-1—Oiclobutyl-4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-pipendine-3-carboxylic acid dimethylamide; (3R,4R)—1—Cyclopropylmethyl-4—{[5—(2,4—difluoro-phenyl)—isoxazole-3-carbonyl]-amino}-pipendine-3-carboxylic acid dimethylamide; (3S.4S)—1—Cyclopropylmethyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4R)-1-CyclopentylmethiM-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3S,4S)-1-Cyclopentylmethyl-4-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4RM-{[5-(2,4-Difluoro-phenyl)-isoxazol-3carbonyl]-amino}-1-(1-methyl-cyclopropylmethyl)-piperidine-3-carboxylic acid dimethylamide; IF-2019-79621737-APN-ANP#INPI 124 Page 124 of 351 (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazol-3-carbonyl]amino acid dimethylamide}—1—(1—methyl—cyclopropylmethyl)—piperidine— 3—carboxylic; (3R,4R)—1—Cyclobutylmethyl-4—{[5—(2J4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3S,4S)-1-Cyclobutylmethyl-4-{[5-(2,4-difliioro-phenyl)isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid dimethylamide; (3R,4R)—1—(2—Cyclopropyl—ethyl)-4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide ; (3S,4S)—1—(2—Cyclopropyl—ethyl)—4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide ; (3R,4R)—1—Cyclopropylmethyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (3R,4R)—1—((1R)—1—Cyclopropyl—ethyl)-4—{[5—(2,4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-pipendin acid dimethylamide -3-carboxylic; (3R,4R)—1—((1S)—1—Cyclopropyl—ethyl)—4—{[5—(2)4—difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid dimethylamide -3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2R)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-piperidine-3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2S)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-piperidine-3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-pipendin-3-carboxylic acid; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2S)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2R)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-piperidine-3-carboxylic; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2S)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-piperidine-3-carboxylic; , IF-2019-79621737-APN-ANP#INPI 125 Page 125 of 351 methyl—phenethyl—acid amide (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)- 2-hydroxy-cyclohexyl)-pipendin-3-carboxylic acid; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2S)-2-hydroxy-acid methyl-phenethyl-amide cyclohexyl)-piperidine-3-carboxylic; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2R)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2S)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3R,4R)-4—([5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3R,4R)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2S)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2R)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1R,2S)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino}-1-((1S,2R)-2-hydroxy-acid methyl-phenethyl-amide 1-methyl-propyl)-piperidine-3carboxylic acid; (3S,4S)-4-{[5-(2,4-Difluoro-phenyl)-isoxazole-3carbonyl]-amino acid methyl-phenethyl-amide}—1—((1 S,2S)—2—hydroxy -1—methyl-propyl)-piperidine—3—carboxylic; IF-2019-79621737-APN-ANP#INPI 126 Page 126 of 351 ((1 R)—1—pyridin—2—¡I—ethyl)—acid amide (3R,4R)—4—{[5—(2,4—Difluoro—phenyl)— isoxazole-3 -carbonyl]-amino}-1-((1R,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—(3R,4R)-4-{[5-(2,4-Difluoro-phenyl)isoxazol-3-carbonyl]-amino acid amide} -1-((1R,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—4—{[5—(2,4—Difluoro—phenyl)— isoxazole-3-carbonyl]-amino}-1-((1R,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—(3R,4R)-4-{[5-(2,4-Difluoro-phenyl)isoxazol-3-carbonyl]-amino acid amide} -1-((1R,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—¡I—ethyl)—(3Η,4Η)-4-{[5-(2,4-ΟίΑυοΓθ-ίβηίΙ)isoxazole-3-carbonyl]-amino acid amide}-1-((1S,2R)-2-hydroxy-cyclohexyl)-pipendine-3carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—(3R,4R)-4-{[5-(2,4-Difluoro-phenyl)isoxazol-3-carbonyl]-amino acid amide} -1-((1S,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—acid amide (3R,4R)—4—{[5—(214—Difluoro—phenyl)— isoxazole-3-carbonyl]-amino}- 1-((1S,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 S)—1—pyridin—2—yl—ethyl)—(3R,4R)-4-{[5-(2,4-Difluoro-phenyl)isoxazol-3-carbonyl]-amino acid amide} -1-((1S,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—I—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide}-1-((1R,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI 127 Page 127 of 351 ((1 S)—1—pyridin—2—yl—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl acid amide ]-amino}-1-((1R,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—I—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide}-1-((1R,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1S)—1—pyridin—2—yl—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide} -1-((1R,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide} -1-((1S,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 S)-1-pyridin-2-yl-ethyl)-acid acid amide (3S,4S)—4—{[5—(2,4—Óifluoro—pheníl)— isoxazole-3-carbonyl] -amino}-1-((1S,2R)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1 R)—1—pyridin—2—yl—ethyl)—(3S,4S)—4—{[5—(2,4—Difluoro—phenyl)—isoxazole-3-carbonyl]-amino acid amide}-1-((1S,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; ((1S)—1—pyridin—2—yl—ethyl)—(3S,4S)-4-{[5-(2,4-Difluoro-phenyl)isoxazole-3-carbonyl]-amino acid amide} -1-((1S,2S)-2-hydroxy-cyclohexyl)-piperidine-3carboxylic; (1—pyrimidin—2-yl-cyclopropyl)-acid acid (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1-(2- methoxy-ethyl)-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-ethyl-piperidin -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1 -(1, 1,2,2,2—ephe—ethyl)—piperidine—3—carboxylic; IF-2019-79621737-APN-ANP#INPI 128 Page 128 of 351 acid dimethylamide (3R,4R)—1—Cyclohexyl—4—{[5—(2,4—difluoro—phenyl)— [1,3,4]oxadiazol-2-carbonyl]-amino}- piperidine-3-carboxylic; (3R,4R)—1—Cyclohexyl-4—{[5—(2,4,6—trifluoro—phenyl)—isoxazole-3-carbonyl]-amino)-piperidine-3-carboxylic acid dimethylamide; (3S,4S)—1—Cyclohexyl—4—{[5—(2,4,6—trifluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid dimethylamide; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-[1,2,4]oxadiazol-3- carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro—phenyl)—[1,2,4]oxadiazol-3- carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-oxazol-2-carbonyl]-amino}-piperidine acid amide -3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro-phenyl)-oxazol-2-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-[1,3,4]oxadiazol-2- carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(2,4—difluoro-phenyl)-[1,3,4]oxadiazole -2-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-[1,3,4]oxadiazol- 2-carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3S,4S)-1-CyclohexiM-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine -3-carboxylic; ((1R)-1-[1,2,4]oxadiazol-3-yl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((1 S)—1—[1,2,4]oxadiazol—3—yl—ethyl)—(3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl) acid amide )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; IF-2019-79621737-APN-ANP#INPI 129 Page 129 of 351 ((R)—1—phenyl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazole-3-carbonyl]- amino}-pipendine-3-carboxylic acid; ((S)-2-hydroxy-1-phenyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendine-3-carboxylic acid; (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol3-carbonyl]-amino}-piperidine-3-carboxylic acid benzylamide; [(1 R)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; [(1 S)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—3—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; (1-pyridin-4-yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyridin—4—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyridine—2—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2-yl-cyclopropyl)-acid acid (3S,4S)—1—Cyclopentyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopentyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -pipendin-3-carboxylic; (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4-{[5— (2>4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; . IF-2019-79621737-APN-ANP#INPI 130 Page 130 of 351 [1—methyl—1—(5—methyl—[1,2,4]oxadiazol—3—yl)—ethyl]—acid amide (3S,4S)-1Cyclopentyl-4-{[5-(2,4 -difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine3-carboxylic; ((1R)-1-isoxazol-3-yl-ethyl)-acid acid (3S,4S)—1—Cyclopentyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((1S)-1-isoxazol-3-yl-ethyl)-acid acid (3S,4S)-1-Cyclopentyl-4-{[5-(2,4difliioro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [(1 R)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-CiclopentiM-{[5(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [(1 S)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-Cyclopentyl-4-{[5(2,4-difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—3—¡I—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; and [1—methyl—1—(5—methyl—[1,2,4]oxadiazol—3—yl)—ethyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4 -difluoro-phenyl)-isoxazole-3-carbonyl]-amino}piperidine-3-carboxylic. 24) In addition to the compounds of embodiment 23), other preferred compounds according to embodiment 1) are selected from the following compounds: (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-CyclopropylmethiM{[5-(2,4-dichloro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-dichloro-phenyl)-isoxazole-3-carbonyl]-amino}- p¡perídin-3-carboxylic; (1—pyrimidin—2-yl-cyclopropyl)—(3R,4R)-1-Cyclopropylmethyl-4{[5-(2,3,4-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piper¡dine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmeth¡M{[5-(2,3,4-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-p¡peridine-3-carboxylic; (1-pyridin-2-yl-cyclobutyl)-acid acid (3R,4R)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 131 Page 131 of 351 (1—pyridin—2—yl—cyclobutyl)—(3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] acid amide -amino}-piperidine-3-carboxylic; [1-(2-methoxy-phenyl)-cyclopropyl]-acid acid (3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [1-(2-methoxy-phenyl)-cyclopropyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-((1R ,2R)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic acid; · (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-(( 1R,2S)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic acid; (1—pyrimidin—2—I—cyclopropyl)—(3R,4R)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(( 1S,2R)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-((1S ,2S)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic acid; (1—pyrimidin—2—I—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(( 1R,2R)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic acid; (1—pyrimidin—2—I—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(( 1R,2S)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic acid; '(1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1-(( 1S,2R)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic; IF-2019-79621737-APN-ANP#INPI 132 · Page 132 of 351 (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1 -((1S,2S)-2-hydroxy-cyclohexyl)-piperidine3-carboxylic; [1—(1—oxy—pyridin—2—¡I)—cyclopropyl]—acid amide (3R,4R)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}piperidine-3-carboxylic; [1—(1—oxy—pyridin—2—¡I)—cyclopropyl]—acid amide (3S,4S)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [1—(1—oxy—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1-Cyclopentyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (l-cyano-cyclobutyl)-(3R,4R)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide ; (l-cyano-cyclobutyl)-acid acid (3S,4S)—1—Cyclopentyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopentylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(1-Difluoromethylcyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}p i per rid i n-3-ca rboxí I ico; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(4- fluoro-benzyl)-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4—{[5—(2,4—Difliioro—phenyl)-isoxazole-3-carbonyl]-amino}-1-( 2,2-dimethyl-propyl)-piperidine-3carboxylic; (1—pyrimidin—2—I—cyclopropyl)—acid amide (3S,4S)—4—{[5—(2,4—Difluoro—phenyl)—isoxazole—3—carbonyl]—amino}— 1— isobutyl—piperidine—3—carboxylic acid; (1—pyrimidin-2—I—cyclopropyl)-acid acid (3S,4S)-1-BenzyM-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin- 3-carboxylic; IF-2019-79621737-APN-ANP#INPI 133 Page 133 of 351 (1-pyrimidin-2-yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclobutylmethyl-4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-pipendine-3-carboxylic acid; (1—pyrimidin—2—I—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-isopropyl-acid amide pipendin-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclobutyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -pipendin-3-carboxylic; (3R,4R)—1—Cyclopentyl—4—{[5—(2,4—difluoro—phenyl)—isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid ethyl-methyl-amide; methyl—(2—pyridin—2—yl—ethyl)—acid amide (3R,4R)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; methyl—(2—pyridin—2—¡I—ethyl)—acid amide (3R,4R)—1—Cyclopropylmethyl-4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-((1R)-2,2-Difluorocyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-((1S)-2,2-Difluorocyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(3- fluoro-propyl)-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)—1—Cyclobutyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-CyclobutyM-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(1- methyl-cyclopropylmethyl)-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI 134 Page 134 of 351 (1—pyridin—2—¡l—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[1— (2,4—difluoro—phenyl)—1 H—[ 1,2,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[1—(2,4—difluoro-phenyl)-1H-[1,2,3] triazole-4-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Allyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S) acid amide—1—Bicyclo[3,1,0]hex—3—yl-4-{[5-(2,4-difluoro- phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—amide. (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-propyl-piperidine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(3,3-Difluorocyclobutylmethyl)-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 acid amide -carbonyl]-amino}piperidine—3—carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1—Cyclobutyl-4—{[5—(2,4—difluoro-phenyl)-[1,3,4]thiadiazol- 2-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-difluorophenyl)—[1,3,4]thiadiazol—2—carbonyl]—amino acid amide}—1—(1—fluoro—cyclopropylmethyl)—piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—(Cyclopropyl—(d2—methyl))-4-{[5-(2,4-difluorophenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)—1—Cyclopropylmethyl—4— {[4-fluoro-5-(4-fluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI 135 Page 135 of 351 (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[4-fluoro-5-(4-fluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-4-fluoro-isoxazole-3-carbonyl] -amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-4-fluoro-isoxazole-3-carbonyl] -amino}-piperidine-3carboxylic; [1-(1-oxy-pyridin-2-yl)—cyclopropyl]—(3S,4S)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(1- fluoro-cyclopropylmethyl)-piperidine-3carboxylic; (l-phenyl-cyclopropyl)-amide (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid ; [1—(3—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}piperidine-3-carboxylic; (1—pyrimidin—4—I—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; 1-[((3S,4S)-1-CyclopropylmetiM-{[5-(2,4-difluoro-phenyl)isoxazol-3-carbonyl]-amino}-piperidin-3-carbonyl)-amino acid ethyl ester cyclopropanecarboxylic; (1—phenyl—cyclobutyl)—(3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid amide ; (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piper acid benzyl-(2-fluoro-ethyl)-amide din-3-carboxylic! IF-2019-79621737-APN-ANP#INPI 136 Page 136 of 351 [1—(3—methoxy—phenyl)—cyclopropyl]—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [1—(2—tnfluoromethyl—phenyl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} piperidine-3-carboxylic; [1-(2-fluoro-phenyl)-cyclopropyl]-acid acid (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [2—(2—chloro—phenyl)—ethyl]—acid amide (3S,4S)—1—Cyclopropylmethyl-4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [(3S,4S)-1-cyclopropylmethyl-3-((R)-2-phenyl-azetidin-1-carbonyl)-piperidin-4¡I]—5-(2,4-Difluoro-phenyl) acid amide -isoxazole-3-carboxylic acid [(3S,4S)—1—cyclopropylmethyl—3—((S)—2—phenyl—azetidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-difluoro-phenyl) acid amide -isoxazole-3-carboxylic; [1-(3-chloro-phenyl)-cyclopropyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-pipendin-3-carboxylic; [1—(4—methyl—thiazol—2—yl)—cyclobutyl]—acid amide (3S,4S)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; [(R)-1-(2-methoxy-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [(S)-1-(2-methoxy-phenyl)-ethyl]-acid acid (3S,4S)—1—cyclopropylmethyl—4—{[5— (2,4-difluorophenyl)-isoxazole-3 -carbonyl]-amino)-piperidine-3-carboxylic; [1-(2-methoxy-phenyl)-cyclopropyl]-acid acid (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [(R)-1-(3-bromo-phenyl)-ethyl]-acid acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [1—(2—hydroxy—phenyl)—cyclopropyl]—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI ' 137 Page 137 of 351 [1—(1—oxy—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}piperidine—3—carboxylic; [(3S.4S)—1—cyclopropylmethyl—3—((R)—2—pyrimidin—2—yl—pyrrolidin—1—carbonyl)—piperidin-4-yl]-acid 5-(2,4- Difluoro-phenyl)-isoxazole-3-carboxylic¡ [(3S.4S)—1—cyclopropylmethyl—3—((S)—2—pyrimidin—2—yl—pyrrolidin—1—carbonyl)—piperidin—4—yl] —5-(2,4-Difluoro-phenyl)-isoxazole-3-carboxylic acid amide; [(3S.4S)—1—cyclopropylmethyl—3—((R)—2—pyrimidin—2—yl—azetidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-) acid amide Difluoro-phenyl)-isoxazole-3-carboxylic acid; [(3S.4S)—1—cyclopropylmethyl—3—((S)—2—pyrimidin—2—yl—azetidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-) acid amide difluoro-phenyl)-isoxazole-3-carboxylic; ((R)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl-4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((S)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; [1—(3—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)—1—Cyclobutyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; (1—methyl—1—pyrimidin—2—yl—ethyl)—(3S,4S)-1-CyclobutiM-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; ((R)—1—pyrimidin-2-yl—ethyl)—acid amide (3S,4S)-1-CyclobutiW-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; ((S)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)-1-CyclobutiM-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (3-Benzyl-oxetan-3-yl)-acid acid (3R,4R)—1—Cyclobutyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (3-phenyl-oxetan-3-ylmethyl)-acid acid - (3R,4R)—1—Cyclobutyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [(R)—1—(6—methyl—pyridin—2—yl)—ethyl]—(3S,4S)-4-{[5-(2,4Difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-1-ethyl-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 138 Page 138 of 351 (1—methyl—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]- amino}-1-ethyl-piperidine-3-carboxylic; [3-(3-chloro-phenyl)-oxetan-3-yl]-acid acid (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [(R)—1—(3-fluoro-pyridin-2-¡I)-ethyl]-acid acid (3S,4S)—1—Cyclobutyl—4— {[5-(2,4-difluoro-phenyl )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(S)—1—(3—fluoro—pyridin—2—yl)—ethyl]—acid amide (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)—1—ter—Butyl—4—{[5—(2,4—difluoro-pheryyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—ter—Butyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3R,4R)—1—ter—Butyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic acid (enantiomer 1); (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—ter—Butyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic acid (enantiomer 1); (1—methyl—1—pyrimidin—2—yl—ethyl)—(3S,4S)-1-CyclopropylmethiM{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-CyclopropylmethiM{[4-fluoro-5-(4-fluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[1—(2;4—difluoro—phenyl)—1 H—[1,2,3] triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-djmethyl-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; . IF-2019-79621737-APN-ANP#INPI 139 Page 139 of 351' (1—pyrimidin—2—¡I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[3-(2,4-difluoro-phenyl)-isoxazole-5 -carbonyl]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-[1,2,4]oxadiazol-3 -carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[4-(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino}- piperidine-3-carboxylic¡ (1—pyrimidin—2—¡I—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-oxazole-2 -carbonyl]-amino}-piperidine-3-carboxylic¡ and (1—pyrimidin—2—¡I—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5—(2, 4—difluoro—phenyl)—[1,3,4]thiadiazole—2—carbonyl]—amino}—piperidine—3— carboxylic. 25) Another embodiment refers to particularly preferred compounds according to embodiment 1) which are selected from the following compounds: (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl-4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-p¡peridín-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5— (2 ,4-difluoro-phenyl)-isoxazol-3-carbonyl]-amino}-p¡per¡din-3-carboxylic¡ (2-methoxy-1,1-dimethyl-ethyl)-am¡ (3S,4S)—1—Cyclopropylmethyl—4—{[5—(2,4,6-trifluoro-phenyl)-isoxazol-3-carbonyl]-amino}-piper acid n-3-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide (3S,4S)-1-CyclohexiM-{[1-(2,4difluoro—phenyl)—1 H —[1,2,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclopentyl-4-{[1-(2,4difluoro-phenyl)-1H-[1,2, 3]triazol-4-carbonyl]-amino}-p¡peridine-3-carboxylic¡ ((R)—1—pyridin—2—yl—ethyl)—(3S,4S)-1-Cyclohexyl-4 acid amide -{[5-(2,4,6trifluoro-phenyl)-isoxazol-3-carbonyl]-amino}-p¡per¡din-3-carboxylic: <(R)—1—pyridin—2—¡I—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4,6—trifluoro-phenyl)-isoxazole- 3-carbonyl]-amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 140 Page 140 of 351 ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4,6-trifluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)-1-pyridin-2-yl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[3-(2,4difluoro-phenyl)-isoxazole-5-carbonyl]- amino}-pipendin-3-carboxylic acid; ((R)—1—pyrazin—2—yl—ethyl)—(3S,4S)-1-Cyclohexyl-4-{[5-(2,4,6trifluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-piperidine-3-carboxylic; ((R)-1-cyclobutyl-ethyl)-acid acid (3S,4S)—1—Cyclopentyl—4—{[5—(2>4,6—trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendin-3-carboxylic acid; ((R)—1—cyclobutyl—ethyl)—acid amide (3S,4S)-1-CyclopropylmetiM-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[3(2,4-difluoro-phenyl)-isoxazole-5-carbonyl] -amino}-piperidine-3-carboxylic; ((R)—1—pyridin-2-yl—ethyl)—acid amide (3S,4S)—1—Cyclohexyl—4—{[5—(214— difluoro-phenyl)-[1,2,4] oxadiazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclohexyl—4—[[1—(2l4— difluoro-phenyl)-1H-[1,2,3]triazol- 4-carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridine—2—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxylic; (1—pyridin—2—I—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopentyl-4-{[5(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyrazin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrazin—2—I—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [1-(4,6—dimethyl—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopentyl-4-([5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine3-carboxylic; IF-2019-79621737-APN-ANP#INPI 141 Page 141 of 351 [1-(4,6—dimethyl—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}piperidine—3—carboxylic; ((R)—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [(R)—1 —(6—methyl—pyridin—2—yl)—ethyl]—acid amide (3S,4S)-1-Cyclohexyl-4-{[5(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(2- methoxy-ethyl)-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-ethyl-piperidin -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(1, 1,2,2,2—ds—ethyl)—piperidine—3—carboxylic; (1—pyridin—2—yl—cyclopropyl)—(3S,4S) acid amide—1—Cyclopropylmethyl—4—{[5— (2,4—difluoro—phenyl)—[1,3,4]oxadiazol- 2-carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4,6-trifluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendin-3-carboxylic acid; (2-methoxy-1,1-dimethyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; ((1R)-1-[1,2,4]oxadiazol-3-yl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((1 S)—1—[1,2,4]oxadiazol—3—¡I—ethyl)—(3S,4S)-1-Cyclohexyl-4{[5-(2,4-difluoro-)acid phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)-1-phenyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluorophenyl)-isoxazol-3-carbonyl]-amino}-piperidine -3-carboxylic; ((S)-2-hydroxy-1-phenyl-ethyl)-acid acid (3S,4S)-1-Cyclohexyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-pipendin-3-carboxylic acid; IF-2019-79621737-APN-ANP#INPI 142 Page 142 of 351 (3S,4S)-1-Cyclohexyl-4-{[5-(2,4-difluoro-phenyl)-isoxazol3-carbonyl]-amino}-p¡pendine-3-carboxylic acid benzylamide; [(1 R)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S.4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [(1 S)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; ((R)—1—pyridin—3—¡I—ethyl)—(3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-piperidine-3-carboxylic; (1—pyridin—4—yl—cyclopropyl)—(3S,4S)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; (1—pyridin—4—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-CiclopentiM-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—methyl—1—pyridin—2—I—ethyl)—acid amide (3S,4S)—1—Cyclopentyl-4—{[5—(2,4— difluorophenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}— piperidine-3-carboxylic; (1—methyl—1—pyridin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl-4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; [1—methyl—1—(5—methyl—[1,2,4]oxadiazol—3—yl)—ethyl]—acid amide (3S,4S)—1— Cyclopentyl-4-{[5-(2 ,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine3-carboxylic acid; ((1R)-1-isoxazol-3-yl-ethyl)-acid acid (3S,4S)-1-Cyclopentyl-4-{[5-(2,4difluoro-phenyl)-isoxazol-3-carbonyl]- amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 143 Page 143 of 351 ((1 S)—1—isoxazole—3—¡I—ethyl)—acid amide (3S,4S)—1—Cyclopentyl—4—{[5—(2,4— diffiioro-phenyl) -isoxazol-3-carbonyl]-amino}-pipendine-3-carboxylic acid; [(1 R)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)-1-CiclopentiM-{[5(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [(1 S)—1—(2H—pyrazol—3—yl)—ethyl]—acid amide (3S,4S)—1—Cyclopentyl—4—{[5— (2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; ((R)—1—pyridin—3—yl—ethyl)—acid amide (3S,4S)-1—Cyclopentyl-4—{[5—(2l4— difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; and [1—methyl—1—(5—methyl—[1,2,4]oxadiazol—3—yl)—ethyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4 -difluoro-phenyl)-isoxazole-3-carbonyl]-amino}piperidine-3-carboxylic. 26) In addition to the compounds of embodiment 25), other particularly preferred compounds according to embodiment 1) are selected from the following compounds: (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-dichloro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidín-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl-4{[5-(2,3,4-trifluoro-phenyl) acid amide )-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid; [1—(1—oxy—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1-CiclopentiM{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl] -amino}-piperidine-3-carboxyl; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cíclopentylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidín-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(1-Difluoromethylcyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}p¡ perid i n-3-ca rboxí I ico; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-( 4-fluoro-benzyl)-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI 144 Page 144 of 351 (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1 -(2,2-dimethyl-propyl)-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(214-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-isobutyl-piperidin-3 -carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Benzyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine acid amide -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Gyclobutylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazol-3-carbonyl]-amino}-1-isopropyl-piperidin -3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclobutyl—4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino} -piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-((1R)-2,2-Difluorocyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-((1S)-2,2-Difluorocyclopropylmethyl)-4-{[5-(2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}piperidine—3—carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—4—{[5—(2,4—Difluoro—phenyl)-isoxazole-3-carbonyl]-amino}-1-( 3-fluoro-propyl)-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-CyclobutyM-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-pipendin-3 -carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1-(1- methyl-cyclopropylmethyl)-piperidine-3carboxylic; (1—pyridin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[1— (2,4—difluoro—phenyl)—1 H—[1,2,3 ]triazol-4-carbonyl]-amino}-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI 145 Page 145 of 351 (1—pyridin—2—ylUcyclopropyl)—acid amide (3S,4S)—1—Cyclopentyl-4—{[1—(2,4—difluoro—phenyl)—1 H—[1,2 ,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic acid; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Allyl—4—{[5—(2>4— difluoro-phenyl)-isoxazole-3-carbonyl]-am! no}-piper¡din-3-carboxylic¡; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)—1—Bicyclo[3,1,0]hex—3—yl-4—{[5—(2, 4—difluoro—phenyl)—isoxazole—3—carbonyl]—amino}—piperidine—3— carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-D¡fluorophenyl)-isoxazole-3-carbon¡l]-amino acid amide} -1-propyl-piper¡din-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopentyl-4-{[5(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(3,3-Difluorocyclobutylmethyl)-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 acid amide -carbonyl]-amino}piperidine—3—carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-spiro acid amide [2,3]hex-5-il-p¡per¡din-3- . carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S) acid amide—1—Cyclobutyl-4—{[5—(2,4—difluoro—phenyl)—[1,3,4]thiadiazole— 2—carbonyl]—amino}—piperidine—3—carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(214-difluorophenyl)-[1,3,4]thiadiazol-2-carbon! l]-amino}-1-(1-fluoro-cyclopropylmethyl)piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-(Cyclopropyl-(d2methyl))-4-{[5-(2,4-difluoro-phenyl)-isoxazole acid amide -3-carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-cyclopropylmethiM{[5-(2,4-difluoro-phenyl)-4-fluoro-isoxazole-3-carbonyl]-amino acid amide}-piperid¡n-3carboxylic; . IF-2019-79621737-APN-ANP#INPI 146 Page 146 of 351 [1-(1-oxy-pyridin-2-yl)—cyclopropyl]—(3S,4S)-1-Cyclopropylmethyl4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl acid amide ]-amino}-p¡perídin-3-carboxylic¡ (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-4-{[5-(2,4 -Difluorophenyl)-isoxazole-3-carbonyl]-amino}-1-(1-fluoro-cyclopropylmethyl)-piperidine-3carboxylic; (l-phenyl-cyclopropyl)-acid acid (3S,4S)—1—Cyclopropylmethyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; [1—(3—fluoro—pyridin—2—¡I)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}piperidine-3-carboxylic; (1—pyrimidin—4—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic acid ethyl ester 1—[((3S,4S)—1—Cyclopropylmethyl—4—{[5—(2,4—difluoro—phenyl)— isoxazole-3-carbonyl]-amino}- piperidin-3-carbonyl)-amino]cyclopropanecarboxylic acid; , (l-phenyl-cyclobutyl)-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3- carboxylic; benzyl-(2-fluoro-ethyl)-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidin-3 -carboxylic; [1-(3-methoxy-phenyl)-cyclopropyl]-acid acid(3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [1—(2—trifluoromethyl—phenyl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino} piperidine-3-carboxylic; [1-(2-fluoro-phenyl)-cyclopropyl]-acid acid (3S,4S)—1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; [2-(2-chloro-phenyl)-ethyl]-acid acid (3S,4S)—1—Cyclopropylmethyl-4—{[5-(2,4— difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic; IF-2019-79621737-APN-ANP#INPI 147 Page 147 of 351 [(3S,4S)—1—cyclopropylmethyl—3—((R)—2—phenyl—azetidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-Difluoro-phenyl) acid amide -isoxazole-3-carboxylic acid; [(3S,4S)—1—cyclopropylmethyl—3—((S)—2—phenyl—azetidin—1—carbonyl)—piperidin—4—yl]—5-(2,4-difluoro-phenyl) acid amide -isoxazole-3-carboxylic acid; [1-(3-chloro-phenyl)-cyclopropyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [1—(4—methyl—thiazol—2—yl)—cyclobutyl]—acid amide (3S,4S)—1—Cyclopropylmethyl— 4-{[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [(R)-1-(2-methoxy-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [(S)-1-(2-methoxy-phenyl)-ethyl]-acid acid (3S,4S)-1-cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]-amino}-piperidine-3-carboxylic; [1-(2-methoxy-phenyl)-cyclopropyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic; [(R)-1-(3-bromo-phenyl)-ethyl]-acid acid (3S,4S)-1-Cyclopropylmethyl-4-{[5(2,4-difluoro-phenyl)-isoxazole- 3-carbonyl]-amino}-piperidine-3-carboxylic; [1—(2—hydroxy—phenyl)—cyclopropyl]—(3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3-carboxylic; [1—(1—oxy—pyrimidin—2—yl)—cyclopropyl]—acid amide (3S,4S)-1Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}piperidine-3-carboxylic; [(3S,4S)—1—cyclopropylmethyl—3—((R)—2—pyrimidin—2—yl—pyrrolidin—1—carbonyl)— piperidin—4—yl]—5-(2,4-) acid amide Difluoro-phenyl)-isoxazole-3-carboxylic acid; [(3S,4S)-1-cyclopropylmethyl-3-((S)-2-pyrimidin-2-I-pyrrolidin-1-carbonyl)piperidin—4—yl]—acid 5-(2,4- Difluoro-phenyl)-isoxazole-3-carboxylic acid; [(3S.4S)—1—cyclopropylmethyl—3—((R)—2—pyrimidin—2—yl—azetidin—1—carbonyl)—piperidin—4-yl]-5-(2,4- Difluoro-phenyl)-isoxazole-3-carboxylic acid; [(3S,4S)—1—cyclopropylmethyl—3—((S)—2—pyrimidin—2—yl—azetidin—1—carbonyl)— piperidin—4—yl]—5-(2,4-) acid amide difluoro-phenyl)-isoxazole-3-carboxylic acid IF-2019-79621737-APN-ANP#INPI 148 Page 148 of 351 ((R)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole -3-carbonyl]-amino}-piperidine-3-carboxylic; ((S)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclopropylmethyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; [1—(3—fluoro—pyridin—2—yl)—cyclopropyl]—acid amide (3S,4S)—1—Cyclobutyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; (1—methyl—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-pipendine-3-carboxylic acid; ((R)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclobutyl—4—{[5—(2,4— difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; ((S)—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)—1—Cyclobutyl-4—{[5—(2,4—difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; [(R)—1— (6-methyl-pyridin-2-yl)-ethyl]-acid acid (3S,4S)-4-{[5-(2,4Difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-1-ethyl-piperidine-3-carboxylic;. (1—methyl—1—pyrimidin—2—yl—ethyl)—(3S,4S)-4-{[5-(2,4-Difluorophenyl)-isoxazole-3-carbonyl]-amino acid amide}-1 -ethyl-piperidine-3-carboxylic; [3-(3-chloro-phenyl)-oxetan-3-yl]-acid acid (3S,4S)-1—Cyclobutyl-4—{[5— (2,4-difluoro-phenyl)-isoxazole-3 -carbonyl]-amino}-piperidine-3-carboxylic; [(R)-1-(3-fluoro-pyridin—2—yl)—ethyl]—acid amide (3S,4S)-1-CyclobutiM{[5-(2,4-difluoro-phenyl)-isoxazole- 3-carbonyl]-amino}-piperidine-3-carboxylic; I(S)—1—(3-fluoro-pyridin-2-yl)—ethyl]—acid amide (3S,4S)—1—Cyclobutyl—4—{[5— (2,4-difluoro-phenyl) -isoxazol-3-carbonyl]-amino}-piperidine-3-carboxylic acid; (1—methyl—1—pyrimidin—2—yl—ethyl)—acid amide (3S,4S)-1—Cyclopropylmethyl—4— {[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl ]-amino}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl-4{[4-fluoro-5-(4-fluoro-phenyl)-isoxazole-3-carbonyl]-amino acid amide}-piperidine-3carboxylic; IF-2019-79621737-APN-ANP#INPI - 149 Page 149 of 351 (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[1—(2,4—difluoro—phenyl)—1 H—[1, 2,3]triazole—4—carbonyl]—amino}—piperidine—3—carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-dimethyl-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic; (1—pyrimidin—2—I—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[3-(2,4-difluoro-phenyl)-isoxazole-5-carbonyl]-amino} -pipendin-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-Cyclopropylmethyl-4{[5-(2,4-difluoro-phenyl)-[1,2,4]oxadiazol-3 -carbonyl]-amino}-piperidine-3carboxylic; (1—pyrimidin—2—I—cyclopropyl)—(3S,4S)-1-Cyclopropylmethyl-4{[4-(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino acid amide}-piperidine-3-carboxylic; (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-CyclopropylmethiM{[5-(2,4-difluoro-phenyl)-oxazol-2-carbonyl]-amino}-piper! din-3-carboxylic¡ and (1—pyrimidin—2—yl—cyclopropyl)—acid amide (3S,4S)-1-CyclopropylmethiM{[5—(2,4—difluoro—phenyl)—[1,3, 4]thiadiazole—2—carbonyl]—amino}—piperidine—3— carboxylic. 27) Another aspect of the invention relates to new piperidine derivatives of the formula (II); O 11 oR-ArAm I / 7 RC JRAr1i R2 Formula (II) where the two substituents of the piperidine ring: R1-CO- and -NH-CO-Ar—Ar2, are in a relative trans configuration (that is, the relative configuration of the two IF-2019-79621737-APN-ANP#INPI 150 Page 150 of 351 chiral carbon atoms in position 3 and 4 of the piperidine ring is (3R*,4R*))! Ar1 represents a 5-membered heteroarylene group (especially a 5-membered heteroarylene containing one to a maximum of three heteroatoms, each independently selected from oxygen and nitrogen; notably, oxazole-diyl, isoxazole-diyl, oxadiazol- diyl or triazoldiyl), where the -NH-CO- group and Ar2 are linked in a meta arrangement with ring atoms of Ar1; wherein said 5-membered heteroarylene is unsubstituted or monosubstituted with RAr1¡ wherein RAr1 represents (C^ 4 alkyl), alkoxy (Ci-4), halogen, fluoroalkyl (Ci_3) or fluoroalkoxy (C1-3) (especially said 5-membered heteroarylene is unsubstituted); Ar2 represents phenyl that is mono-, di- or trisubstituted, wherein the substituents are, independently, fluoro or chloro (especially Ar2 represents phenyl that is mono-, di- or trisubstituted with fluoro); R5 represents alkyl (Ci-e); R2represents • hydrogen; • alkyl (Ci-β) (especially ethyl, isopropyl, 2,2-dimethylpropyl, 3-methyl-butyl, 3,3-dimethylbutyl); • (C2-6)alkyl which is monosubstituted with (Ci_8)alkoxy (especially methoxy)0hydroxy (especially 2-hydroxyethyl, 2-methoxy-ethyl, 2-hydroxy-1-methyl-propyl); • fluoroalkyl (C2-3); • cycloalkyl (C3_8)-alkyl (C0-3); wherein said (C3_8) cycloalkyl group may optionally contain a ring oxygen atom; wherein the cycloalkyl (C3_e) is unsubstituted or mono- or disubstituted wherein the substituents are independently selected from alkyl IF-2019-79621737-APN-ANP#INPI 151 Page 151 of 351 (Ci_3) (especially methyl), fluoro, hydroxy, hydroxy-alkyl (Ci_3) (especially hydroxy-methyl) or alkoxy (Ci_3) (especially methoxy); (especially cyclobutyl, 2-methylcyclobutyl, 2,2-dimethylcyclobutyl, 3,3-dimethylcyclobutyl, cyclopentyl, cyclohexyl, spiro[2,4]hept-4-yl, spiro[3,3]hept-2-yl, bicyclo [2,2,1]hept—2—yl, 2-methylcyclopentyl, 2(hydroxymethyl)—cyclopentyl, 3,3—dimethylcyclopentyl, 2—ethylcyclopentyl, 3,3—dimethylcyclohexyl, 2-fluoro-cyclohexyl, 4-fluoro- cyclohexyl, 4,4-difluorocyclohexyl, 2-hydroxy-cyclohexyl, 2-methoxy-cyclohexyl, 3-methoxycyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 1-cyclopropyl-ethyl, (1-methyl-cyclopropyl)-methyl, (1-methyl —cyclobutyl)—methyl, 2—cyclopropyl—ethyl); either . • cycloalkenyl (C3_e)-alkyl (Ci_3) (especially cyclopenten-1-yl-methyl); and R3 represents hydrogen or methyl (especially hydrogen). Compounds of formula (II) are important intermediates suitable for the preparation of compounds of formula (I) as described in reaction scheme A below. Furthermore, such compounds of formula (II) can also react as antagonists of the CXCR7 receptor and may thus be useful for the prevention or treatment of diseases that respond to the activation of CXCL12 receptors and / or CXCL11 receptors, in especially cancer. It is understood that the characteristics of embodiments 2) to 10) and 15) to 19), especially as set out in embodiment 20), apply mutatis mutandis also to the compounds of formula (II). The compounds of formula (I) according to embodiments 1) to 26) and their pharmaceutically acceptable salts can be used as medicaments, for example, in the form of pharmaceutical compositions for enteral administration (as in especially oral) or parenteral administration (including topical application or inhalation). IF-2019-79621737-APN-ANP#INPI 152 Page 152 of 351 The production of the pharmaceutical compositions can be carried out in a manner that will be familiar to anyone skilled in the art (see, for example, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins], carrying the described compounds of formula (I) or (II), or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, in a galenic administration form together with inert solid or liquid carrier materials, not toxic and therapeutically compatible and, if desired, common pharmaceutical adjuvants. The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I) as defined in any of the embodiments 1 ) to 26). In a preferred embodiment of the invention, the amount administered is between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day. Whenever the word between is used to describe a numerical range, it should be understood that the endpoints of the indicated range are explicitly included in the range. For example: if a temperature range between 40°C and 80°C is described, this means that the endpoints 40°C and 80°C are included in the range; or if you define a variable as an integer between 1 and 4, this means that the variable is the integer 1, 2, 3, or 4. Unless used with respect to temperatures, the term approximately placed before a numerical value IF-2019-79621737-APN-ANP#INPI 153 Page 153 of 351 plus 10% of refers in the current application to a range extending from the temperature Y minus 10°C to Y plus 10°C, and preferably to a range extending from Y minus 5°C to Y plus 5°C. For the avoidance of doubt, if the compounds are described as useful for the prevention or treatment of certain diseases, such compounds are equally suitable for use in the preparation of a medicament for the prevention or treatment of said diseases. The compounds of formula (I) defined in any one of embodiments 1) to 26) are useful for the prevention / prophylaxis or treatment of disorders related to the CXCR7 receptor or its ligands which are especially disorders related to a dysfunction of the CXCR7 receptor or dysfunction of ligands that signal through CXCR7, or dysfunction of CXCR7 ligands (CXCL12 and CXCL11) that signal through its other receptors (CXCR4 and CXCR3). Diseases or disorders related to the CXCR7 receptor or its ligands are especially selected from the group consisting of • cancer (especially brain tumors including malignant gliomas, glioblastoma multiforme; neuroblastoma; pancreatic cancer including pancreatic adenocarcinoma / pancreatic ductal adenocarcinoma; gastrointestinal cancers including colon carcinoma, Kaposi sarcoma; adult T cell leukemia; breast cancer; endometrial; thyroid carcinoma including papillary thyroid carcinoma; metastatic lung cancers; 154 Page 154 of 351 including melanoma and metastatic melanoma; bladder cancer; multiple myelomas; osteosarcoma; Head and neck cancer; and renal carcinomas including renal clear cell carcinoma, metastatic renal clear cell carcinoma); • inflammatory diseases (especially chronic rhinosinusitis, asthma, chronic obstructive pulmonary disorder, atherosclerosis, myocarditis and sarcoidosis, especially chronic rhinosinusitis, asthma and atherosclerosis); • autoimmune disorders (especially demyelinating (inflammatory) diseases), multiple sclerosis (MS), Guillain Barré syndrome, rheumatoid arthritis (RA), inflammatory bowel diseases (IBD, especially including Crohn's disease and ulcerative colitis), systemic lupus erythematosus (SLE ), lupus nephritis, interstitial cystitis, celiac disease, autoimmune encephalomyelitis, osteoarthritis and type I diabetes, especially autoimmune disorders that have an inflammatory component such as demyelinating (inflammatory) diseases, multiple sclerosis, Guillain Barré syndrome, rheumatoid arthritis, inflammatory diseases intestinal, systemic lupus erythematosus, lupus nephritis and autoimmune encephalomyelitis); • transplant rejection (especially renal allograft rejection, cardiac allograft rejection, and graft-versus-host diseases caused by hematopoietic stem cell transplantation); and · fibrosis (especially liver fibrosis, liver cirrhosis, pulmonary fibrosis, especially idiopathic pulmonary fibrosis). In particular, such diseases or disorders related to the CXCR7 receptor or its ligands are cancers, autoimmune disorders IF-2019-79621737-APN-ANP#INPI 155 Page 155 of 351 (especially autoimmune disorders that have an inflammatory component) and fibrosis. Furthermore, other diseases or disorders related to the CXCR7 receptor or its ligands are diseases that involve CXCR7 and / or CXCL12 and / or CXCL11-mediated metastasis, chemotaxis, cell adhesion, trans-endothelial migration, proliferation and / or cell survival. In addition, other particular diseases or disorders related to the CXCR7 receptor or its ligands are proliferative diabetic retinopathy; West Nile virus encephalitis; pulmonary vascular disease, acute renal failure, ischemia including cerebral ischemia, acute coronary syndrome, injured central nervous system, hypertension, pulmonary hypertension, Shiga-toxin associated hemolytic uremic syndrome, preeclampsia, vascular injury, HIV / AIDS, angiogenesis and cerebral dysfunctions and neuronal (such as inflammatory components of Alzheimer's disease), stress-related disorders (such as anxiety, depression, and post-traumatic stress disorder), and diseases involving opioid receptors. In a sub-embodiment, such additional particular disease or disorder related to the CXCR7 receptor or its ligands is especially pulmonary hypertension. The term “cancer” refers to all kinds of cancers such as carcinomas; adenocarcinomas; leukemias; sarcomas; lymphomas; myelomas; metastatic cancers; brain tumors; neuroblastomas; pancreatic cancers; gastrointestinal cancers; lung cancers; breast cancers; prostate cancers; endometrial cancers; skin cancers; bladder cancers; head and neck cancers; neuroendocrine tumors; ovarian cancers; cervical cancers; oral tumors; nasopharyngeal tumors; thoracic cancers; and virus-induced tumors. IF-2019-79621737-APN-ANP#INPI 156 Page 156 of 351 Especially the term refers to brain tumors including brain metastases, malignant gliomas, glioblastoma multiforme, medulloblastoma, meningiomas; neuroblastoma; pancreatic cancer including pancreatic adenocarcinoma / pancreatic ductal adenocarcinoma; gastrointestinal cancers including colon carcinoma, colorectal adenoma, colorectal adenocarcinoma, metastatic colorectal cancer, familial adenomatous polyposis (FAP), gastric cancer, gallbladder cancer, cholangiocarcinoma, hepatocellular carcinoma; Kaposi sarcoma; leukemias including acute myeloid leukemia, adult t-cell leukemia; lymphomas including Burkitt lymphoma, Hodgkin lymphoma, MALT lymphoma, and primary intraocular B-cell lymphoma; lung cancer including non-small cell lung cancer; breast cancer including triple negative breast carcinoma; rhabdomyosarcoma; prostate cancer including castration-resistant prostate cancer; esophageal squamous cancer; squamous cell carcinoma (oral); endometrial cancer; thyroid carcinoma including papillary thyroid carcinoma; metastatic cancers; lung metastasis; skin cancer including melanoma and metastatic melanoma; bladder cancer including urinary bladder cancer, urothelial cell carcinoma; multiple myelomas; osteosarcoma; Head and neck cancer; and renal carcinomas including renal cell carcinoma, clear cell carcinoma, metastatic renal cell carcinoma, metastatic renal clear cell carcinoma; as well as qeuroendocrine tumors; ovarian cancer; cervical cancer; oral tumors; nasopharyngeal tumors; chest cancer; choriocarcinoma; Ewing sarcoma; and virus-induced tumors. especially the term cancer refers to malignant glioma in particular glioblastoma multiforme, neuroblastoma; pancreatic cancers in particular pancreatic ductal adenocarcinoma; Kaposi sarcoma; leukemia IF-2019-79621737-APN-ANP#INPI 157 Page 157 of 351 adult T cells, lymphoma; lung cancer; breast cancer; rhabdomyosarcoma; prostate cancer; esophageal squamous cancer; squamous cell carcinoma (oral); endometrial cancer; papillary thyroid carcinoma; metastatic cancer; lung metastasis; melanoma; bladder cancer; multiple myelomas; osteosarcoma; gastrointestinal cancers, in particular colon carcinoma, hepatocellular carcinoma; Head and neck cancer; and renal clear cell carcinoma. Preferably, the term cancer refers to malignant glioma, in particular glioblastoma multiforme; pancreatic cancers, particularly pancreatic ductal adenocarcinoma; papillary thyroid carcinoma; hepatocellular carcinoma; lung cancer; breast cancer; metastatic cancers; lung metastasis; melanoma; colon carcinoma; and head and neck cancer. The compounds of formula (I) defined in any of embodiments 1) to 26) may be useful in particular as therapeutic agents for the prevention / prophylaxis or treatment of a cancer as defined above, such cancer being a metastatic cancer / a cancer that forms metastasis. The compounds of formula (I) defined in any one of embodiments 1) to 26) are in particular useful as therapeutic agents for the prevention / prophylaxis or treatment of a cancer. They can be used as single therapeutic agents or in combination with one or more chemotherapy and / or radiotherapy agents and / or targeted therapy. In a sub-embodiment, when a compound of formula (I) is used for the prevention / prophylaxis or treatment of a cancer in combination with one or more chemotherapeutic agents and / or radiotherapy and / or targeted therapy, such cancer is especially a malignant glioma, in particular glioblastoma ultiformis; pancreatic cancer, especially pancreatic ductal adenocarcinoma; papillary thyroid carcinoma; lung metastasis; melanoma; lung cancer; metastatic cancers; hepatocellular carcinoma; breast cancer; cancer IF-2019-79621737-APN-ANP#INPI 158 Page 158 of 351 colorectal; or head and neck cancer. Such combined treatment can be carried out simultaneously, separately or over a period of time. Therefore, the invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier material, and: • a compound of formula (I) defined in any of the forms '. of realization 1) to 26); • and one or more cytotoxic chemotherapeutic agents. Therefore, the invention further relates to a kit comprising • a pharmaceutical composition, said composition comprising a pharmaceutically acceptable carrier material, and a compound of formula (I) as defined in any of embodiments 1) to 26) ; • and instructions on how to use said pharmaceutical composition for the prevention or treatment of a cancer (especially a malignant glioma, in particular a glioblastoma multiforme), in combination with chemotherapy and / or radiotherapy and / or targeted therapy. . The terms radiotherapy or radiation therapy or oncological radiotherapy refer to the medical use of ionizing radiation in the prevention (adjuvant therapy) and / or treatment of cancer; which include external and internal radiotherapy. The term “targeted therapy” refers to the prevention / prophylaxis (adjuvant therapy) and / or treatment of cancer with one or more antineoplastic agents such as small molecules or antibodies that act on specific types of cancer cells or stromal cells. Some therapies IF-2019-79621737-APN-ANP#INPI 159 Page 159 of 351 targeted drugs block the action of certain enzymes, proteins or other molecules involved in the growth and spread of cancer cells. Other types of targeted therapies help the immune system kill cancer cells (immunotherapies); or deliver toxic substances directly to cancer cells and kill them. An example of a targeted therapy that is particularly suitable for combination with the compounds of the present invention is immunotherapy, especially immunotherapy targeting the programmed cell death receptor 1 (PD-1 receptor) or its ligand PD-L1 (Feig C etal, PNAS 2013). When used in combination with the compounds of formula (I), the term targeted therapy refers especially to agents such as: a) Epidermal growth factor receptor (EGFR) inhibitors or blocking antibodies (e.g. Gefitinib, Erlotinib, Afatinib, Icotinib, Lapatinib, Panitumumab, Zalutumumab, Nimotuzumab, Matuzumab and Cetuximab); b) B-RAF inhibitors (e.g. Vemurafenib, Sorafenib, Dabrafenib, GDC-0879, PLX-4720, LGX818); c) Aromatase inhibitors (for example Exemestane, Letrozole, Anastrozole, Vorozole, Formestane, Fadrozole); d) Immune checkpoint inhibitors (for example, anti-PD1 antibodies such as Pembrolizumab (Lambrolizumab, MK-3475), Nivolumab, Pidilizumab, AMP-514 / MED10680; small molecule anti-PD1 agents such as for example compounds described in WO2015 / 033299, WO2015 / 044900 and WO2015 / 034820; anti-PD1L antibodies, such as BMS-936559, atezolizumab (MPDL3280A), MEDI4736, avelumab (MSB0010718C); —4, such as ipilimumab, tremilmumab); IF-2019-79621737-APN-ANP#INPI 160 Page 160 of 351 e) Vaccination approaches (for example, vaccination with dendritic cells, vaccination with peptides or proteins (for example with gp1OO peptide or MAGE-A3 peptide); f) Reintroduction of patient-derived or allogeneic (non-self) cancer cells genetically modified to secrete immunomodulatory factors such as granulocyte monocyte colony-stimulating factor (GMCSF) gene-transfected tumor cell vaccine (GVAX), or tumor cells transfected with the FMS-related tyrosine kinase 3 (Fit—3) ligand gene or the Toll receptor-enhanced GM-CSF tumor-based vaccine (TEGVAX); g) T cell-based adoptive immunotherapies, including chimeric antigen receptor (CAR) genetically engineered T cells (e.g. CTL019); h) Therapy based on cytokines or immunocytokines (for example Interferon alfa, interferon beta, interferon gamma, interleukin 2, interleukin 15); i) Toll-like receptor (TLR) agonists (for example, resiquimod, imiquimod, glucopyranosyl lipid A, CpG oligodeoxynucleotides); j) Thalidomide analogues (e.g. Lenalidomide, Pomalidomide); k) Indoleamine-2,3-dioxygenase (IDO) and / or tryptophan2,3-dioxygenase (TDO) inhibitors (e.g. NLG919 / lndoximod, 1MT (1-methyltryptophan), INCB024360); I) T cell costimulatory receptor activators (e.g., lymphocyte activation gene 3 (LAG-3) antibodies (such as BMS-986016), T cell immunoglobulin anti-mucin antibodies, anti-CD137 / 4 antibodies - 1BB (e.g. BMS - 663513 / urelumab), anti-kill cell immunoglobulin-like receptors (KIR), e.g. Lirilumab (IPH2102 / BMS - 986015), anti-OX40 / CD134 (tumor necrosis factor receptor superfamily, member 4), anti-OX40 antibodies IF-2019-79621737-APN-ANP#INPI 161 Page 161 of 351 Ligand / CD252; anti-glucocorticoid-induced TNFR family-related gene (GITR) (such as TRX518), anti-CD40 (TNF receptor superfamily member 5) antibodies (such as CP-870,893); anti-CD40 ligand antibodies (such as BG9588); anti-CD28 antibodies) m) Molecules that bind a tumor-specific antigen as well as a T cell surface marker, such as bispecific antibodies or antibody fragments, antibody mimetic proteins such as designed ankyrin repeat proteins (DARPINS) , bispecific T cell engagement agent (BITE, e.g. AMG103, AMG330); n) Small molecular weight antibodies or inhibitors targeting the colony-stimulating factor 1 receptor (CSF-1R) (e.g. RG7155 or PLX3397). When used in combination with the compounds of formula (I), immune checkpoint inhibitors such as those listed in d), and especially those targeting the programmed cell death receptor 1 (PD-1 receptor) or its PD-L1 ligand. . The term chemotherapy refers to the treatment of cancer with one or more cytotoxic antineoplastic agents (cytotoxic chemotherapy agents). Chemotherapy is often used along with other cancer treatments, such as radiation therapy or surgery. The term refers especially to conventional chemotherapeutic agents that act by destroying rapidly dividing cells, one of the main properties of most cancer cells. Chemotherapy may use one drug at a time (single-agent chemotherapy) or several drugs at once (combination chemotherapy or polychemotherapy). The. Chemotherapy with drugs that convert to cytotoxic activity only after exposure to light is called photochemotherapy or photodynamic therapy. IF-2019-79621737-APN-ANP#INPI 162 Page 162 of 351 The term cytotoxic chemotherapeutic agent or chemothe...

Claims

1. A compound characterized in that said compound is: (1-pyrimidin-2-yl-cyclopropyl)-amide of (3S,4S)-1-cyclobutyl-4-{[5-(2,4-difluorophenyl)-[1,3,4]thiadiazol-2-carbonyl]-amino}-piperidin-3-carboxylic acid (Ex. 2.105); (1-pyrimidin-2-yl-cyclopropyl)-amide of (3S,4S)-4-{[5-(2,4-difluorophenyl)-[1,3,4]thiadiazol-2-carbonyl]-amino}-1-(1-fluorocyclopropylmethyl)-piperidin-3-carboxylic acid (Ex. 2.106); or (1-pyrimidin-2-yl-cyclopropyl)amide of (3S,4S)-1-cyclopropylmethyl-4-{[5-(2,4-difluorophenyl)-[1,3,4]thiadiazol-2-carbonyl]amino}piperidin-3-carboxylic acid (Ex. 7.016); or one of its pharmaceutically acceptable salts. Claim 1 follows